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Summary 
 
Endothelial cells, lining all blood vessels, can release both relaxing and contracting 
factors to modulate the tone of the underlying smooth muscle. Endothelium-dependent 
relaxation is mediated by multiple factors including nitric oxide (NO), prostacyclin and an 
unidentified endothelium-derived hyperpolarizing factor (EDHF). Diabetes mellitus is 
characterized by hyperglycaemia resulting from a defective secretion or action of endogenous 
insulin. It is well established that diabetes often causes macro- and microvascular 
complications in human and animal models of diabetes, and several lines of evidence suggest 
that endothelial dysfunction is an early phenomenonin in the development of these 
complications. It remains unclear how the relative contribution of endothelium-derived factors 
to relaxation were modulated over the course of diabetes-induced hyperglycaemia. The aim of 
this thesis was to examine the effects of early and later stages of diabetes on vascular 
function, and to explore the potential use of a flavonol as an alternative treatment for diabetic 
vascular diseases.  
In the first study, early diabetes (6 weeks) caused a significant increase in vascular 
superoxide production, it did not affect the sensitivity or maximum response to acetylcholine 
(ACh), but there were marked changes in the mechanism of endothelium-dependent 
relaxation. Diabetes caused a resistance of ACh-induced relaxation to NO synthase (NOS) 
inhibition which could be attenuated by scavengers of NO and nitroxyl (HNO), and 
degradation of nitrosothiols with copper ions. Western blot analysis indicated that diabetes 
caused an increased expression of endothelial NOS (eNOS) and decreased expression of 
caveolin-1 protein, and it also significantly reduced the proportion of eNOS that is expressed 
as a dimer, indicating that eNOS was uncoupled and could in part be producing superoxide 
instead of NO. In the early stages of diabetes, despite marked hyperglycaemia, causes an 
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increase superoxide production, and decreased NO synthesis, endothelium-dependent 
relaxation was maintained possibly by a NOS-independent source of NO such as nitrosothiols.  
The second study demonstrated that endothelial dysfunction in the rat aorta was due to 
a decreased contribution of NO to endothelium-dependent relaxation in the later stage of 
diabetes (10 weeks). In contrast, the contribution of HNO-mediated relaxation to 
endothelium-dependent relaxation is preserved in the diabetic aorta. Furthermore, HNO 
appears to be derived from eNOS in normal aorta, whereas in the diabetic aorta it may in 
addition also arise from an eNOS-independent source. Consistent with this observation, 
vascular relaxation to the NO donor, DEANONOate or endothelium-derived NO was 
significantly attenuated by the presence of pyrogallol-induced superoxide anions. Similarly, 
vascular relaxation to the HNO donor, Angeli‟s salt, or endothelium-derived HNO was not 
affected by the presence of superoxide anions.  
The third study utilized an animal model that is artificially selected for low- and high- 
capacity runners (LCR and HCR respectively), β-adrenoceptor-mediated relaxation was 
significantly attenuated in both macro- and microvasculature of LCR animals. In the LCR 
microvasculature, the impairment of β-adrenergic signal transduction was at least in part 
caused by the loss of β2-adrenergic responses. In addition, impaired microvascular endothelial 
function was also evident in the LCR animals which were caused by diminished EDHF-
mediated relaxation.  
The fourth study demonstrated that endothelial dysfunction was evident in the rat 
small mesenteric artery after 10 weeks of diabetes, which is due to a decreased contribution of 
both NO-mediated and EDHF-type relaxation to endothelium-dependent relaxation. Diabetes 
causes an increase superoxide production in mesenteric arteries associated with an increase in 
Nox2 expression. Western blot analysis also indicated that diabetes significantly decreased 
the proportion of eNOS expressed as a dimer and decreased the activation of eNOS by 
decreasing the level of phosphorylation of Akt, actions that would decrease NO synthesis. 
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Uncoupled eNOS may also contribute to the increase in superoxide production. Furthermore, 
the basal level of NO release was also decreased. In contrast, diabetes caused a significant 
increase in the expression of the endothelial Ca
2+
-activated K
+
 (KCa) channels, suggesting 
that, rather than a decrease in channels expression, the impairment of the EDHF-type 
relaxation may be attributed to defective downstream processes such as microdomain 
signaling or myoendothelial gap junction pathways. 
There is accumulating evidence that oxidant stress contributes to the impairment of 
endothelium-dependent relaxation in the microvasculature, however, it has not been clearly 
demonstrated that antioxidants are able to reverse microvascular endothelial dysfunction. The 
fifth study demonstrated that the synthetic flavonol 3‟,4‟-dihydroxyflavonol (DiOHF) acutely 
reduced the levels of oxidative stress and improved endothelium-dependent relaxation in 
mesenteric arteries from both type I and type II diabetic rats. Following this, the sixth study 
was to test the hypothesis that short term DiOHF treatment (7 days, 1 mg/kg per day s.c.) 
would improve relaxation in mesenteric arteries from diabetic rats where endothelial 
dysfunction is associated with elevated oxidant stress. This study demonstrated that treatment 
with DiOHF reduced the levels of vascular oxidative stress and improved endothelium-
dependent relaxation in mesenteric arteries. Treatment with DiOHF selectively improved NO-
mediated relaxation in diabetic rats accompanied by an increased expression of eNOS, 
reduced eNOS uncoupling and downregulation of Nox2 expression. 
In conclusion, this thesis provided further insights in the pathological process 
underlying endothelial dysfunction in both macro- and microvasculature over the duration of 
hyperglycaemia. At the early stages of diabetes, hyperglycaemia caused oxidative stress 
through the increase in NADPH oxidase expression/activity and eNOS uncoupling but 
endothelial function was maintained. At the later stages of diabetes, the increase in NADPH 
oxidase expression/activity and eNOS uncoupling continued to contribute to oxidative stress, 
suggesting that the increase in NADPH oxidase expression/activity and eNOS uncoupling are 
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an early contributor to hyperglycaemia-induced endothelial dysfunction. Short term treatment 
with DiOHF in diabetic rats had no effect on the glycaemic levels, indicating that DiOHF 
improves vascular function via a glucose lowering-independent pathway. The protective 
actions of DiOHF occur through at least two mechanisms: DiOHF is able to rapidly scavenge 
ROS and/or inhibit the enzymatic source for superoxide production (i.e. NADPH oxidase and 
eNOS uncoupling) to preserve NO activity. The ability of DiOHF to inhibit superoxide 
production derived from NADPH oxidase and eNOS uncoupling makes it a potential 
adjunctive treatment for diabetic vascular complications. 
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1.1 Introduction 
Diabetes mellitus, characterized by increased blood glucose levels, is a disease that 
affects 340 million people worldwide. The World Health Organization (WHO) estimated that 
a total of 3.4 million people died from diabetes in 2004, and projected that diabetic deaths will 
double from 2005-2030 (World Health Organization, 2011). Consequently, diabetes 
represents a heavy economic burden to individuals, families, health systems and countries. 
For example, the direct health care expenditure for diabetes in Australia is estimated to be $6 
billion per annum (Diabetes Australia, 2006).  
Hyperglycaemia can result from the deficient production of insulin due the 
autoimmune destruction of pancreatic β-cells or as a result of insulin resistance. Diabetic 
patients are characterized as having type I (insulin-dependent) or type II (non-insulin 
dependent) diabetes mellitus. Patients with long standing type I or type II diabetes, develop 
many complications affecting both the macro- and microvasculature. This is a result of 
multiple metabolic and haemodynamic disturbances that occur as a consequence of altered 
glucose homeostasis. Complications may arise in the eye (retinopathy), nervous system 
(neuropathy), kidney (nephropathy), heart and blood vessels, all of which contribute to the 
increased mortality and morbidity associated with diabetes.  
The current treatments available for diabetic patients include insulin replacement for 
type I diabetic patients, as insulin is not produced by the pancreas, and oral hypoglycaemic 
agents for type II diabetic patients to improve insulin sensitivity. These treatments aim to 
tightly regulate glucose levels and reduce tissue damage caused by elevated glucose 
concentrations. However, large scale prospective studies for both type I and type II diabetes, 
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the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and 
Complication (DCCT/EDIC) and the UK Prospective Diabetes Study (UKPDS), have shown 
that tight glycaemic control slows, but not prevent the progression of cardiovascular 
complications (Holman et al., 2008; The Diabetes Control and Complications 
Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study 
Research Group, 2005). Several lines of evidence suggest that hyperglycaemia-induced 
reactive oxygen species (ROS) is responsible for the development of diabetic cardiovascular 
complications, and the loss of the modulatory role of the vascular endothelium could be a 
critical and initiating factor in the development of these complications (Brownlee, 2001; De 
Vriese et al., 2000; Nishikawa et al., 2000a). As a result, alternative therapies are required to 
reduce the mortality and morbidity associated with diabetic cardiovascular complications.  
This review aims to describe the role of diabetes-induced ROS production and its 
effects on the vascular endothelium during diabetes. In addition, the evidence that flavonols 
which are known to have a broad range of biological actions that exhibit cardio-protective 
mechanisms therefore could be used as a potential adjunctive therapy for treating diabetes and 
its vascular complications is examined.  
 
1.2 Role of the vascular endothelium 
The vascular endothelium is a single layer of cells that lines the interior surface of 
blood vessels, serving as a barrier between blood and tissues and actively participates in the 
regulation of vascular function. Vascular tone is modulated by the endothelium via the 
synthesis and release of various endothelium-derived relaxing and contracting factors. The 
endothelium-derived relaxing factors include nitric oxide (NO), prostacylin (PGI2) and 
endothelium-derived hyperpolarizing factor (EDHF) (Figure 1.1). The endothelium also 
synthesizes contracting factors such as endothelin-1 (ET-1) and endoperoxides/prostanoids.  
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1.2.1 Prostacyclin 
 Prostacylin is recognised as one of the most important prostanoids, a family of 
bioactive lipid mediators that are synthesized by cyclooxygenase (COX) which is derived 
from the cell membrane containing arachidonic acid (AA) (Moncada et al., 1976). Under 
normal conditions, PGI2 is a potent vasodilator and caused inhibition of platelet aggregation, 
leukocyte adhesion, and vascular smooth muscle cell (VSMC) proliferation (Gryglewski et 
al., 1976). These actions of PGI2 are mediated via the stimulation of the PGI2 receptors (IP) 
leading to activation of adenylate cyclase and caused an increase in the production of cyclic 
adenosine monophosphate (cAMP) (Narumiya et al., 1999). 
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Figure 1.1 Schematic diagram summarizing the mechanism of endothelium-dependent 
relaxation. Upon receptor activation, the endothelium can synthesize at least 3 vasodilators 
which include endothelium-derived hyperpolarizing factor (EDHF), nitric oxide (NO) and 
prostacyclin (PGI2) to cause vascular smooth muscle cell relaxation. Adapted from 
(Vanhoutte et al., 2009) 
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1.2.2 Nitric oxide  
 In 1980, Robert Furchgott demonstrated the obligatory role of the endothelium to 
mediate acetylcholine (ACh)-induced relaxation of isolated arteries (Furchgott et al., 1980). 
This was found to be mediated by an endothelium-derived relaxing factor, which has 
subsequently been identified as NO (Palmer et al., 1987), synthesized from the amino acid L-
arginine by NO synthase (NOS) (Palmer et al., 1988). The synthesis of NO also requires 
cofactors/prosthetics such as the flavinmononucleotide (FMN), tetrahydrobiopterin (BH4), 
calmodulin, nicotinamide adenine dinucleotide phosphate (NADPH) and flavin adenine 
dinucleotide (Figure 1.2). Besides ACh, a variety of more physiological stimuli such as shear 
stress, circulating hormones (catecholamines), platelet products (serotonin, adenosine 
diphosphate (ADP)), autocoids (histamine, bradykinin) and receptor-independent agonists 
(e.g. calcium ionophores) can cause endothelial NO synthesis (Vanhoutte et al., 2009). 
NO has a half-life of only a few seconds as it is rapidly scavenged by oxygenated 
haemoglobin, molecular oxygen and superoxide anions. In addition to being a very potent 
vasodilator, endothelium-derived NO also has antiatherogenic properties including decreasing 
platelet and leukocyte adhesion to the endothelium, and inhibition of VSMC migration. All 
these effects are mediated largely through activation of soluble guanylate cyclase (sGC), 
leading to increases in cyclic guanosine monophosphate (cGMP) within platelets or smooth 
muscle cells, leading to reduced aggregation and relaxation respectively (Moncada et al., 
1991). 
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Figure 1.2 Schematic of possible mechanisms by which production of nitric oxide (NO) is 
regulated in endothelial cells. Upon receptor activation which leads to an increase in 
intracellular calcium concentration and NO is produced through enzymatic conversion of L-
arginine to L-citrulline by endothelial nitric oxide synthase (eNOS). The synthesis of NO also 
requires cofactors/prosthetics such as flavinmononucleotide (FMN), tetrahydrobiopterin 
(BH4), calmodulin, nicotinamide adenine dinucleotide phosphate (NADPH) and flavin 
adenine dinucleotide (FAD). Adapted from (Vanhoutte et al., 2009) 
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1.2.3 Endothelium-derived hyperpolarizing factor 
 The term EDHF was introduced to describe an unidentified factor that is responsible 
for causing VSMC hyperpolarization that is not associated with NO or PGI2 (Chen et al., 
1988; Edwards et al., 1998). The function of the endothelium exhibits heterogeneity in with 
differences evident between species and between the large conduit conductance vessels and 
the smaller resistance vessels of the microcirculation (Clark et al., 1997). The contribution of 
EDHF to endothelium-dependent relaxation is often observed in resistance vessels 
(Shimokawa et al., 1996) which are particularly important for controlling blood pressure. The 
nature of EDHF is thought to be complex and also to display heterogeneity between species 
and resistance vessels (Edwards et al., 1998; Edwards et al., 1999; Edwards et al., 2000). 
There are two broad categories of EDHF reponses, that is, classical type and non-classical 
type EDHF responses (Figure 1.3). 
 
  
Chapter 1-Literature review 
12 
 
 
Figure 1.3 Schematic of possible mechanisms by which the classical and non-classical 
endothelium-derived hyperpolarizing factor (EDHF) causes vascular hyperpolarization. 
The classical EDHF response involves the opening of the intermediate (IKCa) and small 
(SKCa) conductance calcium activated K
+
 channels which lead to vascular hyperpolarization 
by either the activation of the Na
+
/K
+
 ATPase and KIR channels respectively, or via 
myoendothelial gap junctions (MEGJs). In addition, non-classical EDHF responses causes 
vascular hyperpolarization through the activation of K
+
 channels by the endothelium-derived 
mediators such as nitric oxide (NO), nitroxyl (HNO), epoxyeicosatrienoic acids (EETs) or 
hydrogen peroxide (H2O2). Adapted from (Edwards et al., 2010) 
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1.2.3.1 Classical EDHF type responses 
The activation of endothelial cells by endothelium-dependent agonists such as ACh 
causes an increase in intracellular Ca
2+
, leading to the initiation of EDHF responses. The basic 
process of classical EDHF type responses involves the opening of the Ca
2+
-activated K
+
-
channels (KCa), small-conductance Ca
2+
-activated K
+
-channels (SKCa) and intermediate-
conductance Ca
2+
-activated K
+
-channels (IKCa) (Edwards et al., 1998). Combined inhibition 
using apamin (selective SKCa blocker) and charybdotoxin (large-conductance Ca
2+
-activated 
K
+
-channels (maxi KCa) and IKCa blocker) blocked EDHF responses, revealing the critical 
role of these channels since iberiotoxin (selective maxi KCa blocker) was unable to inhibit the 
EDHF responses (Waldron et al., 1994). The SKCa and IKCa are expressed in endothelial cells 
and arranged in endothelial microdomains. Opening of either IKCa or SKCa channel 
hyperpolarizes endothelial cells, and K
+
 efflux through these channels can act as a diffusible 
„EDHF‟ like NO and activating the Na+/K+-ATPase and inwardly-rectifying K+-channels 
(KIR) respectively (Absi et al., 2007; Edwards et al., 1998; Sandow et al., 2006).  
 Whilst both IKCa and SKCa channels are expressed on endothelial cells, these channels 
are also located in different endothelial microdomains and mediate VSMC hyperpolarization 
via distinct downstream pathways (Absi et al., 2007; Dora et al., 2008; Sandow et al., 2006). 
The SKCa channel is located in the caveolar compartment and preferentially activates the KIR 
channel on the VSMC (Absi et al., 2007). This is supported by the observations that VSMC 
hyperpolarizations, due to the selective opening of endothelial SKCa channels by CyPPA, are 
specifically abolished by either apamin or a KIR selective inhibitor, barium (Weston et al., 
2010). On the other hand, the IKCa channels are not reside in the caveolar compartments 
(Weston et al., 2008) and are highly expressed within the endothelial cell projections that 
traverse the internal elastic lamina (Dora et al., 2008; Sandow et al., 2006). The opening of 
IKCa channels causes VSMC hyperpolarization specifically by stimulation of Na
+
/K
+
-ATPase 
(Dora et al., 2008). 
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 The concept of the efflux of K
+
 as the mediator of EDHF has been well-defined 
(Chrissobolis et al., 2000; Edwards et al., 1998; McNeish et al., 2005). This is, however, not 
the only mediator responsible for EDHF responses. The discovery of specialised 
microdomains signialling in blood vessels has allowed a better understanding of how 
endothelium-derived hyperpolarization responses can be facilitated via the contribution of 
both electrical (coupling through projections for myoendothelial gap junctions (MEGJs)) and 
chemical (changes in extracellular K
+
) mediators (Sandow et al., 2006). High resolution 
immunochemistry data demonstrated that both the MEGJs containing connexins Cx37, Cx40 
and Cx43 and SKCa expression were localized to the adjacent endothelial cells gap junction in 
the rat mesenteric arteries. In contrast, the expression of IKCa are reported to be associated 
with MEGJs containing Cx37 and Cx40 (Sandow et al., 2006). This observation was further 
supported by electrophysiological data which also indicated that IKCa were associated with 
MEGJs (Crane et al., 2003). The importance of specialised microdomains for endothelial-
VSMC communication has also been supported by the observations that the electrical 
coupling between the endothelium and the VSMC via MEGJs can be attenuated by inhibitors 
of direct cell-cell coupling, causing impairment of EDHF-type smooth muscle 
hyperpolarization and relaxation (Edwards et al., 1999; Little et al., 1995; Mather et al., 
2005). Overall, both myo-endothelial electrical coupling and K
+
 were regarded as potential 
candidates for EDHF (Ding et al., 2010; Edwards et al., 2010). These candidates appear 
equally attractive explanations for classical EDHF responses in different preparations, but 
perhaps not in all cases (Ding et al., 2010). Based on the findings in mesenteric arteries, the 
working hypothesis for EDHF responses was proposed by Dora and colleagues wherein 
activation of endothelial cells by endothelium-dependent agonists such as ACh increases 
endothelial cell Ca
2+
 levels. This resulted in the activation of SKCa with consequent spread 
through MEGJs and, dependent on Ca
2+
 levels in the region of endothelial cell projections, 
following the subsequent activation of IKCa (Ding et al., 2010; Dora, 2010; Dora et al., 2008). 
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Upon activation of IKCa, within the endothelial cell projections, there is then sufficient 
endothelial cell K
+
 efflux to stimulate VSMC Na
+
/K
+
-ATPase and possibly KIR to result in 
hyperpolarization of VSMC (Ding et al., 2010; Dora, 2010; Dora et al., 2008). Taken 
together, these two classical EDHF pathways may act separately, in parallel or even 
synergistically. In any case, both pathways require activation of endothelial KCa channels as 
the initiation of the EDHF process (Ding et al., 2010). 
 
1.2.3.2 Non-classical EDHF type responses 
 As described earlier, the classical EDHF-type response involves the opening of the 
endothelial KCa channels. In contrast, the non-classical EDHF-type response causes VSMC 
hyperpolarization and thus relaxation independently of endothelial KCa channels. Thus, it is 
also proposed that when the endothelial cells are stimulated by local hormones such as ACh, 
bradykinin, substance P or histamine or by shear stress, factors such as nitrogen oxides (NO 
and nitroxyl (HNO)), epoxyeicosatrienoic acids (EETs) or hydrogen peroxide (H2O2), leading 
to VSMC hyperpolarization and relaxation (Andrews et al., 2009; Bolotina et al., 1994; 
Edwards et al., 2000; Matoba et al., 2000).  
 It is widely recognized that NO is an endothelium-derived relaxing factor, causing 
relaxation via the activation of sGC (Palmer et al., 1987), however, there is also evidence to 
suggest that NO causes VSMC hyperpolarization via the opening of a number of K
+
 channels 
including maxi KCa channels (Bolotina et al., 1994; Plane et al., 1998; Tare et al., 1990). 
Together with NO, the one electron reduced and protonated form of NO, HNO is formed 
endogenously and contributes to endothelium-dependent relaxation and hyperpolarization 
(Andrews et al., 2009; Ellis et al., 2000a; Wanstall et al., 2001). The hyperpolarizing effects 
of HNO are partially blocked by iberiotoxin or 4-aminopyridine, suggesting the involvement 
of both maxi KCa and voltage-gated K
+
 (KV) channels respectively (Andrews et al., 2009; 
Favaloro et al., 2009; Yuill et al., 2011). 
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EETs are cytochrome P450 metabolites of AA that are produced by the vascular 
endothelium in response to agonists such as bradykinin and ACh or physical stimuli such as 
shear stress or cyclic stretch (Fisslthaler et al., 1999). There is evidence to suggest that EETs 
activate KCa channels on VSMC and the endothelium causing membrane hyperpolarization 
and relaxation (Baron et al., 1997; Earley et al., 2005; Earley et al., 2009; Edwards et al., 
2000; Fleming et al., 2007; Weston et al., 2005). In porcine coronary arteries, bradykinin 
generates the endothelial release of 11,12 EET and 14,15 EET which produces EDHF 
responses that involve activation of both endothelial SKCa and IKCa, as well as  maxi KCa-
dependent VSMC hyperpolarization. This action could be inhibited by both iberiotoxin and 
the EET antagonist 14,15-EEZE (Edwards et al., 2000; Weston et al., 2005). Furthermore, 
experiments have demonstrated the ability of EETs to activate maxi KCa channels in the 
VSMC (Baron et al., 1997; Edwards et al., 2000). The mechanism underlying maxi KCa 
activation by EETs remains controversial and likely to be dependent on the isoform being 
investigated, but the most physiologically relevant pathway is likely to involve activation of 
transient receptor potential (TRP) channels. The activation of TRP channels causes Ca
2+
 entry 
into the VSMC, leading to the release of Ca
2+
 from ryanodine sensitive Ca
2+
 stores and 
subsequently resulting in the elevation of Ca
2+
 levels. The rise in local Ca
2+
 levels activates 
maxi KCa, causes VSMC hyperpolarization and relaxation (Earley et al., 2005; Edwards et al., 
2010; Watanabe et al., 2003). In addition to activation of TRP channels in VSMC, EETs can 
also activate TRP channels on the endothelium to cause endothelial hyperpolarization 
subsequently causing VSMC hyperpolarization (Earley et al., 2009; Fleming et al., 2007). 
Taken together, these effects indicate that EETs exhibit both classical and non-classical 
EDHF responses however, this is not a universal finding as the mechanism of EET action 
varies according to the arteries studied (Baron et al., 1997; Earley et al., 2009; Edwards et al., 
2010; Edwards et al., 2000; Fleming et al., 2007; Watanabe et al., 2003; Weston et al., 2005). 
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H2O2 is formed by the reduction of superoxide anions; either spontaneously or through 
the enzyme Cu–Zn superoxide dismutase (SOD). Studies have demonstrated that H2O2 elicits 
relaxation and hyperpolarization of VSMC of mouse mesenteric arteries by opening KCa 
channels and that ACh causes endothelial H2O2 production in mouse mesenteric arteries. This 
EDHF-mediated relaxation and hyperpolarization is inhibited by catalase, an enzyme that 
metabolizes H2O2, in mesenteric arteries of normal mice and are significantly reduced in 
eNOS
−/−
 mice, confirming that H2O2 is derived from eNOS (Fujiki et al., 2005; Matoba et al., 
2000). Based on the studies performed, evidence has been obtained that the hyperpolarizing 
effect of eNOS-derived H2O2 involves, at least in part, the activation of maxi KCa (Barlow et 
al., 1998) and  KATP channels (Wei et al., 1996), which allowed H2O2 to be considered as an 
EDHF candidate. 
 
1.2.4 Endothelium-derived contracting factors 
 Apart from causing relaxation, the endothelial cells can initiate contraction of the 
underlying VSMCs in responses to endothelium-dependent agonist such as ACh, ATP and the 
calcium ionophore A23187 in variety of vascular preparations (Félétou et al., 2010; Feletou et 
al., 2009; Vanhoutte et al., 2009). Although the endothelium can synthesize ET-
1(Yanagisawa et al., 1988a; Yanagisawa et al., 1988b) and other non-prostanoid 
vasoconstrictor substances (Félétou et al., 2010; Vanhoutte et al., 2009), the available 
evidence strongly suggests that vasoconstrictor prostanoids produced by COX in the 
endothelium explain most of the endothelium-dependent contractions (Vanhoutte et al., 2009; 
Wong et al., 2010). 
 
1.2.4.1 Endothelin-1 
 First reported in 1988, the endothelium-derived contracting factor, ET-1, is one of 
most potent vasoconstrictors known (Yanagisawa et al., 1988a; Yanagisawa et al., 1988b). 
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ET-1 elicits its effects through two receptors, which is ETA receptors, located in VSMC 
mediate contraction, whereas ETB receptors, located on vascular endothelial cells, mediate 
dilation and ET-1 uptake, and regulate ET-1 production (Arai et al., 1990; Dashwood et al., 
1998; Farhat et al., 2008; Sanchez et al., 2002). Additionally, ETB receptors are expressed on 
VSMC and elicit contraction (Sanchez et al., 2002; Teerlink et al., 1994). ET-1 is not only a 
potent vasoconstrictor, but also proinflammatory and promotes VSMC proliferation 
(Anggrahini et al., 2009). The production of ET-1 is regulated at a gene level and can be 
upregulated by a number of physical and chemical factors, including low shear stress, 
hypoxia, angiotensin II, growth factors, and ROS (Kähler et al., 2001; Kourembanas et al., 
1993; Maemura et al., 1992). By contrast, the expression of ET-1 can be downregulated by 
NO, PGI2, and shear stress (Boulanger et al., 1990; de Nucci et al., 1988; Lüscher et al., 
1990). Overall, the endothelium-derived ET-1 is produced constitutively and acts in concert 
with other endothelium-derived factors to maintain vascular homeostasis. 
 
1.2.4.2 Endoperoxides/Prostanoids 
 Beside ET-1, the endothelial cells can synthesize other endothelium-derived 
contracting factors such as metabolities of AA. The enzyme COX metabolizes AA into 
endoperoxides, which are the precursors of all isoforms of prostaglandins. There are two 
isoforms of COX, namely COX-1 and COX-2 (Garavito et al., 1999). Evidence from studies 
using pharmacological tools have demonstrated activation of COX-1 is preferred over COX-2 
in mediating endothelium-dependent contractions, as selective inhibitors of COX-1 abolished 
endothelium-dependent contractions, while the selective COX-2 inhibitor only modestly 
reduced the contractile response (Ge et al., 1995; Tang et al., 2009; Yang et al., 2003; Yang et 
al., 2004). Furthermore, using genetic models, endothelium-dependent contractions were 
observed in aortae of COX-2 but not in COX-1 knockout mice. This finding is in consistent 
with pharmacological evidence earlier that the requirement of COX-1 for mediated  
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endothelium-dependent contractions (Tang et al., 2005; Tang et al., 2009). Endoperoxides are 
the immediate products of COX, which are converted into PGI2, thromboxane A2, 
prostaglandin D2, prostaglandin E2 and/or prostaglandin F2α either spontaneously or 
enzymatically by their respective synthases (Bos et al., 2004; Tang et al., 2009). The COX-
derived contracting factors and endoperoxide itself diffuses to the underlying smooth muscle 
to interact with specific seven transmembrane, G-protein-coupled receptors, which are 
classified in five subtypes, that are DP, EP, FP, IP, and TP receptors, according to their 
sensitivity to the five primary prostanoids, prostanglandins D2, E2, F2α, I2, and thromboxane 
A2, respectively (Bos et al., 2004; Coleman et al., 1994). Although thromboxane A2 is the 
preferential physiological ligand of the TP receptor (Félétou et al., 2010; Kiriyama et al., 
1997), endoperoxide and the other prostaglandins, with a range of potencies, can also activate 
this receptor (Félétou et al., 2010; Gluais et al., 2005). The stimulation of TP receptors 
promotes calcium entry into VSMC through receptor-operated channels and voltage gated 
calcium channels, leading to increase Rho-kinase mediated sensitization of the myofilaments 
(Okon et al., 2002; Tang et al., 2009). This increases the calcium concentration in the VSMC 
causes contraction. In addition to vasoconstriction, stimulation of TP receptors also causes 
platelet aggregation (Saussy et al., 1985). Furthermore, the activation of TP receptors 
promotes the expression of adhesion molecules and infiltration of monocytes/macrophages 
(Félétou et al., 2010; Nakahata, 2008). As discussed earlier, under normal conditions, PGI2 is 
a potent vasodilator but under pathphysiological conditions such as aging and hypertension, 
the ability of PGI2, or its stable analog iloprost, to induce relaxation is impaired due to 
dysfunction of the IP receptors (Gluais et al., 2005; Levy, 1980; Rapoport et al., 1996).  
Furthermore, in aging and hypertension, the protein expression of PGI2 synthase is enhanced, 
causing an increase in PGI2 concentrations that evoke endothelium-dependent contraction 
rather than relaxation via the TP receptors (Numaguchi et al., 1999; Tang et al., 2008; 
Williams et al., 1994). 
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1.3 Experimental model of diabetes and aerobic capacity 
 Diabetes is a metabolic disease characterized by hyperglycaemia due to insufficiency 
of secretion or action of endogenous insulin. A number of experimental models of diabetes 
have been developed and used to study diabetes-induced organ damage. In this thesis, three 
types of diabetic models were used: STZ-induced diabetes, obese Zucker rats and rats 
artificially selected for low aerobic capacity.  
 
1.3.1 Streptozotocin (STZ) model of diabetes 
 Type I diabetes is caused by selective destruction of pancreatic beta cells by immune 
cells, leading to a deficiency in the secretion of endogenous insulin. STZ is a chemical that is 
selectively taken up into the pancreatic beta cells via the GLUT2 glucose transporter in the 
plasma membrane. It exerts its diabetogenic action by causing beta cell toxicity through 
alkylation, resulting in beta cell necrosis and insulin deficiency (Lenzen, 2008). Reduction in 
the secretion of endogenous insulin produces a hyperglycaemia phenotype in the animal 
treated with STZ, which mimics type I diabetes. Nevertheless, it should be noted that the 
STZ-treated animals over an extended period may exhibit chronic hyperglycaemia along with 
severe body weight loss and high mortality (Breyer et al., 2005). To avoid these undesirable 
side effects, intermittent insulin treatment may be given to promote weight gain and reduce 
mortality while not acheiving euglycaemia (Kelly et al., 1998). 
 
1.3.2 Obese Zucker rats 
 Type II diabetes involves the insufficient action of endogenous insulin leading to the 
progressive development of mild hyperglycaemia. Type II diabetes is often associated with 
obesity and physical inactivity (World Health Organization, 2011). The obese Zucker (fa/fa) 
rat is developed by the spontaneous mutation of the “fa” gene located in the chromosome 5. 
The obese Zucker rat is characterized by hyperphagia and early onset of obesity together with 
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increased deposition of subcutaneous fat. It is also associated with mild hyperglycaemia, 
insulin resistance, mild glucose intolerance, hyperlipidaemia, hyperinsulinaemia and moderate 
hypertension (Srinivasan et al., 2007).  
 
1.3.3 Artificial selection for low aerobic capacity  
Koch and Britton (2001) developed a novel rodent model for intrinsic aerobic capacity 
where rats were artificially selected for low-capacity runners (LCR) and high-capacity runners 
(HCR).  This model is developed by selecting a population of lowest and highest-capacity rats 
from each sex which are then randomly paired for mating. After 11 and 21 generations of 
selection, the LCR and HCR differed by 347% and 461% in aerobic running capacity 
respectively (Koch et al., 2001). The LCR phenotype is associated with increased 
cardiovascular risk and displayed characteristics of metabolic syndrome, including higher 
blood pressure and elevated free fatty acid, visceral adiposity, triglycerides, insulin resistance, 
decreased insulin sensitivity, glucose intolerance and mild hyperglycaemia (Koch et al., 2008; 
Lessard et al., 2009; Rivas et al., 2011; Wisløff et al., 2005) 
 
1.4 Production of reactive oxygen and nitrogen species in diabetes 
 Normal cellular metabolism of living organisms produces ROS as byproducts which 
can be either beneficial or detrimental to health. The beneficial effects of ROS occur at low 
physiological concentrations and are involved in host defense mechanisms and also in a 
number of cellular signaling pathways.  The detrimental effect of ROS, commonly known as 
oxidative stress, occurs in situations where there is an overproduction of ROS and/or a 
deficiency of antioxidant defense mechanisms, so that the cellular redox balance is in favor of 
the pro-oxidant state versus antioxidant (Fatehi-Hassanabad et al., 2010). There is strong 
evidence that diabetes/hyperglycaemia results in the overproduction of ROS. Excess ROS in 
diabetes can damage cellular DNA, lipids and proteins, thereby inhibiting normal cellular 
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function. For example, excess ROS production in the diabetic vascular endothelium causes 
endothelial dysfunction, which could be an initiating factor in the progression of diabetic 
cardiovascular complications. Cellular enzyme systems that are important sources of ROS 
include NADPH oxidases, eNOS, xanthine oxidase and the mitochondrial respiratory chain. 
These systems are discussed in detail below.  
 
1.4.1 Types of reactive oxygen and nitrogen species  
 Reactive oxygen and nitrogen species can exist as free radicals or non-radicals. Free 
radicals are molecules containing one or more unpaired electrons, which have a high degree 
of reactivity. In mammalian cells, molecular oxygen is used as a terminal electron acceptor to 
metabolized organic carbon to provide energy. Thus, the most important class of free radicals 
are derived from oxygen. The major ROS include free radicals such as superoxide anion (O2˙
-
) and the hydroxyl radical (˙OH), and the non-radicals H2O2 and peroxynitrite (ONOO
-
).  
 
1.4.1.1 Superoxide anion 
 Superoxide anion is the primary source of ROS and it is able to interact with other 
molecules either directly or indirectly through enzymes or metal catalyzed processes to 
promote secondary ROS formation. For example, under normal conditions, superoxide has a 
short half-life and is either rapidly converted to hydrogen peroxide by SOD or to peroxynitrite 
upon reaction with NO (Reiter et al., 2000).   
 
1.4.1.2 Hydroxyl radical 
 The hydroxyl radical is the most reactive free radical. It is short-lived and 
indiscriminately oxidizes its closest available target in the cells, including DNA (mutation), 
lipids (lipid peroxidation) and protein (protein oxidation)(Kehrer, 2000). The hydroxyl radical 
is formed chemically by the reactions of the precursor ROS, superoxide and hydrogen 
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peroxide (Haber-Weiss reaction) (Kehrer, 2000). It can also be formed by hydrogen peroxide 
in the presence of reduced metals (Fenton reaction) (Thomas et al., 2009). The chemical 
reactions for hydroxyl radical formation are as following: 
Fenton reaction:  
H2O2 + Fe
2+
/Cu
+
 → Fe3+/Cu2+ + OH- + ˙OH 
Haber-Weiss reaction: 
H2O2 + O2˙
- → O2 + OH
-
 + ˙OH 
 
1.4.1.3 Hydrogen peroxide 
 Hydrogen peroxide is a small, uncharged, non-radical ROS, which is readily mobile 
and freely crosses both cellular and nuclear membranes. In physiological states, H2O2 is either 
produced from oxygen by peroxisomes or as a result of dismutation of superoxide anion by 
SOD. The cells have various enzymes such as catalase, glutathione peroxidase (GPx) and 
thioredoxin which act to reduce H2O2 to H2O.  
 
1.4.1.4 Peroxynitrite 
 Peroxynitrite is formed by the reaction between NO and superoxide. Peroxynitrite is a 
potent oxidizing agent that can nitrate and hydroxylate phenolic compounds, especially at 
tyrosine residues (Jourd'heuil et al., 2001; Reiter et al., 2000), which in turn can alter the 
activities of key enzymes (Zou et al., 2002a) and ion channel (Liu et al., 2002b). In addition, 
protonation of peroxynitrite can generate the hydroxyl radical via the following chemical 
reactions (Hogg et al., 1992): 
NO˙ + O2˙
- → ONOO-  
ONOO
- 
+ H
+ → ˙OH + ˙NO2 
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1.4.2 Sources of reactive oxygen and nitrogen species in diabetes 
 Hyperglycaemia causes tissue damage through four major mechanisms: (1) increased 
flux of glucose and other sugars through the polyol pathway; (2) increased intracellular 
formation of advanced glycation end products (AGEs) and binding to its receptor for AGEs; 
(3) activation of protein kinase C (PKC) isoforms; and (4) overactivity of the hexosamine 
pathway. The results from clinical studies in which one of these pathways was inhibited are 
disappointing, as hyperglycaemia-induced tissue damage was not significantly altered 
(Geraldes et al., 2010; Ramasamy et al., 2010). These results suggest that all of these 
pathways could be activated by a single upstream pathway during diabetes. Indeed, several 
lines of evidence indicate that all four mechanisms are activated by a single upstream event, 
that is mitochondrial overproduction of ROS, as by normalizing mitochondrial ROS 
hyperglycaemia-induced tissue damage was reduced (Brownlee, 2001; Nishikawa et al., 
2000a). 
 
1.4.2.1 Mitochondria 
 One of the most important function of mitochondria is oxidative phosphorylation. The 
system of oxidative phosphorylation includes five large multi-enzyme complexes, namely, 
complexes, I, II, III, IV and ATP synthase and the mobile electron carriers, coenzyme Q and 
cytochrome c (Forbes et al., 2008)(Figure 1.4). Under normal conditions, once glucose is 
taken up into the cells, glucose derived pyruvate from glycolysis enters the mitochondria, 
where it is oxidized by the tricarboxylic acid (TCA) cycle to generate nicotinamide adenine 
dinucleotide (NADH) and flavin adenine dinucleotide (FADH2). Electrons derived from 
oxidation of NADH and FADH2 are transferred through the electron transport chain which 
consists of complexes I–IV and finally reach the electron acceptor, molecular oxygen. During 
the process of electron transfer through the chain, protons are pumped across the 
mitochondrial membrane creating a voltage gradient, which is collapsed to generate ATP via 
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the ATP synthase (Forbes et al., 2008). During the electron transport process, the 
mitochondria generate superoxide radical due to the leakage of an electron before it is added 
to an oxygen molecule (Forbes et al., 2008). The two major sites of electron leakage are 
NADH dehydrogenase (complex I) and the interface between coenzyme Q and complex III 
(Turrens et al., 1980). In addition, the proton gradient across the mitochondria membrane is 
also collapsed by the uncoupling protein-1 (UCP-1) which resulted in the reduction of ROS. 
In normal physiological conditions, this system is an important source of ROS and these 
processes are tightly regulated. Nevertheless, under physiological conditions it is estimated 
that approximately 1% of oxygen is reduced to superoxide, instead of fully to water (Forbes et 
al., 2008).  
In the setting of diabetes, where hyperglycaemia is present, there is more pyruvate 
available to be oxidized in the TCA cycle. This pushes more electron donors (NADH and 
FADH2) into the electron transport chain, causing the voltage gradient across the 
mitochondrial membrane to reach a critical threshold (Forbes et al., 2008). In this instance, 
electron transfer within the complex III is disrupted (Korshunov et al., 1997), causing the 
accumulation of electrons at coenzyme Q, which generates superoxide when the electrons 
react with molecular oxygen (Nishikawa et al., 2000a). The overproduction of mitochondrial 
ROS has been recognized as a key initiating factor in the activation of at least three major 
underlying pathways: (1) increased flux of glucose and other sugars through the polyol 
pathway; (2) increased intracellular formation of AGEs and binding to its receptor for AGEs 
and (3) activation of PKC isoforms, which have been shown to further exacerbate the 
condition of oxidative stress in the cytosolic compartments as detailed below (Figure 1.5). 
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Figure 1.4 Schematic diagram of electron transport chain of the mitochrondria. 
Increased hyperglycaemia-derived electron donors (NADH and FADH2) from the 
tricarboxylic acid (TCA) cycle generate a high mitochondrial membrane potential (ΔμH+) by 
pumping protons across the mitochondrial inner membrane. As a result, the increased electron 
flux caused the voltage gradient across the mitochondrial membrane to increase until a critical 
threshold is reached. This inhibits electron transport at complex III, increasing the half-life of 
free-radical intermediates of coenzyme Q (ubiquinone), which reduce O2 to superoxide. 
Figure obtained from (Brownlee, 2001). 
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Figure 1.5 A summary of signaling pathways involved in hyperglycaemia-induced 
diabetic tissue damage. Diabetes increased mitochrondria ROS production, leading to the 
activation of several pathways such as polyol pathway, hexosamine pathway, PKC and AGE 
formation.  Adapted from (Nishikawa et al., 2000a) 
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1.4.2.2 Polyol pathway 
The polyol pathway is based on a family of aldo-keto reductase enzymes that can use 
as substrates a wide variety of carbonyl compounds and reduce these by NADPH to their 
respective sugar alcohols (polyols). Glucose is converted to sorbitol by the enzyme aldose 
reductase. In the situation of diabetes, where there is increased concentration of glucose, 
aldose reductase converts high intracellular glucose concentrations to sorbitol using NADPH 
as cofactor. During hyperglycaemia, it is likely that the consumption of NADPH by this 
reaction inhibits regeneration of reduced glutathione, which is required to maintain GPx 
activity (Forbes et al., 2008). This would ultimately decrease cellular antioxidant activity and 
because NADPH is a cofactor required to regenerate reduced glutathione, and glutathione is 
an important scavenger of ROS, this could induce or exacerbate intracellular oxidative stress 
(Ii et al., 2004; Lee et al., 1999). Indeed, overexpression of human aldose reductase increased 
atherosclerosis in diabetic mice and reduced the expression of genes that regulate regeneration 
of glutathione (Vikramadithyan et al., 2005). 
After the conversion of glucose to sorbitol by the aldose reductase, sorbitol is then 
oxidized to fructose by the enzyme sorbitol dehydrogenase. At the same time, this reduced 
NAD
+
 to NADH, providing increased substrate to complex I of the mitochondrial respiratory 
chain. As discussed earlier, the mitochondrial respiratory chain is a major source of ROS 
production in diabetes, thus by providing additional electrons for transfer to oxygen-forming 
superoxide would increase mitochondrial ROS production (Forbes et al., 2008). 
 
1.4.2.3 Increased intracellular formation of AGEs 
AGEs are formed by the nonenzymatic reaction of glucose and other glycating 
compounds derived both from glucose and from increased fatty acid oxidation with protein. 
At normal physiological levels, the formation of AGEs allows the labeling of senescent 
cellular proteins for their recognition and ultimate turnover, however, in diabetes, due to 
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persistent hyperglycaemia and oxidative stress, the formation of AGEs and its receptors is 
increased (Fu et al., 1994; Thornalley et al., 1999). The binding of AGEs to its receptors 
could upregulate the transcription factor NF-κB, through the activation of cytokines, leading 
to generation of ROS (Wautier et al., 1994; Yan et al., 1994). Thus, diabetes causes a vicious 
cycle of ROS generation, AGE and AGE receptor formation, NF-κB activation, cytokine 
formation and further free radical formation. 
 
1.4.2.4 Activation of PKC 
PKCs are a family of at least 11 isoforms that are widely distributed in mammalian 
tissues. The enzyme phosphorylates various target proteins. The activity of the classic 
isoforms is dependent on both Ca
2+
 ions and phosphatidylserine, and is greatly enhanced by 
diacylglycerol (DAG). Hyperglycaemia causes de novo synthesis of DAG, leading to the 
activation of primarily the β- and δ- isoforms of PKC (Inoguchi et al., 1992), which increase 
stress signaling pathways such as NF-κB, p38 MAPK and Jak/STAT (Haneda et al., 1997). 
Activation of PKC has been implicated in decreased NO production and has been shown to 
inhibit insulin-stimulated expression of eNOS in cultured endothelial cells. In addition, the 
activation of PKC also increases the activity of ROS generating enzymes, such as NADPH 
oxidase, causing endothelial dysfunction which could be reversed by treatment with a PKC 
inhibitor (Hink et al., 2001). 
 
1.4.3 Sources of reactive oxygen and nitrogen species in endothelial cells 
 As introduced earlier, the proper function of the endothelium is important for 
maintaining vascular health. The mitochondria have been shown as the primary source of 
ROS production in diabetes, the increase in production of ROS in the endothelium could also 
be caused by other enzymatic sources present in endothelial cells which may have a more 
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direct impact on vascular health. The important sources of ROS generation in endothelial cells 
include NADPH oxidase, xanthine oxidase and eNOS. 
 
1.4.3.1 NADPH oxidases 
The NADPH oxidase is a cytosolic enzyme complex which is first discovered in 
neutrophils. It has an important role in nonspecific host-pathogen defense by producing 
millimolar quantities of superoxide by electron transport. The enzyme complex is composed 
of five subunits comprising a membrane-associated p22
phox
 and a gp91
phox
 subunit and at least 
four cytosolic subunits: p47
phox
, p67
phox
, p40
phox
, and GTPase rac1 or rac2 (Drummond et al., 
2011; Forbes et al., 2008). This NADPH oxidase is present in vascular tissues and at 
physiological levels, NADPH oxidase-derived superoxide is implicated in modulating 
vascular tone together with influencing vascular cell growth, migration, proliferation, and 
activation (Feng et al., 2010). However, in the numerous cardiovascular diseases including 
diabetes, the activity and expression of NADPH oxidase is upregulated and higher amounts of 
ROS are produced, resulting in oxidative stress (Guzik et al., 2002; Hink et al., 2001; 
Takayama et al., 2004).  
 
1.4.3.2 Xanthine oxidases 
Xanthine oxidase is the enzyme that catalyzes the oxidation of hypoxanthine to uric 
acid using molecular oxygen as the electron acceptor. During this process, there is a number 
of ROS being liberated which includes superoxide, hydroxyl radical, and hydrogen peroxide. 
Localisation studies by immunohistochemistry have shown that xanthine oxidase is located in 
endothelial cells (Jarasch et al., 1981) and electron spin resonance data have confirmed 
xanthine oxidase as an important source of vascular superoxide production in animal models 
of type 1 diabetes (Matsumoto et al., 2003a). 
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1.4.3.3 Endothelial nitric oxide synthase 
There are three major isoforms of NOS, inducible (iNOS), neuronal (nNOS), and 
endothelial (eNOS). All of these enzymes convert L-arginine to L-citrulline and producing 
NO. Both eNOS and nNOS are constitutively expressed in endothelial and neuronal tissue 
respectivity and produce small amounts of NO in a short time. Each of these isoforms requires 
cofactors/prosthetics such as the FMN, BH4, calmodulin, and flavin adenine dinucleotide to 
produce NO. In the absence of either L-arginine or BH4, eNOS can produce superoxide in 
preference to NO. This phenomenon has been referred to as NOS uncoupling (Cai et al., 
2002; Cai et al., 2005; Hink et al., 2001; Ryoo et al., 2008; Zou et al., 2002b). For example, 
under conditions causing oxidative states including diabetes, reduction in levels of BH4 or the 
NOS substrate L-arginine results in uncoupling of eNOS resulting in production of superoxide 
by the eNOS monomer (Cai et al., 2002; Cai et al., 2005; Hink et al., 2001; Ryoo et al., 2008; 
Zou et al., 2002b). 
 
1.4.4 Sources of endogenous antioxidants in diabetes 
 In diabetes, oxidative stress occurs where the cellular redox balance is in favor of the 
pro-oxidant versus antioxidant state. This happens when there is increased production of ROS 
(discussed above) and/or compromised function of endogenous antioxidant systems. There are 
several sources of antioxidant systems present endogenously such as SOD, catalase, GPx and 
thioredoxin. 
 
1.4.4.1 Superoxide dismutase 
 SOD catalyzes the dismutation of superoxide into oxygen and hydrogen peroxide, 
serving a key antioxidant role by preventing superoxide radical-induced cellular damage. 
There are three isoforms of this enzyme which are located in different compartments within 
the cell: (1) copper-zinc SOD (SOD 1) is located in the cytoplasm, (2) manganese SOD (SOD 
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2) is located in the mitochondria and (3) there is also extracellular copper-zinc SOD (SOD3). 
Several lines of evidence indicate that the antioxidant activity of SOD is compromised in 
diabetes to, at least in part, contribute to oxidative stress. For example, Ding et al., (2007) 
demonstrated that the expression of SOD 1 and SOD 3 were decreased in hyperglycaemic 
conditions, contributing to oxidative stress (Ding et al., 2007a). Overproduction of ROS in 
mitochondria in diabetes has also been implicated with decreased SOD 2 activity and 
upregulation of SOD 2 expression normalized ROS production in the mitochondria 
(Nishikawa et al., 2000a). 
 
1.4.4.2 Glutathione peroxidase 
The biochemical function of GPx is to reduce lipid hydroperoxides to their 
corresponding alcohols and to reduce free hydrogen peroxide to water. The most abundant 
isoform of GPx is GPx1 which is found in the cytoplasm of nearly all mammalian tissues. In 
diabetes, the expression of GPx has been reported to be decreased (Shi et al., 2008). 
Furthermore, GPx has also been shown to have a protective role against diabetes associated 
atherosclerosis. For instance, in ApoE knockout diabetic mice, the additional deletion of 
GPx1 accelerated the progression of atherosclerosis via upregulation of proinflammatory and 
profibrotic pathways (Lewis et al., 2007; Torzewski et al., 2007). Treatment with ebselen, a 
GPx1 mimetic, in these double knockout diabetic mice reduced the progression of 
atherosclerosis (Chew et al., 2010).  
 
1.4.4.3 Catalase 
 The enzyme catalase promotes the degradation of hydrogen peroxide to water and 
oxygen. Despite an increased expression of catalase in diabetes, the activity was reduced, 
thereby contributing to oxidative stress (Shi et al., 2007b; Shi et al., 2008).  
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1.4.4.4 Thioredoxin 
The thioredoxin system has recently been recognized as a critical system for 
maintaining cellular redox balance in endothelial cells and vascular smooth muscle. Oxidized 
cysteine groups on protein can be reduced by the thioredoxin system (thioredoxin, thioredoxin 
reductase, and NADPH) through an interaction with the redox-active center of thioredoxin 
(Cys-Gly-Pro-Cys). During this process, a disulfide bond is formed, which in turn can be 
reduced by thioredoxin reductase and NADPH. Thioredoxin seems to exert most of its 
antioxidant properties through thioredoxin peroxidase, which uses SH groups as reducing 
equivalents. Thioredoxin reduces the oxidized form of thioredoxin peroxidase, and the 
reduced thioredoxin peroxidase scavenges ROS such as hydrogen peroxide (Yamawaki et al., 
2003). The antioxidant activity of thioredoxin is modulated by the thioredoxin-interacting 
protein, the endogenous inhibitor of thioredoxin. Several studies have demonstrated that 
diabetes increases the expression of thioredoxin-interacting protein (TXNIP) and inhibits the 
antioxidant activity of thioredoxin, thereby contributing to oxidative stress (Qi et al., 2009; 
Tan et al., 2011).  
 
1.5 Endothelial dysfunction in diabetes 
Endothelial dysfunction is recognized as an early and independent predictor of poor 
prognosis in many forms of cardiovascular diseases. It plays a critical role in the initiation of 
cellular events leading to the development of vascular complications in many forms of 
cardiovascular diseases including diabetes (De Vriese et al., 2000; Ding et al., 2010). 
Endothelial dysfunction is characterized by, and broadly defined as the impairment of a blood 
vsessl to cause relaxation in response to an endothelium-dependent vasodilator, such as ACh 
or bradykinin, or to flow-mediated vasodilatation (De Vriese et al., 2000; Ding et al., 2010). 
Both agonist-induced and flow-mediated vasodilatation can be used to measure endothelial 
function in human through the use of either noninvasive or invasive techniques. Besides the 
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diminished production and function of endothelium-derived relaxing factors such as NO, 
EDHF and PGI2, there are also changes in the expression of adhesion molecules, 
proinflammatory molecules and overproduction of vasoconstrictors including ET1, ROS, and 
COX-derived metabolites of AA. The combined effects of all these factors have 
pathophysiological consequences leading to the development of endothelial dysfunction. For 
instance, in diabetic arteries, reduced endothelium-dependent relaxation is often accompanied 
by increased expression of proinflammatory molecules and ROS production. Collectively, it is 
the combination of diminished responses to endothelium-dependent stimuli and increased 
production of proinflammatory molecules that defines endothelial dysfunction and leading to 
the development of diabetic micro- and macro-vascular disease. The mechanism underlying 
vascular dysfunction in diabetes has been extensively investigated in humans and in animal 
models of diabetes, but single pathway has been identified as the primary mechanism that 
links diabetes to vascular disease (De Vriese et al., 2000; Ding et al., 2010; Vanhoutte et al., 
2009). Thus, in the following section the possible mechanisms that contribute to endothelial 
dysfunction in diabetic vascular diseases are outlined.  
 
1.5.1 Glucose-induced daamge 
 Diabetes is characterized by an elevation of blood glucose levels, the primary link to 
diabetes-induced vascular disease. Endothelial cells universally express a number of glucose 
transporters, such as GLUT1-5, and the sodium-dependent glucose transporter, SGLT-1. The 
GLUT transporters were expressed in different levels in different vascular beds and 
expression levels can be altered by diabetes (Ding et al., 2010; Gaudreault et al., 2006; 
Gaudreault et al., 2004). For example, in STZ-induced diabetic rats, expression of GLUT2 
transporters was upregulated in coronary arteries (Ding et al., 2010; Gaudreault et al., 2004). 
The upregulation of GLUT transporters in the diabetic coronary arteries would increase 
glucose transport into endothelial cells, thus enhancing glucose-induced toxicity. It was 
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proposed that transport of glucose into the endothelial cell leads to the initiation of glucose-
induced changes in endothelial cell function (Ding et al., 2010; Gaudreault et al., 2004). As 
described in detail earlier, hyperglycaemia-induced ROS and endothelial dysfunction can be 
manifested, subsequent to glucose metabolism, via multiple mechanisms that include 
activation of the polyol pathway, glucose auto-oxidation, alterations of cellular redox state, 
increased formation of DAG and activation of PKC, as well as the nonenzymatic formation of 
AGEs (Brownlee, 2001; Ding et al., 2010; Nishikawa et al., 2000a). Indeed, a number of 
studies have demonstrated that incubation of isolated blood vessels in a high concentration of 
glucose (Doriga et al., 1997; Kawano et al., 1999; Qian et al., 2006; Tesfamariam et al., 
1992a) or acute hyperglycaemia by glucose loading in healthy human subjects (Akbari et al., 
1998; Kawano et al., 1999) impairs ACh-induced endothelium-dependent relaxation in 
conduit and resistance arteries. 
In addition, a serious consequence of hyperglycaemia known as “hyperglycaemic 
memory”, is a phenomenon where, even after glycaemic control has been monitored in a 
diabetic patient, the effects of the prior hyperglycaemia insult continue to develop (Cooper et 
al., 2010; Ding et al., 2010; Pirola et al., 2010). Recently, hyperglycaemia has been shown to 
result in long-lasting epigenetic modifications that lead to changes in chromatin structure and 
gene expression, which mediate persistent gene-activating events (Brasacchio et al., 2009; 
Cooper et al., 2010; El-Osta et al., 2008; Pirola et al., 2010). Recent studies have shown that 
in both in vitro and  nondiabetic mice, brief period of hyperglycaemia activates long-lasting 
epigenetic changes in the promoter of the NF-κB subunit p65 in aortic endothelial cells 
leading to the increased level of p65 gene expression (El-Osta et al., 2008). In addition, the 
persistent upregulation of the NF-κB -p65 gene was associated with the modulation of gene-
activating epigenetic marks that coexist on the lysine tail (Brasacchio et al., 2009). Both the 
epigenetic changes and the gene expression changes sustain for at least 6 days of subsequent 
normal glycaemia. This was also the case for NF-κB-induced increases in monocyte 
Chapter 1-Literature review 
36 
 
chemoattractant protein-1 (MCP-1) and vascular cell adhesion molecule-1 (VCAM-1) 
expression. Reducing mitochondrial superoxide production prevented hyperglycaemia-
induced epigenetic changes and increased p65 expression (El-Osta et al., 2008).  
 
1.5.2 Diminished NO bioavailability 
 The bioavailability of endothelium-derived NO is defined by a relative excess of NO 
in comparison to ROS levels, which is a critical indicator of endothelial function. Any 
circumstances in which there is reduced NO levels and/or increased ROS production can lead 
to reduce NO bioavailability and thus impairment of endothelium-dependent relaxation 
(Vanhoutte et al., 2009). The mechanisms underlying the reduced NO-dependent dilatation in 
diabetes include: (1) increased production of superoxide anions and thus scavenging of NO 
and increased presence of peroxynitrite; (2) decreased synthesis of NO by eNOS; (3) 
increased activity of arginase competing with eNOS for the common substrate, L-arginine; (4) 
elevated levels of the endogenous inhibitor of eNOS, asymmetric dimethylarginine (ADMA) 
and (5) reduced bioavailability of BH4 and uncoupling of eNOS which will be discussed in 
detail later. 
 
1.5.2.1 Direct inactivation of NO 
 In diabetic arteries, the overproduction of ROS has been shown to cause direct 
inactivation of NO activity. Indeed, many studies have demonstrated that diabetes causes an 
increase in expression and/or activity of pro-oxidant enzymes, thus increasing superoxide 
production and attenuating endothelium-derived NO-dependent relaxation (Ding et al., 2007a; 
Ding et al., 2005; Guzik et al., 2000; Kitada et al., 2003; Malakul et al., 2007; Woodman et 
al., 2009; Woodman et al., 2008).  
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1.5.2.2 eNOS expression and phosphorylation 
Apart from direct inactivation of NO by superoxide, NO synthesis can be inhibited at 
an enzymatic level. Diabetes-induced endothelial dysfunction may be attributed to the 
alteration in eNOS expression. In this regard, however, it still remain  controversial as studies 
using cultured endothelial cells and/or isolated blood vessels have shown that the expression 
of eNOS could be decreased (Okon et al., 2005; Srinivasan et al., 2004), unchanged 
(Matsumoto et al., 2006; Pannirselvam et al., 2006) or increased (Ding et al., 2007a; Hink et 
al., 2001) in diabetes. The phosphorylation of eNOS at Ser
1177
 activates the enzyme and 
causes NO production. The phosphorylation of eNOS at Ser
1177
 is found to be decreased in 
diabetic mouse aortae (Zhang et al., 2009; Zhong et al., 2007b) and renal arteries (Zhong et 
al., 2007a), causing decreased NO synthesis.  
 
1.5.2.3 Increased arginase activity 
The enzyme arginase catalyzes the hydrolysis of L-arginine into ornithine and urea, 
thereby acting as an endogenous competitive inhibitor of eNOS for the common substrate, L-
arginine. In diabetes, Romero et al., (2008) showed that the expression and activity of 
arginase was increased, leading to impairment of endothelium-dependent relaxation which 
could be reversed with acute treatment of arginase inhibitors. Similarly, arginase activity was 
increased in endothelial cells when incubated with high glucose medium (25 mM, 24 hr), 
leading to diminished NO production. The augmented arginase activity and diminished NO 
production in high glucose-treated cells was prevented by transfecting endothelial cells with 
arginase I small interfering RNA. This suggested that there is a role of arginase I in reduced 
NO production associated with diabetes (Romero et al., 2008).  
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1.5.2.4 Increased levels of ADMA 
 ADMA is an endogenously produced molecule that inhibits NOS enzyme which 
could modulate NO synthesis. In diabetes, there is an elevation in ADMA levels which is 
associated with an impairment of vasodilatory responses to endothelium-dependent dilators in 
aortic rings (Xiong et al., 2003). The accumulation of ADMA in diabetes is accompanied by a 
reduction in the activity of dimethylarginine dimethylaminohydrolase (DDAH), an enzyme 
that degrades ADMA, leading to impaired NO activity (Lin et al., 2002). Restoration of 
DDAH activity, by either drug treatments or overexpression of DDAH enzyme by gene 
transfer, significantly decreased ADMA levels, leading to increased NO synthesis and 
improved endothelium-dependent relaxation in diabetic aortae (Lu et al., 2010; Xiao et al., 
2009; Yin et al., 2005). 
 
1.5.2.5 eNOS uncoupling and BH4 
BH4 is synthesized by the rate-limiting enzyme guanosine 5-triphosphate 
cyclohydrolase I (GTPCH-1) which is an essential co-factor in the regulation of eNOS to 
synthesize NO (Ding et al., 2010). In the vascular wall, there is approximately 60% of the 
BH4 associated with the endothelium and is regulated by shear stress, thus the levels of BH4 is 
an important indicator of endothelial function (Ding et al., 2010; Harrison et al., 2010; 
Tsutsui et al., 1996; Widder et al., 2007). Under physiological conditions, eNOS exist as a 
dimer which is stabilised by appropriate levels of BH4; otherwise, eNOS destabilised into a 
monomeric state and behaves like NADPH oxidase, in which molecular oxygen becomes an 
electron acceptor rather than L-arginine (Cai et al., 2005). When eNOS exist in a monomeric 
state, the phenomenon of eNOS uncoupling occurs, where eNOS produces superoxide rather 
than NO (Cai et al., 2005). The actual levels of BH4 were less important as it was 
demonstrated that the ratio of BH4 to oxidized 7,8- dihydrobiopterin (BH2) is critical for the 
maintenance of optimal endothelial function (Ding et al., 2010). Indeed, Pannirselvam et al. 
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(2003) reported that BH2 levels were significantly increased in mesenteric arteries from 
diabetic mice in comparison to non-diabetic control animals. Whlist the levels of BH4 were 
not significantly reduced in the blood vessels from diabetic mice, the BH4/BH2 ratio was 
significantly attenuated (Ding et al., 2010; Pannirselvam et al., 2003). In support of this 
observation, Crabtree and coworkers reported that both BH4 and BH2 have similar binding 
affinity to eNOS, thus BH2 is able to readily displaces bound BH4 from eNOS to promote an 
uncoupled eNOS-BH2 complex to reduce NO generation, further confirming the importance 
of BH4/BH2 ratio rather than the actual levels of BH4 in maintaining endothelial function 
(Crabtree et al., 2008; Crabtree et al., 2009; Ding et al., 2010). A number of studies have 
demonstrated that endothelial dysfunction resulting from a reduction in NO bioavailability via 
eNOS uncoupling is linked to a reduced tissue BH4/BH2 ratio, and these deficiencies are 
corrected by dietary provision of the BH4 precursor, sepiapterin or BH4 supplementation (Cai 
et al., 2002; Cai et al., 2005; Ding et al., 2010; Hink et al., 2001; Pannirselvam et al., 2003). 
In addition to hyperglycaemia-induced overproduction of ROS formation and subsequent 
reduction in BH4/BH2 ratio, it has also been shown that peroxynitrite triggered the 
ubiquitination and 26S proteasome-dependent degradation of GTPCH-1 in diabetic arteries, 
causing a further reduction in BH4/BH2 ratio (Wang et al., 2009b; Xu et al., 2007). Inhibition 
of eNOS or the 26S proteosome inhibited all of these hyperglycaemia-induced damage to the 
endothelium (Xu et al., 2007). Similarly, the SOD mimetic, tempol, also reverses diabetes-
induced reduction of GTPCH-1 and BH4 in STZ-induced diabetic mice (Ding et al., 2010; Xu 
et al., 2007). 
Besides the BH4 biosynthetic pathway, BH4 recycling via dihydrofolate reductase 
(DHFR) is now recognized as an important pathway for regenerating BH4 from BH2 and 
maintaining eNOS in its dimerized state (Crabtree et al., 2011; Crabtree et al., 2009; Ding et 
al., 2010). Whether the changes in the expression levels of DHFR contribute to diabetes-
related eNOS uncoupling remains inconclusive (Ding et al., 2010). Several studies have 
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shown that the expression of DHFR is decreased in diabetic tissues (Oak et al., 2007; Ren et 
al., 2008; Yamamoto et al., 2010). In contrast, Wenzel and coworkers reported that the 
expression of DHFR is increased in diabetic aorta (Wenzel et al., 2008). Despite the 
differences of DHFR expression reported, all of the studies have demonstrated that the ratio of 
BH4/BH2 was decreased in diabetes and endothelial dysfunction was associated with eNOS-
uncoupling (Oak et al., 2007; Ren et al., 2008; Wenzel et al., 2008; Yamamoto et al., 2010). 
 
1.5.3 Diminished EDHF responses 
In order to examine the contribution of EDHF to endothelium-dependent relaxation, 
most investigations involve the prior inhibition of the generation of NO and PGI2, and thus, 
these studies often reported selective changes to the contribution of EDHF to endothelium-
dependent relaxation in disease states such as in diabetes (Fukao et al., 1997; Matsumoto et 
al., 2003b; Matsumoto et al., 2005). It is important to note, however, that in these studies the 
relative contribution of NO and EDHF is often overlooked as the experiments were conducted 
after inhibition of the generation of NO and PGI2.  In addition, the studies that examined the 
relative contribution of NO and EDHF to endothelium-dependent relaxation in diabetic 
mesenteric arteries produced inconsistent findings (Shi et al., 2006; Wigg et al., 2001). For 
example, a study by Shi et al., (2006) suggested that the contribution of EDHF is increased to 
provide some compensation for the loss of NO  (Shi et al., 2006) whereas Wigg and 
coworkers reported that the contribution of EDHF is selectively impaired as the contribution 
of NO is not affected by diabetes (Wigg et al., 2001). 
As discussed earlier, the nature of EDHF is complex and dependent on the vascular 
beds investigated. Many studies have attempted to investigate the underlying cellular 
mechanism responsible for impaired EDHF responses in diabetic arteries. Possible pathways 
responsible for diminished EDHF responses in diabetes include either altered KCa channel 
expression or activity or impaired MEGJ expression or activity.  
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1.5.3.1 Altered KCa channel expression or activity 
The initiation of EDHF responses requires the activation of endothelial KCa channels, 
thus changes to the expression and/or function of KCa channels could alter the contribution of 
EDHF to endothelium-dependent relaxation. The expression level of endothelial KCa channels 
and its correlation with impaired EDHF responses have been extensively studied in diabetic 
arteries, however, there has been a lack of consistent data (Brøndum et al., 2010; Burnham et 
al., 2006; Ding et al., 2005; Pannirselvam et al., 2006). For example, Ding et al., (2005) 
showed that impaired EDHF-mediated relaxation in STZ-induced diabetic ApoE-deficient 
mice was associated with a reduced expression of SKCa2 and SKCa3 channels (Ding et al., 
2005). In contrast, Burnham et al., (2006) reported that expression of SKCa3 channels was 
increased in small mesenteric arteries from insulin resistant Zucker fatty rats despite an 
impaired EDHF response (Burnham et al., 2006). Several other studies reported no difference 
in expression levels for endothelial KCa channels when compared to tissues from non-diabetic 
controls but reported impaired EDHF responses in diabetic arteries (Brøndum et al., 2010; 
Pannirselvam et al., 2006). It is important to note that the measurement of protein expression 
(even gene expression) of the endothelial KCa channels has the common assumption that the 
molecular weight of the native single channels is indicative of the functional channel 
(Brøndum et al., 2010; Hilgers et al., 2007). This is however not the case, as high molecular 
weight complexes of these channels constitute the functional channel in intact tissue (Chadha 
et al., 2010). A recent study has evaluated the functional SKCa and IKCa expression of such 
complexes (and not monomers) in mesenteric arteries using a model of obesity-induced 
insulin resistance (Haddock et al., 2011). In this study, Haddock et al., (2011) reported that 
the functional expression of the IKCa channel is increased in obese animals but the 
contribution of EDHF to endothelium-dependent relaxation is decreased in the mesenteric 
arteries. The impairment of EDHF responses in the obese mesenteric arteries is due to the 
decreased expression and/or activity of the KIR channel, which is a downstream effect of 
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SKCa-mediated EDHF responses (Haddock et al., 2011). In addition, vasodilatation to K
+
 ions 
has also been reported to be decreased in diabetic mesenteric arteries, indicating that the 
activity of KIR channel and/or Na
+
-K
+
-ATPase is decreased in diabetes (Makino et al., 2000b). 
Taken together, these studies demonstrate that EDHF responses are impaired in diabetic 
arteries despite the inconsistent data regarding the expression level of endothelial KCa 
channels, indicating that the activity/function of the endothelial KCa channels is a more 
important indicator of EDHF responses rather than endothelial KCa channel expression level. 
 
1.5.3.2 Impaired MEGJ expression or activity 
 Myo-endothelial cell communication can also be directly affected in diabetes by 
altering the expression and/or distribution of key vascular connexins of the MEGJs to reduce 
EDHF responses. In small mesenteric arteries from db/db type 2 diabetic mice, the gene 
expression for the key vascular connexins, Cx37, Cx40, Cx43, Cx45 levels are reported to be 
unaffected, but the contribution of EDHF to endothelium-dependent relaxation is reduced in 
diabetes (Pannirselvam et al., 2006). In contrast to several other studies, Cx37 expression has 
been demonstrated to be reduced in small mesenteric arteries from STZ-induced type 1 
diabetic ApoE-deficient mice (Ding et al., 2005). Similarly, in the STZ-induced diabetic 
animals, endothelial gap junctions involving Cx37 and Cx40 protein expression are reduced in 
the aorta (Hou et al., 2008) and coronary arteries (Makino et al., 2008), suggesting a 
correlation between diabetes-induced impairment of EDHF responses and connexin 
expression. In addition, both gene and protein levels of Cx40, in combination with EDHF 
responses, are reduced in small mesenteric arteries from insulin-resistant obese Zucker rats 
(Young et al., 2008). Alteration of the vascular connexin expression has a detrimental effect 
on the myo-endothelial cell communication. Indeed, a previous study has demonstrated a 
positive correlation between the expression levels of Cx40 and Cx37 in the cremaster 
arterioles using Cx40-deficient mice (de Wit, 2010). In Cx40-deficient mice, it was shown 
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that Cx37 expression is also decreased and conduction of activated endothelium-dependent 
vasodilation in mouse cremaster arterioles is impaired (de Wit, 2010; Figueroa et al., 2003). 
Thus, diabetes-induced reduction of Cx40 expression will result in a decrease in Cx37 
expression, leading to the impairment of EDHF responses. In addition to Cx37 and Cx40, 
Cx43 expression can also be affected by diabetes. High glucose activates PKC-mediated 
phosphorylation of Cx43, can inhibit gap junction intercellular communication in bovine 
aortic VSMC (Kuroki et al., 1998). Similarly, in rat microvascular endothelial cells, high 
glucose concentrations caused a reduction in gap junction intercellular communication 
activity which is associated with a reduction in Cx43 mRNA and protein expression (Sato et 
al., 2002). Therefore, alteration in the expression and/or regulation of the connexins that 
involved in the MEGJs and impairment of the EDHF responses may play an important 
contribution to the development of endothelial dysfunction in diabetes (Ding et al., 2010). 
 
1.5.4 Augmented EDCF production 
As discussed earlier, the endothelium synthesizes EDCF to cause VSMC contraction 
through a COX-dependent pathway. A number of studies have demonstrated that the 
production of EDCF is augmented in diabetes, contributing to endothelial dysfunction which 
can be inhibited by either indomethacin or TP receptor blockers, suggesting a role for COX-
derived prostanoids (Shi et al., 2007a; Shi et al., 2007b; Shi et al., 2008; Tesfamariam et al., 
1990; Tesfamariam et al., 1992b). Indeed, Tesfamariam et al., (1990) demonstrated that 
incubation of rabbit aortae with elevated glucose (44 mM) significantly decreased ACh-
induced relaxation in comparison with the aortae incubated in control (5.5 or 11 mM) glucose. 
The presence of indomethacin, a cyclooxygenase inhibitor, or SQ29548, a PGH2/TxA2 
receptor antagonist, restored ACh-induced relaxation of rings in incubated with high glucose 
to normal, without affecting relaxation of rings incubated in control glucose (Tesfamariam et 
al., 1990). In addition, data from radioimmunoassay experiments showed a significant 
Chapter 1-Literature review 
44 
 
increase in ACh-induced release of TxA2 and prostaglandin F2α in aortae incubated under 
hyperglycaemic conditions. However, the release of TxA2 and prostaglandin F2α was inhibited 
by the removal of endothelium from the aortae under the same conditions, suggesting that 
hyperglycaemia-induced increased generation of vasoconstrictor prostanoids was derived 
from the endothelium (Tesfamariam et al., 1990). Similarly, in STZ-induced diabetic femoral 
arteries endothelium-dependent contractions was reported and this could also be inhibited by 
indomethacin and selective COX-1 inhibitors (valeryl salicyclate and SC-560) (Shi et al., 
2007a). This is associated with an increase in the protein expression of COX-1 in the diabetic 
femoral arteries (Shi et al., 2007a; Shi et al., 2008). Furthermore, hypersensitivity to the TxA2 
mimetic, U46619 has been reported in the diabetic femoral arteries, indicating an increased 
responsiveness of VSMCs to vasoconstrictors in diabetes (Shi et al., 2008). In addition, the 
overproduction of ROS in the diabetic arteries is an important contributor to endothelium-
dependent contraction as treatment with ROS scavengers normalized those responses. Indeed, 
treatment with either apocynin (a non-selective inhibitor of NADPH oxidase) or MnTMPyP 
(SOD/catalase mimetic) inhibited endothelium-dependent contractions (Shi et al., 2007b; Shi 
et al., 2008; Tesfamariam et al., 1992b). Thus, the endothelial dysfunction in diabetes is at 
least in part due to the release of EDCF. This is likely due to the exposure of endothelial cells 
to high glucose, resulting in augmented ROS production as well as both COX-1 and COX-2 
expression (Shi et al., 2007a; Shi et al., 2008; Tesfamariam et al., 1990). In diabetes, the 
increased oxidative stress might play an important role in the initiation and amplification of 
the EDCF-mediated responses. 
Apart from enhanced prostanoid production, studies have also shown that the 
synthesis of ET-1 is increased in diabetic patients (Böhm et al., 2002; Takahashi et al., 1990) 
and animals (Harris et al., 2005; Makino et al., 2000a; Matsumoto et al., 2009). Diabetic 
subjects has been shown to have an elevated secretion of ET-1, resulting in the impairment of 
endothelium-dependent relaxation which could be reversed by the ETA receptor antagonist 
Chapter 1-Literature review 
45 
 
BQ123, suggesting that endothelial dysfunction in diabetes is, at least in part, caused by 
enhanced ET-1 production (Böhm et al., 2002; Harris et al., 2005). Furthermore, the ET-1-
induced contraction which was increased in the diabetic mesenteric arteries, could be 
attenuated by the selective ETA antagonist BQ123 and MEK/ERK pathway inhibitors (PD-
98059 or U0126) but not the selective ETB antagonist BQ788 (Matsumoto et al., 2009). In 
addition, this is associated with an increased ETA and MEK1/2 protein expression in the 
diabetic arteries (Matsumoto et al., 2009). As discussed earlier, the ETB receptor mediates 
NO-dependent vasodilatation. The increase in ET-1 secretion in diabetes densensitized the 
ETB receptor, causing impairment of NO-mediated relaxation in response to the selective ETB 
receptor agonist, IRL1620 (Makino et al., 2000a; Matsumoto et al., 2009). Taken together, 
the possible mechanism responsible for the hyperreactivity to ET-1-induced contraction in 
diabetic arteries could be due to the increased expression of ETA and an impaired ETB-
mediated NO signaling. 
 
1.6 Preventing diabetes-induced vascular complications  
Large scale epidemiological studies correlated poor glycaemic control with the 
development of vascular complications with type I or type II diabetic patients. These studies 
suggest that early exposure to hyperglycaemia predisposes individuals to the development of 
diabetic complications, a phenomenon known as metabolic memory or the legacy effect 
(Holman et al., 2008; The Diabetes Control and Complications Trial/Epidemiology of 
Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group, 2005). 
Hyperglycaemia-induced oxidative stress has long been suggested to be a common pathway 
linking diverse mechanisms for the pathogenesis of complications in diabetes (Brownlee, 
2001; Nishikawa et al., 2000a), sparking a large number of clinical intervention studies with 
antioxidants aiming to alleviate vascular complications in diabetic patients. 
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1.6.1 Vitamins C and E  
The most frequently studied antioxidants in the prevention of diabetic vascular 
complications are vitamins C and E. Vitamin E (tocopherol) is a lipophilic antioxidant that 
can inhibit lipid peroxidations. On the other hand, Vitamin C (ascorbic acid) is a hydrophilic 
antioxidant that can scavenge free radicals such as hydroxyl radical (Rahimi et al., 2005). It is 
possible that vitamins C and E act in concert to maintain antioxidant activity. For example, 
vitamin E is oxidized to the tocopheroxyl radical after inhibiting lipid peroxidation. Vitamin E 
can be reduced back to tocopherol by vitamin C and glutathione (Rahimi et al., 2005). Thus, 
vitamin C is regarded an important antioxidant, as it has the ability to regenerate vitamin E 
through redox cycling, and simultaneously raise intracellular glutathione levels (Rahimi et al., 
2005). Numerous animal studies have demonstrated that treatment with vitamins C and E 
improves markers indicative of oxidative stress and vascular function in diabetic animals 
(Alper et al., 2006; Cinar et al., 2001; Jariyapongskul et al., 2007; Sridulyakul et al., 2006; 
Wigg et al., 2004). In contrast to animal studies, the treatment of vitamin C and E in diabetic 
patients remains controversial (Bursell et al., 1999; Lee et al., 2004; Liu et al., 2006; Lonn et 
al., 2002). In small scale studies, it has been shown that retinal blood flow and renal function 
can be normalized with high doses of vitamin E (1800 IU/day) in 36 patients with type I 
diabetes in a placebo-controlled trial (Bursell et al., 1999). In larger studies, however, such as 
the Heart Outcomes Prevention Study, using a dose of 400 IU/day of vitamin E, did not show 
improvement of microvascular or cardiovascular damage in greater than 3,000 individuals 
who had diabetes for several years (Lonn et al., 2002). Similarly, Liu et al., (2006) 
demonstrated that in a 10-year follow up trial with 38,716 patients, doses of 600 IU vitamin E 
on alternate days provided no significant benefit for type II diabetes (Liu et al., 2006). In 
contrast, in postmenopausal women with diabetes, high vitamin C intake resulted in an 
increased risk of mortality due to cardiovascular disease (Lee et al., 2004).  
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1.6.2 Possible reasons for the failure of antioxidant vitamins in the prevention of diabetic 
vascular complications 
 There are several possible reasons that may account for the failure of antioxidant 
vitamins to successfully alleviate diabetic complications in clinical intervention studies. 
Drummond and co-workers (2011) recently proposed three possible reasons why antioxidants 
failed in clinical intervention studies (1) concentration of desired antioxidant in the blood 
vessel is insufficient, (2) the active form of antioxidant in the blood vessel was depleted and 
(3) oxidative damage is irreversible in high-risk diabetic patients (Drummond et al., 2011), 
which were outlined in the section below. 
 
1.6.2.1 Concentration of desired antioxidant in the blood vessel is insufficient 
The doses of vitamin E used between each trial varied and produced inconsistent 
outcome. For instance, Bursell and colleagues (1999) reported that high doses of vitamin E 
(1800 IU/day) is effective in improving retinal blood flow (Bursell et al., 1999), whereas a 
dose of 400 IU/day of vitamin E, did not show improvement of microvascular or 
cardiovascular damage in diabetic patients (Lonn et al., 2002). All of these trials have a 
common limitation: the concentration of antioxidant in the vasculature is not determined. It is 
extremely important to determine the concentration of antioxidants in the vasculature where 
the reactions between ROS (superoxide) and NO to form peroxynitrite occurs, causing further 
damage to nucleic acids and proteins in the vessel wall. Thus, in order for an antioxidant to be 
effective in improving vascular health, the reactions between superoxide and NO must be 
outcompeted by the therapeutic antioxidant. For example, the reaction between superoxide 
and NO is extremely rapid, occurring at a rate of approximately 1.9 x 10
10
 M
-1
s
-1
 (Kissner et 
al., 1997) which is six orders of magnitude faster than the reaction between superoxide and 
vitamin E (Gotoh et al., 1992). Similarly, the reaction rate between superoxide and vitamin C 
is estimated to be 3.3 x 10
5
 M
-1
s
-1
 which is approximately five orders of magnitude slower 
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than the reaction between superoxide and NO (Gotoh et al., 1992). The concentration of NO 
within the blood vessel is estimated to be in the low nanomolar range (Simonsen et al., 1999), 
hence for vitamin E to effectively prevent the reaction of superoxide with NO, a concentration 
in the millimolar range in the blood vessel wall would be required. This is unlikely to be 
achievable by even the highest level of vitamin E intake (Drummond et al., 2011). 
 
1.6.2.2 Depletion of active antioxidant in the blood vessel  
During diabetes where oxidative stress is evident, the antioxidant would be rapidly 
oxidized, resulting in the depletion of the active form of the antioxidant. The accumulation of 
the oxidized form of the parent antioxidant resulted in the loss of activity of the antioxidant. 
In addition, after the oxidation of the antioxidant, the product resulting from this reaction may 
result in the formation of another type of ROS. The formation of this new ROS may not react 
with the original antioxidant and may not be effectively removed by the endogenous 
antioxidant system (Drummond et al., 2011). Hence, under these circumstances the treatment 
of antioxidant may have pro-oxidant effects and have adverse effect on vascular health (Lee et 
al., 2004; Witting et al., 1997). 
 
1.6.2.3 Oxidative damage is irreversible in high-risk diabetic patients  
Most of the clinical interventions were performed in high-risk patients in which 
vascular disease was presumed to be quite advanced (Liu et al., 2006; Lonn et al., 2002; Song 
et al., 2009), and so it is plausible that when the antioxidant treatment was commenced, it was 
too late for it to have any substantial effect (Drummond et al., 2011).  
 
1.7 Flavonols, a subfamily of flavonoids 
In the earlier section of this thesis, the ability of ROS to contribute to the induction of 
major pathways of diabetic complications has been discussed. Vitamin E and other 
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antioxidants primarily act to non-enzymatically scavenge certain end-product ROS thereby 
limiting their effectiveness to prevent ROS-induced cellular damage. This may explain why 
traditional antioxidants have failed to improve diabetic vascular complications. To improve 
the effect of antioxidant therapy, compounds that possess activities against superoxide, 
targeting the enzymatic sources of ROS production and preventing the induction of the 
various pathogenic mechanisms may be a better strategy for the prevention of diabetic 
vascular complications. The following section outlines the biological actions of flavonols and 
discusses evidence to suggest why flavonols may be used as potential compounds for the 
prevention of diabetic vascular complications. 
 
1.7.1 Overview of flavonoids 
 Flavonoids are a class of polyphenolic compounds consisting of a benzene ring 
condensed with a six-member ring that has a phenyl ring substituent attached to either the 
carbon C2 or C3 position (Figure 1.6). Flavonoids can undergo different biochemical 
processes such as hydroxylation, methoxylation, sulfation or glycosylation of the ring 
substituents, resulting in more than 8000 different flavonoids being identified so far (Pietta, 
2000). Flavonoids can be further divided into different classes based on their structural 
characteristics (Figure 1.6). For example, flavones and flavonols are two classes of flavonoids 
which are widely found in plants. Flavonols have an extra hydroxyl group at the C3 position 
in comparison to flavones. Other classes of flavonoids include isoflavones, flavanones and 
flavanols. Isoflavones are mainly found in legumes while flavones, flavonols and flavanones 
are mostly distributed in fruits, vegetables, nuts and seeds. In contrast, flavanols are widely 
found in cocoa powder and tea leaves (Pietta, 2000). Thus, flavonoids form an integral part of 
the human diet, in particular flavonols which are abundant in plant flavonoids (Gu et al., 
2004). For example, in Spanish adult populations having a traditional Mediterranean diet, the 
estimated mean daily flavonoids intake is approximately 313 mg and flavonols accounts for 
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approximately 6% of the total flavonoid intake (Zamora-Ros et al., 2010). In addition, 
Hollman and coworkers reported that the peak plasma concentration of the flavonol, quercetin 
was 0.8 µM, 0.7 h after the ingestion of onions, and 0.32 µM 2.5 h after the ingestion of 
apples (Hollman et al., 1997). This and other studies indicate that the intake of flavonoids, 
especially flavonol intake could achieve pharmacologically significant concentrations in 
humans (Gu et al., 2004; Hollman et al., 1996; Pietta, 2000; Zamora-Ros et al., 2010). 
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Figure 1.6 Basic structures and examples of the main subclasses of dietary flavonoids, 
including flavanols, flavonols, flavanones, flavones and anthocyanidines. The possible 
sources of the main subclass of flavonoids are shown below each of their structure 
respectively. Figure obtained from (Heiss et al., 2010). 
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1.7.2 Epidemiological studies on flavonoids 
 It is well-known that there is a positive correlation between a high intake of dietary fat 
and the incidence of cardiovascular diseases, such as coronary heart disease, in most western 
countries (Frankel et al., 1993; Renaud et al., 1992). Epidemiological studies have indicated 
that the French population has a paradoxically lower than expected incidence of 
cardiovascular diseases despite having a high intake of dietary fat. This is known as “The 
French Paradox” (Renaud et al., 1992). Several reports have suggested that regular 
consumption of red wine, which is rich in flavonoids, in the French diet holds the key to 
cardioprotection mechanisms (Frankel et al., 1993; Renaud et al., 1992). The landmark 
epidemiological study that investigated the relationship between dietary flavonoid intake and 
the risk of coronary heart disease in an elderly male population, aged between 65 and 84, was 
conducted in Zutphen, Netherlands (Hertog et al., 1993). The mortality and morbidity 
resulting from coronary heart disease of the subjects was determined after 5 and 10 years from 
the start of the investigation. The mean intake of flavonoids (flavones and flavonols) of the 
subjects was estimated to be 25.9 mg/day at the start of the investigation. After both 5 years 
(Hertog et al., 1993) and 10 years (Hertog et al., 1997) of follow up, these studies reported a 
significant inverse association between flavonoid intake and mortality from coronary heart 
disease. Consistent with these observations, studies from Knekt et al. (1996) and Mink et al. 
(1999) have reported a similar inverse association between flavonoid intake and mortality 
from coronary heart disease (Knekt et al., 1996; Mink et al., 2007).  
 
1.7.3 Clinical intervention studies of flavonoids in diabetic patients 
While the data from epidemiological studies is suggestive that increased flavonoid 
intake is effective in the prevention of cardiovascular diseases, randomized controlled clinical 
intervention studies are the preferred method for generating the evidence that is needed to 
causally link increased flavonoid consumption with effective cardiovascular disease 
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prevention, in particular diabetes-induced cardiovascular disease. Small-scale and short-term 
clinical studies (Balzer et al., 2008; Grassi et al., 2008) have been performed in diabetic 
patients to evaluate the effects of flavonoid intake on cardiovascular surrogate endpoints, such 
as endothelial vasomotor function, which are thought to reflect key pathophysiologically 
relevant entities. These studies are useful as they can help to elucidate the mechanisms by 
which flavonoids mediate their pleiotropic effects, as these surrogate parameters reflect key 
pathophysiologies implicated in cardiovascular disease development and progression. For 
example, in a double blind, randomized and controlled trial, Balzer et al. (2008) evaluated the 
feasibility and efficacy of a dietary intervention based on daily intake of cocoa for improving 
endothelial function indicated by flow-mediated dilatation (FMD) of medicated diabetic 
patients (Balzer et al., 2008). In the feasibility study with 10 diabetic patients, a single 
ingestion of cocoa was associated with a small but significant increase in FMD (at 2 h: from 
3.7±0.2% to 5.5±0.4%, p <0.001) in a dose-dependent manner (75, 371, and 963 mg) (Balzer 
et al., 2008). Similarly, in a subsequent efficacy study of 41 diabetic patients, thrice-daily 
consumption of cocoa (321 mg flavanols per dose) for a period of 30 days, increased baseline 
FMD by 30% (p<0.0001). The acute improvement of FMD upon ingestion of cocoa was 
observed throughout the study (Balzer et al., 2008). In a separate study, Grassi et al. (2008) 
reported that high polyphenol chocolate consumption for 15 days could improve endothelial 
function in patients with impaired glucose tolerance and hypertension (Grassi et al., 2008). 
 
1.7.4 Structure activity relationships of flavonoids 
 Flavonoids have a large range of biological activities including modulating glucose 
homeostasis and anti-inflammatory, antioxidant and vasorelaxant properties which are 
discussed in detail below. Hence, to investigate which subclass of flavonoids contributes to 
their biological actions, structure activity relationships of flavonoids have been extensively 
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studied (Comalada et al., 2006; Cos et al., 1998; Herrera et al., 1996; Rice-Evans et al., 1996; 
Woodman et al., 2005).  
 The number and orientation of hydroxyl groups on the B ring has an important 
influence on their vasorelaxant activity (Figure 1.7). Indeed, flavonols with three contiguous 
hydroxyls in B rings (myricetin), at low concentrations, potentiate the contractions evoked by 
several vasoconstrictors (Herrera et al., 1996). In contrast, the presence of one or two 
hydroxyl groups favors relaxation. The orientation of hydroxyl groups on the C2‟ and C4‟ 
position displayed weak vasodilator activity whereas flavonols with a 3‟,4‟ dihydroxy group 
is associated with strong vasorelaxant activity (Herrera et al., 1996). The vasorelaxant activity 
of flavonols can be abolished when the hydroxyl groups on the C3‟ and C4‟ positions are 
substituted with methoxy groups, indicating the importance of the C3‟ and C4‟ positions on B 
ring for vasorelaxing activity (Woodman et al., 2005).   
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Figure 1.7 The general chemical structure of flavonols and flavones. The hydroxyl 
substitution at the C3 position distinguishes flavonols from flavones. Figure obtained from 
(Woodman et al., 2004a).  
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 Structure activity relationship studies examining flavonols as inhibitors of pro-oxidant 
enzymes and as scavengers of the superoxide radical have demonstrated that the hydroxyl 
groups at C5 and C7 and the double bond between C2 and C3 are essential for a high 
inhibitory activity on pro-oxidant enzymes such as xanthine oxidase (Cos et al., 1998). On the 
other hand, the presence of hydroxyl groups at the C3' and C4‟ positions in ring B and at C3 
afforded potent scavenging of superoxide radicals (Cos et al., 1998; Woodman et al., 2005). 
In addition, flavonols with hydroxyl groups at the C3' and C4‟ positions in ring B and at C3 
are reported to be 10-fold more potent than ebselen, a well-known scavenger of peroxynitrite 
(Haenen et al., 1997). It has been suggested that the conformation of the C3 hydroxyl group 
and 3‟,4‟-catechol group is important for the stability of the flavonols and optimizing 
antioxidant activity (Rice-Evans et al., 1996). The disruption of the 3‟,4‟-catechol group of 
the flavonols can impair its antioxidant ability. Indeed, the substitution of a methoxy group on 
the C3‟ position of the flavonol abolished its ability to scavenge superoxide radicals (Qin et 
al., 2008).  
 The anti-inflammatory actions of flavonoids are diverse and dependent on the specific 
flavonoids tested, experimental conditions (stimuli used to induce inflammation) and targets 
(inhibiting pro-inflammatory gene expression or cytokines). Thus, structure activity 
relationship studies on the anti-inflammatory actions of flavonoids are inconsistent (Comalada 
et al., 2006; Lotito et al., 2006). Comalada et al., (2006) showed that four hydroxyls groups at 
positions C5, C7, C3' and C4', together with the double bond at C2-C3 and the position of the 
B ring, seem to be necessary for the highest anti-inflammatory effect via the inhibition of the 
NF-κB pathway, resulting in the inhibition of TNFα secretion and iNOS expression in LPS-
activated macrophages (Comalada et al., 2006). In comparison, Lotito and colleagues reported 
that the inhibitory activity of flavonoids on TNFα-induced adhesion molecule expression in 
human aortic endothelial cells was dependent on the 5,7-dihydroxyl substitution of a 
flavonoid A-ring and 2,3-double bond and 4-keto group of the C-ring, whereas hydroxyl 
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substitutions of the B- and C-rings but not the A-ring were essential for antioxidant activity 
only (Lotito et al., 2006).  
 Taken together, structure activity relationship studies indicated that the presence of 
hydroxyl groups at the C3, C3' and C4‟ positions in ring B are the main requirement for 
vasorelaxant, antioxidant and anti-inflammatory activities of flavonols (Figure 1.8). Indeed, 
3‟,4‟-dihydroxyflavonol (DiOHF) has been demonstrated to exhibit potent vasorelaxant, 
antioxidant and anti-inflammatory actions in comparison to other naturally occurring 
flavonols (Chan et al., 2000; Jiang et al., 2009; Woodman et al., 2005).  
 
 
 
Figure 1.8 Chemical structure of the synthetic flavonol, 3’,4’-dihydroxyflavonol. 3‟,4‟-
dihydroxyflavonol has a flavone backbone with the addition of hydroxyl groups on the 3, 3‟ 
and 4‟ position.  
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1.7.5 Biological actions of flavonols as potential treatment for diabetic vascular 
complications  
 As described earlier, hyperglycaemia-induced elevation of vascular ROS is recognized 
as an important contributor to pathology in diabetes. The biological actions of flavonols have 
been extensively studied and of particular interest, they have been shown to modulate glucose 
homeostasis and possess anti-inflammatory, antioxidant and vasorelaxant properties which 
may have the potential for the prevention of diabetic vascular disease. 
 
1.7.5.1 Modulation of glucose homeostasis 
 Insulin resistance is defined as a reduced blood glucose response to a given amount of 
insulin. It is associated with type II diabetes which is resulted from a complex interaction 
between nutrient overload, excess levels of fatty acids, inflammation of the adipose tissue and 
ROS production. Current pharmacological treatments for insulin resistance and type II 
diabetes include glitazones (agonists of peroxisome proliferator-agonist receptor gamma, 
PPARγ), metformin (an activator of AMP-activated protein kinase, AMPK), sulphonylureas 
(ATP-dependent potassium channel blockers), acarbose (α-glucosidase inhibitor), amylin 
analogs, 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors (Ge et al., 2010; 
Perez-Vizcaino et al., 2010), incretin mimetics and dipeptidyl-peptidase 4 inhibitors (Rodbard 
et al., 2007; Tahrani et al., 2011).  
 Flavonols have been reported to modulate glucose homeostasis and to improve insulin 
resistance (Fang et al., 2008; Youl et al., 2010). Indeed, using a PPARγ reporter gene assay, 
kaempferol and quercetin has been shown to be weak partial agonists, but unlike traditional 
PPARγ agonists they were unable to induce 3T3-L1 preadipocytes differentiation (Fang et al., 
2008). The combined presence of kaempferol and quercetin with the PPARγ agonist 
rosiglitazone, they could inhibit PPARγ agonist-induced differentiation of 3T3-L1 
preadipocytes. A subsequent competitive ligand-binding assay confirmed that kaempferol and 
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quercetin were able to bind to the same binding pocket site as rosiglitazone (Fang et al., 
2008). In a separate study, quercetin has been demonstrated to potentiate insulin secretion and 
protects INS-1 pancreatic β-cells against oxidative damage. The ERK1/2 kinase signalling 
pathway played a crucial role in the potentiation of glucose-induced insulin secretion by 
quercetin in the INS-1 β-cell line (Youl et al., 2010).  
 AMPK belongs a member of a metabolite-sensing protein kinase family and is an 
important regulator of glucose transport in skeletal muscle (Fryer et al., 2002). The skeletal 
muscle accounts for uptake of approximately 80% of an oral glucose load and type II diabetes 
is associated with reduced muscle glucose disposal, suggesting that AMPK may be a key 
modulator of whole body glucose homeostasis (Perez-Vizcaino et al., 2010). Flavonoids have 
been shown to up-regulate the level of phosphorylated AMPK and improve glucose 
homeostasis. Indeed, in skeletal muscle cells, quercetin and naringenin enhance glucose 
uptake in the absence of insulin through a mechanism related to AMPK activation (Eid et al., 
2010; Zygmunt et al., 2010). 
 11β-hydroxysteroid dehydrogenase type 1 is predominantly expressed in human liver 
and adipose tissues as well as pancreatic β cells and mediates glucocorticoid hormone action 
in target tissues for insulin action, and thus it has been suggested to play a regulatory role in 
glucose homeostasis. 11β-HSD1 inhibitors are therefore of considerable interest as potential 
treatments for a number of diseases including type 2 diabetes, obesity and metabolic 
syndrome (Ge et al., 2010). Treatment with quercetin, (50 mg/kg) in type II (STZ-
nicotinamide) diabetic rat significantly attenuated total cholesterol, glucose, triglycerides and 
low density lipoprotein (LDL) and augmented high density lipoprotein (HDL) levels. 
Molecular docking studies of these flavonoids against 11β-HSD1 have shown that quercetin 
was docked into the crystal structure of 11β-HSD1, indicating that quercetin is able to inhbit  
11β-HSD1 (Torres-Piedra et al., 2010). 
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 Despite the positive modulation of insulin resistance in vitro by flavonols, in vivo 
studies investigating their effect on insulin resistance produced inconsistent findings. Daily 
oral administration of quercetin to obese Zucker rats, reduced dyslipidemia, insulin resistance 
and hypertension (Rivera et al., 2008). Consistent with this observation, Agouni and 
coworkers demonstrated that 8 weeks treatment of obese Zucker rats with red wine 
polyphenols (20 mg/kg) reduced plasma glucose and fructosamine, thus improving glucose 
metabolism. Moreover, the red wine polyphenols reduced circulating triglycerides and total 
cholesterol as well as LDL-cholesterol in obese Zucker rats (Agouni et al., 2009). Similarly, a 
recent study evaluated the anti-diabetic effects of pentamethylquercetin, a methylated 
quercetin derivative, in a model of type II diabetes. In this study, pentamethylquercetin was 
administered for a period of 10 weeks and it was found that the intervention dose-dependently 
reduced postprandial glucose and triglyceride levels. The treatment prevented the onset of 
overt diabetes by attenuating glucose intolerance and enhancing insulin sensitivity (Wang et 
al., 2011). In contrast to these studies, several other studies have shown that flavonol 
treatment had no effect on the insulin resistance or glucose, total cholesterol and triglycerides 
levels but improving oxidative, inflammatory state and endothelial function in both diabetic 
animal models (Stewart et al., 2008; Stewart et al., 2009; Valsecchi et al., 2011) and patients 
(Muniyappa et al., 2008), indicating a glucose-independent effect of flavonols.  Thus, it still 
remains controversial whether flavonols modulate glucose homeostasis in diabetes. The 
conflicting results observed in animal studies could possibly be due to the differences in 
treatment duration of flavonols and the severity/type of the animal model being used.  
 
1.7.5.2 Vasorelaxant 
 Numerous studies have shown that acute exposure to flavonoids can cause vascular 
relaxation in isolated blood vessels (Andriambeloson et al., 1997; Duarte et al., 1993a; Duarte 
et al., 1993b; Fitzpatrick et al., 1993; Ibarra et al., 2002; Pérez-Vizcaíno et al., 2002; Qin et 
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al., 2008).  Flavonols causes relaxation mainly through an endothelium-independent pathway 
in healthy vessels (Perez-Vizcaino et al., 2010). Flavonols-induced relaxation occurs with 
different potency in arteries constricted by different agonist (Perez-Vizcaino et al., 2010). For 
example, quercetin and its methylated metabolites are more potent in coronary arteries (Ibarra 
et al., 2002) and resistance vessels compared to conductance vessels (Pérez-Vizcaíno et al., 
2002). Some reports have suggested that the vasodilator effect of flavonols is partially 
endothelium-dependent and is related to the release of endothelium-derived relaxing factors 
such as NO (Andriambeloson et al., 1997; Fitzpatrick et al., 1993; Loke et al., 2008). Indeed, 
flavonols have been shown to cause the phosphorylation of eNOS on the Ser
1177
 residue and 
dephosphorylation of eNOS on the Thr
495
 residue, leading to the activation of eNOS and 
subsequently NO synthesis in endothelial cells (Anter et al., 2004). Similarly, quercetin 
ingestion increased plasma S-nitrosothiols, plasma nitrite, and urinary nitrate concentrations 
in healthy men, indirectly indicating that endothelial NO synthesis is increased (Loke et al., 
2008). In addition, Chan et al. (2000) demonstrated that endothelium removal reduced the 
sensitivity to flavonols-mediated relaxation without affecting the maximum response, 
indicating a partial contribution of endothelium in the vasodilator effect of flavonols.  
 The precise mechanism by which flavonols exert endothelium-independent relaxation 
remains unclear. VSMC contraction is initiated by a calcium-calmodulin interaction to cause 
myosin light chain (MLC) phosphorylation. The contractile state of the VSMC is maintained 
by the RhoA/Rho kinase pathway which inhibits MLC phosphatase dephosphorylation. 
VSMC relaxation occurs through the removal of calcium from the cytosol and stimulation of 
myosin phosphatase (Webb, 2003). Based on the understanding of the contractile mechanism 
of the VSMC, it has been suggested that flavonols could either interfere with calcium 
utilization or alter the MLC phosphatase activity in the VSMC to cause relaxation. There have 
been reports that flavonols are capable of interfering with calcium utilization in the VSMC by 
several pathways. Firstly, flavonols could inhibit calcium mobilization either by entry into the 
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VSMC via voltage-gated or receptor-operated calcium channels or intracellular calcium 
release from the sarcoplasmic reticulum (Chan et al., 2000; Ko et al., 1991; Qin et al., 2008). 
Ko et al. (1991) measured the influx of radioactive calcium into the aortic smooth muscle in 
response to either noradrenaline or high potassium depolarising stimulation. Under these 
conditions, flavonols were demonstrated to inhibit the influx of calcium in a concentration-
dependent manner via both voltage-gated and receptor-operated calcium channels (Ko et al., 
1991). In addition, previous work from our laboratory demonstrated that flavonols could 
inhibit the contractile response caused by extracellular influx of calcium in calcium-free 
depolarising physiological buffer in rat isolated aorta, possibly via the voltage-gated calcium 
channels (Chan et al., 2000; Qin et al., 2008). In addition, flavonols also impaired the 
contraction caused by phenylephrine-induced calcium release from the intracellular stores in 
rat isolated aorta (Chan et al., 2000). Secondly, flavonols could inhibit the activity of PKC, 
which promotes VSMC contraction through processes such as phosphorylation of calcium 
channels or other proteins that regulate cross-bridge cycling. PKC phosphorylates MLC and 
in conjunction with actin, cross-bridge cycling occurs, initiating shortening of the smooth 
muscle cell (Webb, 2003). Herrera and colleagues demonstrated that flavonols could inhibit 
the contraction-induced by the PKC activator, phorbol 12-myristate-13-acetate (Herrera et al., 
1996). In addition, flavonol also inhibited the phosphorylation of PKC-potentiated inhibitory 
protein for heterotrimeric MLC phosphatase (Song et al., 2010). 
 Apart from interfering with calcium utilization, flavonols may cause vascular 
relaxation by modulating MLC phosphatase activity. The MLC phosphatase dephosphorylates 
MLC to promote VSMC relaxation (Webb, 2003). Several studies have demonstrated that 
quercetin and/or its metabolites could increase cAMP and cGMP content in the isolated blood 
vessels (Duarte et al., 1993a; Suri et al., 2010). Thus, an increase in cAMP or cGMP content 
leads to a reduction of MLC phosphoryation, promoting the dissociation of actin and myosin 
and thus causing vasorelaxation (Webb, 2003).  
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The elevation in calcium concentration to cause VSMC contraction is transient. Thus, 
the maintainence of the VSMC contraction is mediated through a calcium-sensitizing 
mechanism by the activation of the small GTP-binding protein RhoA which inhibits MLC 
phosphatase activity. The activation of RhoA increases Rho kinase activity, leading to 
inhibition of myosin phosphatase and preventing MLC dephosphorylation (Webb, 2003). 
Thus, another potential mechanism for flavonoids to cause vascular relaxation is the ability to 
inhibit the RhoA/Rho kinase signaling pathway. Indeed, recent studies have demonstrated that 
flavonoids caused the inhibition of the RhoA/Rho kinase signaling pathway by decreasing the 
phosphorylation of the myosin phosphatase target subunit (Jeon et al., 2007; Song et al., 
2010). 
Apart from targeting calcium utilization or MLC phosphatase activity to cause 
relaxation, another possible mechanism for flavonoid-induced vasodilatation is the ability to 
open potassium channels on the VSMC causing hyperpolarization. Indeed, Cogolludo and 
coworkers reported that quercetin can cause vascular relaxation by directly activating the 
maxi KCa channels by a H2O2-dependent mechanism in the rat coronary arteries as these 
effects could be abolished by the maxi KCa channel blocker, iberiotoxin and catalase 
(Cogolludo A. et al., 2007). In addition, a previous study from our laboratory has 
demonstrated that global blockade of potassium channels by high potassium depolarizing 
solution significantly reduced the sensitivity to relaxation by flavonols without affecting the 
maximum response, indicating that opening of potassium channels contributes to the 
vasodilator effect of flavonols (Qin et al., 2008). 
 
1.7.5.3 Antioxidant activity 
 In addition to their vascular activity, it has been shown that flavonols could modulate 
the antioxidant status of the cells. The modulation of the antioxidant status of the cells by 
flavonols could occur by several mechanisms such as direct scavenging of free radicals, 
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enhancing the expression and/or activity of the cellular endogenous antioxidant enzymes and 
inhibition of pro-oxidant enzymes. Flavonols have a low redox potential which enables them 
to reduce highly oxidizing free radicals such as superoxide (Pietta, 2000; Rice-Evans et al., 
1996). The predominant mechanism by which flavonols scavenge free radicals involves the 
donation of a single electron to the radical resulting in the formation of a semiquinone radical. 
This semiquinone radical can further donate an electron to form an orthoquinone (Pietta, 
2000; Rice-Evans et al., 1996). The direct free radical scavenging ability of flavonols has 
been extensively studied (Chan et al., 2003; Qin et al., 2008; Yap et al., 2008). Previous 
studies demonstrated that flavonols are able to reduce superoxide levels in a concentration-
dependent manner in both cell-free medium and biological tissue (Chan et al., 2003; Qin et 
al., 2008). There is extensive evidence that the acute exposure of flavonols to biological 
tissues could directly scavenge free radicals, but this does not guarantee an improvement of 
endothelial function, which is impaired under oxidative stress conditions because the 
scavenging effect of flavonols may not be effective in preventing the reaction between NO 
and superoxide. Therefore, the ability of flavonols to preserve endothelial function in the 
presence of oxidant stress was investigated in rat isolated thoracic aorta. Endothelium-
dependent relaxation was impaired in the presence of oxidant stress caused by pyrogallol, 
which auto-oxidizes to form superoxide anions, or the presence of xanthine/xanthine oxidase. 
The generated superoxide anions then react with NO to form peroxynitrite, hence reducing 
NO bioavailability to cause the impairment of endothelial function. The acute exposure of 
flavonols significantly enhanced endothelium-dependent relaxation in the presence of oxidant 
stress, suggesting that it rapidly scavenged superoxide anions to preserve NO activity (Chan 
et al., 2003; Qin et al., 2008; Yap et al., 2008). Similarly, endothelium-dependent relaxation 
has been shown to be impaired under high glucose-induced ROS conditions in rat isolated 
aortae. The presence of luteolin could efficiently scavenge ROS, and improve endothelium-
dependent relaxation by enhancing NO activity (Qian et al., 2010). These observations were 
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also consistent with other studies where the acute exposure of flavonols could reverse 
endothelial dysfunction in the diabetic aorta (Ajay et al., 2007a; Ajay et al., 2007b). In 
addition, acute exposure to flavonols has also been shown to be protective in other oxidative 
stress related disorders such as ischaemia and reperfusion in sheep and rats (Chan et al., 2003; 
Wang et al., 2004; Wang et al., 2009a). Apart from scavenging of superoxide, flavonols have 
been shown to be a scavenger of peroxynitrite (Haenen et al., 1997). 
 Besides the direct scavenging effect, flavonols could improve the antioxidant status of 
the biological system either by enhancing the activity/expression of endogenous antioxidant 
enzymes or inhibition of the activity/expression of endogenous pro-oxidant enzymes. Several 
studies have demonstrated that flavonols could activate signal transduction pathways involved 
in transcriptional activation of genes associated with antioxidant defense system, leading to 
increased expression/activity of endogenous antioxidant enzymes such as SOD, cytochrome c 
oxidase and GPx (Arredondo et al., 2010; Khong et al., 2011; Mahn et al., 2005; Mann et al., 
2007).  The exact cellular pathway responsible for the increase in expression/activity of 
endogenous antioxidant enzymes by flavonols remains controversial but it is likely to be 
dependent on the specific flavonols being investigated. For example, Khong et al. (2011) has 
shown that a synthetic flavonol, DiOHF treatment had no significant effect on the gene 
expression of SOD and GPx. In contrast, the flavonol, quercetin increases the level of 
glutathione through the activation of the protective NF-E2-related factor 2-dependent 
signaling pathway (Arredondo et al., 2010).  
Apart from the upregulation of endogenous antioxidant enzymes, flavonols could also 
inhibit the expression/activity of the endogenous pro-oxidant enzymes. As described earlier, 
one of the critical pro-oxidant enzymes that are present in vascular cells is NADPH oxidase.  
A number of studies have shown that flavonols could inhibit the activity as well as the 
expression of NADPH oxidase, thereby decreasing the production of ROS in the vasculature 
(Jiang et al., 2008; Romero et al., 2009; Sanchez et al., 2006; Sanchez et al., 2007). In 
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addition to inhibition of NADPH oxidase, eNOS-derived superoxide production can also be 
inhibited by quercetin (Romero et al., 2009). Other potential pro-oxidant enzymes that 
contribute to ROS production include xanthine oxidase, lipoxygenase and COX-2 (Cos et al., 
1998; Hong et al., 2001; Laughton et al., 1991; Nagao et al., 1999). Lipoxygenases and COX 
are oxidizing molecules and have the ability to increase ROS production in some tissues. 
Flavonols is able to inhibit COX-2 and lipoxygenase to inhibit oxidative stress (Hong et al., 
2001; Laughton et al., 1991). Furthermore, the xanthine oxidase pathway is regarded as an 
important route in oxidative injury to tissues particularly during ischaemia-reperfusion. 
During ischaemic conditions, xanthine dehydrogenase is converted to xanthine oxidase and 
causes oxygen free radical production which is inhibited by flavonols, resulting in decreased 
oxidative injury (Cos et al., 1998; Nagao et al., 1999). 
As discussed earlier, flavonols have the capability to either act as direct scavengers of 
ROS or to modulate the activity or expression of endogenous antioxidant and pro-oxidant 
enzymes. Oxidative stress has been reported to impair pancreatic β-cell insulin secretion (Bast 
et al., 2002). Thus, reducing ROS-induced damage to the pancreas by flavonols may preserve 
β-cell function and therefore protect against the development of diabetes. Indeed, treatment 
with quercetin prevented ROS-induced β-cell damage in rat pancreas (Coskun et al., 2005) 
and normalized blood glucose concentrations in STZ-induced type 1 diabetes (Coskun et al., 
2005; Kobori et al., 2009). Similarly, several studies have clearly shown that flavonol 
treatment effectively inhibits ROS production and preserves endothelial function in animal 
models of diabetes (Agouni et al., 2009; Machha et al., 2007; Malakul et al., 2011; Valsecchi 
et al., 2011; Woodman et al., 2009). In addition, a recent study has demonstrated that 
treatment with the synthetic flavonol, DiOHF for 6 weeks in STZ-induced diabetic 
m(Ren2)27 rats attenuated diastolic dysfunction and cardiac remodeling. This was associated 
with reduced oxidative stress which, at least in part, resulted from inhibition of Nox2-derived 
superoxide production and TXNIP mRNA expression (Khong et al., 2011).  
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1.7.5.4 Anti-inflammatory activity 
The immune system is regulated through a cell-cell interaction manner, which 
involved a number of intracellular molecules including hormones, cytokines and autacoids 
(Garcia-Lafuente et al., 2009). The pharmacological action of flavonols has the ability to alter 
the immune response by specifically affecting enzyme systems that modulates the immune 
and inflammatory cells function (Garcia-Lafuente et al., 2009; Middleton et al., 2000). 
Examples of these enzyme systems include tyrosine and serine-threonine protein kinases 
which are key regulator of signal transduction and cell activation processes in inmmue 
responses (Garcia-Lafuente et al., 2009) such as T cell proliferation (Mustelin et al., 2002), B 
lymphocyte activation (Campbell et al., 1999) or cytokine production by stimulated 
monocytes (Garcia-Lafuente et al., 2009; Geng et al., 1993).  
 A number of studies have reported that different flavonol molecules have the ability to 
prevent inflammation by modulating the activities of pro-inflammatory enzymes and/or gene 
expression. Several studies have shown that the anti-inflammatory effects of flavonols can be 
partly attributed to the inhibition of transcription factors NF-κB and STAT-1, leading to a 
decreased of pro-inflammatory enzyme expression such as iNOS, C-reactive protein and 
COX2 (Comalada et al., 2006; García-Mediavilla et al., 2007; Hämäläinen et al., 2007; Kim 
et al., 2007). The cellular pathway responsible for the modulation of pro-inflammatory gene 
expression and/or enzymes by flavonols remains unclear (Comalada et al., 2006; Hämäläinen 
et al., 2007). For instance, the activation of STAT-1 and NF-κB were inhibited by the 
presence of either kaempferol or quercetin in activated macrophages. In contrast, in the same 
cells, isorhamnetin only inhibits NF-κB activation together with their inhibitory effect the 
expression of iNOS and NO production (Hämäläinen et al., 2007). In addition, quercetin has 
the ability to stimulate the anti-inflammatory cytokine IL-10 expression at low concentrations 
(<50 µM) (Comalada et al., 2006). 
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 Apart from modulating the gene expression or activities of pro-inflammatory enzymes, 
flavonols have been shown to inhibit the secretion of pro-inflammatory mediators. The 
presence of flavonols could inhibit the release of pro-inflammatory molecules including IL-6, 
IL-8 and tumor necrosis factor-α (TNF-α) in human mast cells (Kempuraj et al., 2005). In 
addition, the synthetic flavonol, DiOHF reduced monocyte chemoattractant protein-1 
expression in rat VSMC either unstimulated or stimulated with platelet-derived growth factor 
(PDGF) or IL-1β (Jiang et al., 2009). Similarly, in animal model of diabetes, treatment with 
quercetin decreased both the expression of TNF-α and iNOS (Rivera et al., 2008). Moreover, 
dietary quercetin reduced circulating markers of inflammation (interferon-γ, interleukin-1α, 
interleukin-4) in diet-induced models of obesity (Stewart et al., 2008). Taken together, 
flavonols exert their anti-inflammatory effects, at least in part, via the modulation of protein 
kinases, pro-inflammatory gene and enzyme expression and pro-inflammatory mediators. 
 
1.8 Aims of project 
The broad aim of the thesis is to examine the pathological processes underlying 
vascular dysfunction in diabetic macro- and micro-vasculature.  Based on our knowledge of 
the biological actions and structure activity relationship of flavonoids as outlined above, we 
hypothesized that the most potent flavonol, DiOHF, may be a potential pharmacological 
intervention for the treatment for diabetic vascular diseases. 
 
1.8.1 Specific aims of project 
(1) It is well established that STZ-induced hyperglycaemia increases ROS production 
and causes endothelial dysfunction after duration of 8 weeks but during the early stages of 
diabetes, where hyperglycaemia and increased ROS are present, endothelial function is 
maintained. This project aims to determine how the endothelium-dependent relaxation is 
maintained in short term diabetes in rat carotid artery. The mechanism of endothelium-
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dependent relaxation was investigated in carotid arteries from STZ-induced hyperglycaemia 
animals after duration of 6 weeks. 
(2) The redox sibling of NO, HNO is formed endogenously and contributes to 
endothelium-dependent relaxation in blood vessels. It is well known that oxidative stress 
causes endothelial dysfunction by impairing the bioavailability of NO. It remains unclear 
whether the contribution of HNO is affected under acute pyrogallol- or hyperglycaemia-
induced oxidative stress conditions.  This project aims to examine the contribution of HNO to 
endothelium-dependent relaxation in the diabetic rat aorta. 
(3) In a novel rodent model for intrinsic aerobic capacity where rats are artificially 
selected for LCR and HCR, which exhibit phenotypes emulating the physiological profiles of 
sedentary and exercise-trained individuals. The LCR animals exhibited decreased whole-body 
insulin sensitivity and impaired metabolic health in comparison to their HCR counterparts. It 
is not known whether the LCR animals would have an impaired vascular function in 
comparison to their HCR counterparts. This project aims to investigate the macro- and micro-
vascular function of rats that are selectively bred for HCR and LCR. 
(4) Endothelium-dependent relaxation is mediated by multiple factors including NO, 
PGI2 and EDHF. The relative contribution of endothelium-derived factors to relaxation in the 
presence of diabetes-induced endothelial dysfunction remains poorly understood especially in 
smaller arteries, such as the mesenteric artery, where both NO and EDHF are contributing to 
endothelium-dependent relaxation. This project aims to investigate the mechanism(s) of 
endothelial dysfunction in diabetic mesenteric arteries. 
(5) It is well known that both type I and type II diabetes-induced impairment of 
endothelium-dependent relaxation in the mesenteric arteries are associated with oxidative 
stress. Structure activity relationship studies have demonstrated that the synthetic flavonol, 
DiOHF is the most potent antioxidant in comparison to other flavonoids (Woodman et al., 
Chapter 1-Literature review 
70 
 
2005).  This project aims to examine the acute effects of DiOHF on vascular reactivity in type 
I and type II diabetic mesenteric arteries. 
(6) Based on the results from (4), it was demonstrated that diabetes-induced 
endothelial dysfunction is due to the impairment of both NO-mediated and EDHF-type 
relaxation, which is accompanied by an increase in Nox2-derived superoxide production and 
eNOS uncoupling in the mesenteric artery. The project aims to investigate whether short term 
DiOHF treatment in vivo preserves microvascular endothelial function in mesenteric artery 
from type 1 diabetic rats and, if so, whether it acts via direct scavenging of ROS and/or by 
inhibiting the sources of ROS production in the diabetic microvasculature. 
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Chapter 2 
 
General Methods 
 
2.1 Animal experiments 
 Male Sprague-Dawley and Wistar rats were purchased from either the University of 
Melbourne Animal Facility (Parkville, VIC, Australia) or Animal Resource Center (Perth, 
WA, Australia). Male lean and obese Zucker rats were purchased from the Monash University 
Animal Facility (Clayton, VIC, Australia). Female rats with high and low aerobic capacity 
were bred from genetically heterogeneous N:NIH stock rats by artificial selection for low and 
high treadmill running capacity and obtained from National Institute of Health (USA). All 
animals were kept in the Research Animal Facility at RMIT University under controlled 
conditions of illumination (12 hr light/12 hr darkness) and temperature (20–25◦C). All 
animals were given free access to food (standard pellet diet) and water ad libitum. The use of 
the animals was approved by the RMIT Animal Ethics Committee and conformed to the 
Australian National Health and Medical Research Council guidelines (Code of Practice for 
the Care and Use of Animals for Scientific Purposes).   
 
2.1.1 Induction of diabetes 
STZ causes pancreatic islet cell destruction which reduces insulin release. This creates 
an experimental model of chronic hyperglycaemia (type I diabetes). STZ was dissolved in 
sterile 0.1 M citrate buffer at pH 4.5 and prepared to a stock concentration of 100 mg/ml. 
After fasting the rats overnight, a single-dose of STZ was used to induce type I diabetes at 6-
8-weeks of age (~200g). Immediately prior to the injection, the rats were briefly exposed to 
heat lamps (~3-5 min) to increase blood flow to the tail vein. The rats were gently wrapped in 
a towel to restrict their movement and expose the tail. The tail was cleaned with 70% ethanol 
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to minimize the risk of infection. A single injection (26G/27G needle) of 0.1 ml of STZ (50 
mg/kg of body weight) was given into the tail vein. Age-matched rats injected with the same 
volume of vehicle (0.1 M citrate buffer) were used as controls. After injection, STZ-treated 
and vehicle-treated animals were housed separately and were given free access to food and 
water ad libitum. 
 
2.1.2 Analysis of blood glucose 
 A week following STZ injection, blood glucose level of the rats was measured using a 
one touch glucometer (Accu-chek advantage, Roche, U.S.A). Briefly, rats were pre-warmed 
under the heat lamp and wrapped in a towel, allowing access to the tail. The tail was cleaned 
with 70% ethanol to minimize the risk of infection. Using a 26G needle, the tail was pricked 
at the tail vein to allow bleeding to occur and blood was placed onto a blood glucose strip 
connected to the glucose monitor. Animals with blood concentration greater than 20 mM were 
considered diabetic.  In some situations where the diabetic rats exhibited weight loss 
(approximately 5% weight loss from the initial weight), these rats were treated with a low 
dose of insulin (4-5 IU, Protaphane, Novo Nordisk, NSW, Australia) to promote weight gain 
and reduce mortality. This was done in accordance to the AEC guidelines to provide welfare 
to the animals and to reduce mortality due to weight loss (approximately 15%). In addition, 
the study described in Chapter 8, the diabetic rats received a low dose of insulin (4-5 IU, s.c, 
3x per week, Protaphane, Novo Nordisk, NSW, Australia) to promote weight gain and reduce 
mortality, without achieving euglycaemia. In these studies, approximately 15% of the diabetic 
animals died before experimentation. The control animals were not treated with insulin. All 
insulin treatment was given on Mondays, Wednesdays and Fridays in the evening (4-6 pm). 
Weekly blood glucose level of these rats was monitored on Wednesday mornings (10-11 am). 
At the end of the experimental period, blood samples were obtained from the left ventricle 
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using a heparinized 18G needle and 3 ml syringes, and the glucose concentration was 
determined as described earlier.  
 
2.1.3 Analysis of glycated haemoglobin 
At the end of the experimental period, blood samples were obtained from the left 
ventricle using a heparinized 18G needle and 3 ml syringes and transferred to vaccum blood 
collection tubes to be used for subsequent glycated haemoglobin (HbA1c) analysis. The blood 
was diluted 1:1 with milliQ water in an eppendorf tube. HbA1c was measured using a 
Micromat HbA1c analyser (Biorad, Sydney, NSW, Australia) following the manufacturers‟ 
instruction.  
 
2.1.4 Flavonol treatment intervention 
In the study described in Chapter 8, seven weeks after vehicle or STZ injection, the 
rats were further divided into 2 groups receiving either vehicle or DiOHF treatment. DiOHF 
was prepared in 10% DMSO:90% peanut oil daily and was administered to the rats at a dose 
of 1mg/kg (s.c per day) for a period of 7 days. 
 
2.2 Isolation of vascular tissue 
At the end of experimental period, the rats were euthanized with pentobarbitone 
sodium (325 mg/kg, i.p, Virbac, Australia). After the rats were euthanized, the thoracic aorta, 
carotid arteries and mesenteric arcade were isolated and immediately placed in ice cold Krebs 
bicarbonate solution (118 mM NaCl, 4.7 mM KCl, 1.18 mM MgSO4, 1.2 mM KH2PO4, 25 
mM NaHCO3, 11.1 mM D-glucose, and 2.5 mM CaCl2), which were used for further 
functional experiments and ROS measurement. The remaining arteries were snap frozen in 
liquid nitrogen and stored at -80˚C for subsequent western blot analysis. 
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2.2.1 Preparation of carotid arteries 
Carotid arteries were removed and placed in Krebs bicarbonate solution. Using 26G 
needles, the carotid artery was pinned to the sylgard coated Petri dish and were cleared of fat 
and connective tissue, and cut into 2-3 mm long ring segments under the dissection 
microscope. Carotid artery rings were mounted in a myograph (model 610M, Danish Myo 
Technology, Aarhus, Denmark) by carefully inserting two pins into the lumen of the carotid 
artery in the myograph chamber containing Krebs solution bubbled with carbogen (95% O2 
and 5% CO2) at 37˚C. Passive tension was adjusted to 15 mN over 60 min and recorded on a 
chart recorder (model 3721; Yokogawa, Tokyo, Japan). 
 
2.2.2 Preparation of thoracic aorta 
The thoracic aortae were removed and placed in Krebs bicarbonate solution. After the 
removal of superficial connective tissue, the aorta was cut into 2-3 mm long ring segments. 
The aortic rings were mounted between two stainless steel wires with one end linked to an 
isometric force transducer (model #FT03, Grass Medical Instruments, Quincy, MA, USA) 
connected to Maclab/8 (model #MKIII, ADIntruments Co., Sydney, Australia). The other end 
was anchored to a glass rod submerged in a standard 10 ml organ bath filled with Krebs 
solution bubbled with carbogen (95% O2 and 5% CO2) at 37˚C. Passive tension was adjusted 
to 1 g over 60 min and recorded on a Maclab. 
 
2.2.3 Preparation of mesenteric arteries 
 The whole mesenteric arcade was transferred to a large sylgard coated Petri dish 
containing ice-cold Krebs biocarbonate solution. Using 26G needles, the whole mesenteric 
arcade was pinned to the sylgard Petri dish to expose the branches of the mesenteric arteries. 
Small mesenteric arteries (third-order branch of the superior mesenteric artery, internal 
diameter ~300 m) were cleared of fats and connective tissue using a dissection microscope. 
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The small mesenteric artery was isolated and cut into 2mm long rings. Using a 40-μm 
stainless steel wire which was carefully inserted through the lumen of the mesenteric artery, 
great care was taken in inserting the wires through the lumen of the arteries to avoid damage 
to their intimal surface (endothelium). Artery segments with a wire within the lumen of the 
arteries were mounted on in a myograph chamber (model 610M, Danish Myo Technology, 
Aarhus, Denmark) by attaching the wire onto the jaws of the myograph (isometric force 
transducer side). Using the first wire as a guide to locate the lumen, the second wire was 
carefully inserted into the lumen of the arteries and attached to the jaws of the myograph 
(micrometer side). The arteries were slightly stretched by increasing the micrometer reading 
so that both the wires in the lumen were slightly apart and were in near contact with the vessel 
wall (Figure 2.1).  After the arteries were mounted, the vessels were allowed to stabilize at 
zero tension for 15 min before normalization. The classical normalization procedure was used 
to set the optimal resting tension for each vessel preparation which was determined by the 
resting tension-internal circumference relationship (Mulvany and Halpern, 1977; McPherson, 
1992). In brief, vessels were stretched in small increments (2 mN) and allowed to equilibrate 
for 2–5 min between stretches. Passive tension was recorded and the vessel was stretched 
until the passive tension was greater than 90 mmHg. Vessels were then set to an internal 
circumference corresponding to 90% of the calculated circumference at a passive transmural 
pressure of 100 mmHg for the remainder of the experiment, as at this level of stretching, the 
maximum active wall tension is obtained. Hence, the passive tension-internal circumference 
was determined by stretching to achieve an internal circumference equivalent to 90% of that 
of the blood vessel under transmural pressure of 100 mmHg. All experiments were performed 
at 37˚C and bubbled with carbogen (95% O2 and 5% CO2). After normalization, the vessels 
were allowed to stabilize at the optimal tension for 30 min and recorded on a chart recorder 
(model 3721; Yokogawa, Tokyo, Japan). 
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Figure 2.1. Diagrammatic representation of the myograph chamber used to mount small 
mesenteric arteries. Mesenteric artery ring segments were mounted on jaws, one wire to the 
micrometer and the other to the force transducer in a 5-ml chamber in Krebs buffer. The 
solution was maintained at 37 ºC and continuously bubbled with 95% O2 / 5% CO2. 
Micrometer 
3rd order mesenteric artery 
40 µm wires 
Mulvany-Halpern myograph 
Isometric 
force 
transducer 
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2.3 Functional experiments 
 After stabilisation, vessels were maximally contracted with an isotonic high K+-
containing physiological saline solution (KPSS), in which K
+
 ions ([K
+
]KPSS=123 mM) 
replaced Na
+
 ions in the Krebs solution. After several washouts using normal Krebs solution, 
tension was returned to basal tension. To assess the integrity of the endothelium, the arteries 
were precontracted to similar level (~50%) of the KPSS response with phenylephrine (PE, 
0.01-1 μM) and a high dose of ACh (10 μM) was used to relax the artery rings. If ACh-
induced relaxation was greater than 80% of the precontracted tone, the endothelium was 
considered to be functionally intact. Arteries with endothelium that was not functionally intact 
were excluded from our study. These arteries can only be excluded when other artery 
segments from other parallel vessel chambers within the same treatment group have 
functionally intact endothelium, indicating that the endothelium is mechanically damaged due 
to experimental error rather than the nature of the treatment (diseased). In all of the studies 
involved in this thesis, however, ACh-induced relaxation was greater than 80% of the 
precontracted tone, indicating that none of the endothelium was mechanically damaged.  
 
2.3.1 Relaxation and contraction assays 
After further washouts, arteries were again precontracted with PE (0.01-1 μM) to 
achieve similar levels of active tension. The effect of the treatment on relaxant responses was 
examined by cumulative concentration-response curves to ACh (0.1 nM-10 μM), Angeli‟s salt 
(0.1 nM-10 μM), DEANONOate (0.1 nM-10 μM), isoprenaline (0.1 nM-10 μM), fenoterol (1 
nM-10 μM)   and sodium nitroprusside (SNP, 0.01 nM-10 μM). In addition, responses to ACh 
and SNP were examined after incubation with various inhibitors (Table 2.1). The different 
combinations of inhibitors used were described in detail in each chapter. A representative 
recording of the vascular functional experiment protocol was shown in Figure 2.2. Similarly, 
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to evaluate the constrictor reactivity, cumulative concentration-response curves to ET-1 (0.1 
nM-0.1 μM) were also constructed. 
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Figure 2.2 Trace of the vascular functional relaxation protocol. The arteries were maximally contracted with 123 mM KPSS to induced maximum 
contraction. Endothelium was considered intact when 10
-5
 M ACh produced greater than 80% relaxation in PE-induced precontracted arteries. 
Cumulative concentration response curve to ACh (10
-10
 -10
-5
 M) or SNP (10
-11
 -10
-5
 M) were evaluated either in the absence or presence of 
pharmacological inhibitors (Table 2.1). 
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Table 2.1 A glossary of pharmacological agents.  
Pharmacological agents Inhibitory activity Concentration 
N-nitro-L-arginine (L-NNA)  NOS 100 µM, 1 mM 
1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one 
(ODQ) 
sGC 10 µM 
Hydroxycobalamin (HXC) NO scavenger 100 μM, 200 
μM 
1-[(2-chlorophenyl)(diphenyl)methyl]-1H-
pyrazole (TRAM-34) 
 IKCa 1 μM 
Apamin  SKCa 1 μM 
Iberiotoxin (Ibtx) Maxi KCa 0.1 μM 
Indomethacin COX 10 μM 
carboxy-PTIO NO scavenger 200 μM 
Haemoglobin (Hb) Non-selective NO 
scavenger 
20 μM 
L-cysteine HNO scavenger 1 mM, 3mM 
cupric chloride Degradation of S-
nitrosothiol 
10 μM 
K
+
 ions Global blockade of 
K
+
 channels 
30 mM , 45 mM 
Tempol SOD mimetic 100 μM 
Manganese (III) tetrakis (1-methyl-4-pyridyl) 
porphyrin (MnTMPyP) 
SOD mimetic 10 μM 
DiOHF Antioxidant 1 μM 
Pyrogallol Superoxide 
generator 
30 μM, 100 μM 
ICI 118551 β2-adrenoceptor 
antagonist 
1 μM 
CGP 20712 β1-adrenoceptor 
antagonist 
10 μM 
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2.3.2 Assessment of basal NO level assay 
 After further washouts, arteries were again precontracted with PE (10-100 nM) to 
approximately 20% KPSS. The addition of the NOS inhibitor, L-NNA (100 μM), would 
produce further contraction. The contraction produced by L-NNA was due to the removal of 
basal level of NO that was opposing the PE contraction. The magnitude of L-NNA-induced 
contraction was an indication of basal level of NO release which was shown in Figure 2.3. 
This image was created as previously described in Chapter 2, section 2.3.1. 
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Figure 2.3 Trace of the basal NO activity protocol. The arteries were maximally contracted 
with 123 mM KPSS to induced maximum contraction. Endothelium was considered intact 
when 10
-5
 M ACh produced greater than 80% relaxation in PE-induced precontracted arteries. 
In arteries precontracted to approximately 20% of KPSS, the addition of the NOS inhibitor, L-
NNA (100 µM), produced further contraction which was indicative of basal NO activity. 
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2.4 Measurement of reactive oxygen species 
 Two different methods of ROS measurement were employed. Superoxide production 
in the mesenteric artery was measured by using L-012. ROS were measured with 2‟,7‟-
dichlorodihydrofluorescein diacetate (DCFDA). 
 
2.4.1 L-012 assay 
L-012 is a chemiluminescent probe for superoxide and upon reacting with superoxide, 
it generates photons which could be quantified by a photon counter. Arteries were incubated 
at 37 ˚C for 30 min in Krebs-HEPES buffer (composition (mM): NaCl 99.90, KCl 4.7, 
KH2PO4 1.0, MgSO4·7H2O 1.2, D-glucose 11.0, NaHCO3 25.0, CaCl2·2H2O 2.5, Na HEPES 
20.0, pH 7.4) either alone, in the presence of apocynin, a ROS inhibitor (300 μM), tempol and 
MnTMPyP, cell permeable SOD mimetics or L-NNA (100 μM) in order to determine NOS-
uncoupling. 300 μL of Krebs-HEPES buffer, containing L-012 (100 μM, Wako Pure 
Chemicals, Osaka, Japan) and the appropriate treatments were placed into a 96-well Optiplate, 
which was loaded into a Polarstar Optima photon counter (BMG Labtech, Melbourne, VIC, 
Australia) to measure background photon emission at 37°C. After background counting was 
completed, a single ring segment of mesenteric artery was added to each well and photon 
emission was re-counted. Background counts were subtracted from superoxide counts and 
normalized with dry tissue weight. 
 
2.4.2 DCFDA assay 
DCFDA is cell permeable and once it enters the cell, the diacetate moiety is cleaved 
by intracellular esterases. The DCF is cell membrane impermeable and remains in the cell. 
DCF is able to react with intracellular hydrogen peroxide and lipid peroxides, and emits a 
fluorescent signal upon excitation at 485 nm. Rings of artery were loaded with DCFDA 
solution (10 μM) for 60 min, followed by 3 washes in Krebs-HEPES buffer. Background 
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fluorescence was measured using an Optima plate reader (BMG Labtech, Melbourne, VIC, 
Australia) after excitation at 485 nm and emission at 520 nm. After being rinsed three times 
with Krebs-HEPES buffer to remove excess probe, a single segment of the mesenteric artery 
was added to each well, and fluorescence intensity was recounted. The fluorescence counts 
were measured as described above and background counts were subtracted from fluoresence 
counts and normalized with dry tissue weight. 
 
2.5 Nitric oxide measurement in artery preparation 
Intracellular levels of NO in the carotid artery were measured by 4-amino-5-
methylamino-2',7'-difluorofluorescein diacetate (DAF-FM diacetate, Invitrogen, Sydney, 
NSW, Australia). DAF-FM diacetate is cell permeable and once it enters the cell, the diacetate 
moiety was cleaved by intracellular esterases causing the DAF-FM to become cell 
impermeable and remains in the cell. DAF-FM is able to react with intracellular NO, and emit 
fluorescent signal that accumulates in the cells upon excitation at 485 nm. This is not a 
reversible reporter of NO in the cells. Strips of carotid arteries were loaded with DAF-FM 
diacetate (5 μM) for 60 min in Krebs buffer either in the absence or presence of L-NNA (100 
μM), followed by exposure to ACh (10 μM) for 30 min. Background fluorescence was 
measured using an Optima plate reader (BMG Labtech, Melbourne, VIC, Australia) after 
excitation at 485 nm and emission at 520 nm. After rinsing three times with Krebs buffer to 
remove excess probe, a single segment of carotid artery was added to each well and 
fluorescence intensity was recounted. Background fluorescence of the carotid artery were 
subtracted from NO counts and normalized with dry tissue weight. 
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2.6 Western Blot 
2.6.1 Protein extraction 
Frozen arteries from 2-3 animals within the same treatment group were pooled and 
considered as n=1. The tissues (~20 mg) were homogenized in 200 L of ice-cold lysis buffer 
(100 mM NaCl, 10 mM Tris, 2 mM EDTA, 0.5% w/v sodium deoxycholate, 1% vol/vol triton 
X-100, pH7.4, protease and phosphatase inhibitor cocktails (Roche, Sydney, NSW, Australia) 
using a 1 ml glass homogenizer. After incubation with lysis buffer for 20 min at 4˚C, the 
tissues were homogenized and samples were centrifuged at 13,200 g for 10 min at 4˚C. The 
supernatant was collected and stored at -80˚C until required. 
  
2.6.2 Protein assay 
 The protein concentration of homogenized arteries was assessed using the Bradford 
protein assay. Samples were diluted 1:100 with phosphate buffered saline (PBS) to 100 µL in 
a test tube and 100 µL of 0.2 M NaOH was added to the test tube. After incubation for 15 
min, 600 µL of milliQ water and 200 µL of red protein assay reagent dye (Biorad, Sydney, 
NSW, Australia) were added to the test tube. The resulting solution which turned blue in the 
presence of protein was vortexed and 300 µL of the solution was transferred to a 96-well 
plate. The absorbance of the samples was measured at 590 nm. In addition, a bovine serum 
albumin (BSA) standard curve was generated (0-20 µg/ml) and included in the same 96-well 
plate. If the absorbance of the unknown samples were not in the range of the standard curve, 
the unknown samples were further diluted and the procedures were repeated as described 
above. Each protein standard and samples were performed in duplicate. The protein 
concentration of the unknown samples was calculated from the standard curve.  
Each samples containing identical amount of protein (30 µg) were aliquoted and 
topped up with PBS so that each of the samples will contain identical amount of protein (30 
µg) in the same total volume (10 µl or 15 µl). The identical volume (10 µl or 15 µl) of 2X 
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Sample buffer (20% w/v glycerol, 2% SDS, 62.5 mM Tris, 0.05% bromophenol blue and 5% 
-mercaptoethanol, pH 6.8) was added to each of the samples and stored at -80˚C until 
required. 
 
2.6.3 Preparation of gel for sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
(SDS-PAGE) 
 Plates were assembled according to the manufacturers‟ instructions (Biorad, Sydney, 
NSW, Australia). The 7.5%, 10%, 12% and 15% resolving gel (30% acrylamide, distilled 
water, 1.5 M Tris, pH 8.8, 10% SDS, 10% ammonium persulfate and TEMED) was prepared 
and transferred into the glass plates by pipette; isopropyl alcohol (~100 µL) was added to 
remove bubbles. The solution was left to polymerize and form an acrylamide-resolving gel at 
room temperature for 1-1.5 h. Once the resolving gel had set, the alcohol was removed by 
dabbing using filter paper and 4% stacking solution (30% acrylamide, distilled water, 0.5 M 
Tris, pH 6.8, 10% SDS, 10% ammonium persulfate and TEMED) was then added on to the 
top of the resolving gel, the 15-well comb was inserted, and the gel was left to polymerize at 
room temperature for 0.5-1 h. 
 
2.6.4 SDS-PAGE  
SDS-PAGE was carried out using a mini-PROTEAN apparatus (Biorad, Sydney, 
NSW, Australia). Protein samples (30 µg) were denatured in sample buffer by heating at 95˚C 
for 5 min. The denatured protein and a prestained kaleidoscope protein ladder (7 µl, Biorad, 
Sydney, NSW, Australia) were loaded into wells. Electrophoresis was performed in running 
buffer (25 mM Tris, 192 mM glycine, 0.1% SDS, pH 8.3) at 100 V until the separation was 
complete (2 h). Following electrophoresis, the gels were carefully removed from the gasket 
and equilibrated in ice-cold transfer buffer (25 mM Tris, 192 mM glycine, 20% methanol, 
0.037% SDS, pH 8.3). This was to remove excess salt and detergents from the running buffer, 
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which may increase the conductivity of the transfer buffer and decrease the amount of heat 
generated during the transfer. At the same time, the Hybond nitrocellulose membranes, filter 
papers and sponges were also equilibrated in transfer buffer. The sponges, filter papers, 
nitrocellulose membranes and gels were assembled according to the manual for Biorad wet 
transfer cell, and gels were transferred at 350 mA for 2-3 h. Transfer of proteins was 
confirmed by staining the membrane with ponceau stain.  
 
2.6.5 Low temperature SDS-PAGE  
 The low temperature SDS-PAGE was used to identify the eNOS monomers and 
dimers. A 6% resolving gel was prepared as described in section 2.6.2. Ice cold resolving and 
stacking gel were used in low-temperature SDS-PAGE. Non-denatured protein samples (60 
µg) and protein ladder (7 µl) were loaded into the wells and electrophoresis was performed in 
ice cold running buffer at 30 V overnight at 4˚C. Following electrophoresis, the proteins were 
transferred at 30 V overnight at 4˚C from the gel to the nitrocellulose membrane. Similarly, 
transfer of proteins was confirmed by staining the membrane with ponceau stain. 
 
2.6.6 Immunoblotting 
For immunoblotting of eNOS, iNOS, Nox2 and caveolin-1 protein levels (all BD 
Transduction Laboratories, Lexington, KY, USA), calmodulin (Millipore, Billerica, MA, 
USA), pSer
473
-Akt and Akt (Cell signalling, Danvers, MA, USA), nitro-cellulose membranes 
were blocked with either 5% w/v skim milk in Tris Buffered Saline plus 0.1% Tween-20 
(TBST) for 1 hr at room temperature or 5% BSA/TBST (phosphorylated proteins) for 1 h at 
4˚C prior to the addition of the primary antibodies (in 5 mL 3% BSA/TBST). Membranes 
were incubated with primary antibodies (1:1000, all antibodies except for iNOS which was 
1:500) at 4˚C overnight, followed by 3 x 5 min washes with 10 mL TBST, and incubated with 
sheep anti-mouse (Millipore, Billerica, MA, USA) secondary antibody (in 5 mL, 5% skim 
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milk/TBST) (1:2000) for 1 h at room temperature. After the detection of pSer
473
-Akt, 
membranes were stripped with stripping buffer (Thermo scientific, Rockford, IL, USA) 
following the manufacturer‟s instructions. To confirm that the membrane was stripped 
successfully, the membrane was blocked with 5% skim milk for 1 h at room temperature, 
incubated with secondary antibody (in 5 mL, 5% skim milk/TBST) (1:2000) for 1 h at room 
temperature. The membrane was visualized with enhanced chemiluminescence reagents 
(Amersham, GE Healthcare, Sydney, NSW, Australia) and the loss of protein bands indicated 
that stripping was successful. After stripping the membrane was then probed with Akt. 
Following incubation, the membranes underwent 3 x 5 min washes with 10 mL TBST. The 
secondary antibody conjugated with horseradish peroxidase was detected after incubating the 
membrane with either enhanced chemiluminescence reagents (Amersham, GE Healthcare, 
Sydney, NSW, Australia) or Supersignal West Femto (Thermo Scientific, Rockford, IL, USA) 
for 1 min, and the chemiluminescence signals on the membrane were detected by digital 
image scanner (Biorad Chemidoc). Protein bands detected were then quantified by 
densitometry. To normalize for the amount of protein, membranes were reprobed with a 
loading control antibody (actin), diluted 1:1000 in 5 mL 1% BSA/TBST after blocking non-
specific binding with 5% w/v skim milk. Membranes then underwent 3 x 10 min washes with 
10 mL TBST, and again probed with secondary antibody (Millipore, Billerica, MA, USA) 
diluted 1:2000 in 5 mL 5% skim milk/TBST for 1 hr, before bands were visualized and 
quantified as above.  
 
2.7 NADPH oxidase activity 
The NADPH oxidase-driven superoxide production were measured by using 
lucigenin-enhanced chemiluminescence assay. The NADPH oxidase activity can be 
determined either by using intact vascular tissue or vascular homogenates.  
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2.7.1 Intact vascular tissue 
Arteries were preincubated for 45 min at 37 °C in Krebs–HEPES buffer containing 
diethylthiocarbamic acid (1 mM) to inactivate SOD and NADPH (100 μM) as a substrate for 
NADPH oxidase and either alone or in the presence of diphenyl iodonium (DPI, 5 μM) as a 
flavoprotein inhibitor that inhibits NADPH oxidase. 300 μL of Krebs-HEPES buffer, 
containing lucigenin (5 μM) and the appropriate treatments were placed into a 96-well 
Optiplate, which was loaded into a Polarstar Optima photon counter (BMG Labtech, 
Melbourne, VIC, Australia) to measure background photon emission at 37°C. After 
background counting was completed, a single ring segment of vascular tissue was added to 
each well and photon emission was re-counted. Background counts were subtracted from 
superoxide counts and normalized with dry tissue weight. 
 
2.7.2 Vascular homogenates 
The vascular homogenates were prepared as described in section 2.6.1. The vascular 
homogenates were diluted 1:40 in Krebs-HEPES buffer containing either lucigenin (5 μM) 
alone or with the addition of NADPH (100 μM). The NAPDH-stimulated signal was also 
measured in the presence of DPI (5 μM). The superoxide counts were measured as described 
in section 2.7.1 and the NADPH-stimulated signal was subtracted from background. 
Superoxide counts were normalized with total protein content.  
 
2.8 Reagents 
 All drugs were purchased from Sigma-Aldrich (St Louis, MO, USA) and dissolved in 
distilled water unless otherwise stated. Acetylcholine perchlorate (BDH Chemicals, Poole, 
Dorset, UK), ET1 (Auspep, Tullamarine, VIC, Australia), and Iberiotoxin (Bachem, 
Bubendorf, Switzerland) were all dissolved in distilled water. Angeli‟s salt and 
DEANONOate (Cayman Chemical, Ann Arbor, MI, USA) were dissolved in 0.01 M NaOH. 
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Haemoglobin was dissolved in Krebs solution. DiOHF (Indofine Chemicals, Hillsborough, 
NJ, USA) was dissolved either in 10% DMSO: 90% peanut oil or 100% DMSO for animal 
injection and experiments respectively. Indomethacin was dissolved in 0.1 M sodium 
carbonate and L-NNA was dissolved in 0.1 M sodium bicarbonate. ODQ and Carboxy-PTIO 
(Cayman Chemical, Ann Arbor, MI, USA) and TRAM-34 were dissolved in 100% DMSO, 
and U46619 (Cayman Chemical, Ann Arbor, MI, USA) was dissolved in 100% ethanol as a 1 
mM stock solution, and subsequent dilution were in milliQ water.  
 
2.9 Statistical analyses 
All results are expressed as the mean±s.e.m., n represents the number of animals per 
group. Concentration-response curves from rat isolated carotid arteries were computer fitted 
to a sigmoidal curve using nonlinear regression (Prism version 5.0, GraphPad Software, 
U.S.A.) to calculate the sensitivity of each agonist (pEC50). Maximum relaxation (Rmax) to 
ACh or SNP was measured as a percentage of precontraction to PE. Group pEC50 and Rmax 
values were compared via one-way ANOVA with post-hoc test using Dunnett‟s test or 
Bonferroni‟s planned comparison test (Chapter 8), as appropriate. Mean intensity from 
western analysis was expressed as a percentage of the loading control and were compared by 
one-way ANOVA with post-hoc test using Bonferroni‟s planned comparison test or Student‟s 
unpaired t-test as appropriate. P<0.05 was considered statistically significant. 
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Chapter 3 
 
Short term type I diabetes alters the 
mechanism of endothelium-dependent 
relaxation in the rat carotid artery. 
 
3.1 Introduction 
Hyperglycaemia is a primary cause of diabetic vascular complications, the principal 
cause of morbidity and mortality in patients with diabetes. A hallmark of these vascular 
complications is the development of endothelial dysfunction which is characterized by 
impaired endothelium-dependent relaxation in various vascular beds and in different models 
of diabetes (De Vriese et al., 2000) as well as in diabetic patients (Guzik et al., 2002; Skyrme-
Jones et al., 2000). A number of studies have demonstrated that incubation of isolated blood 
vessels in a high concentration of glucose (Doriga et al., 1997; Qian et al., 2006; Taylor et al., 
1994; Tesfamariam et al., 1992a) or acute hyperglycaemia by glucose loading in healthy 
human subjects (Akbari et al., 1998) impairs ACh-induced endothelium-dependent relaxation 
in the large conduit and small resistance vessels. Thus, acute hyperglycaemia causes a rapid 
impairment of endothelial function. In contrast, in STZ-induced diabetes, Pieper (1999) 
reported a triphasic change in endothelial function: ie enhanced relaxation at 1-week post-
STZ treatment, unaltered at 1-2 weeks and impaired at 8 weeks post-STZ treatment, even 
though the animals were hyperglycaemic at all of those times after STZ treatment. 
Furthermore, other studies demonstrated that endothelial dysfunction was not observed until 
at least 7 weeks of initial STZ treatment (Hattori et al., 1991; Kitayama et al., 2006; Lund et 
al., 2000; Pieper, 1999; Wenzel et al., 2008). The inconsistency between the acute effect of 
hyperglycaemia in vitro and in vivo and the absence of impairment of relaxation in response 
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to short term hyperglycaemia in vivo, led us to postulate that there may be changes in the 
mechanism of relaxation between 3 to 7 weeks post-STZ treatment in order to preserve 
endothelial function in the early stages of diabetes.  
Endothelium-dependent relaxation is mediated by multiple factors, including NO, 
PGI2 and EDHF. The relative contribution of these various endothelium-derived factors to 
relaxation in the presence of diabetes-induced endothelial dysfunction remains controversial 
(De Vriese et al., 2000; Wigg et al., 2001). For example, whereas endothelium-dependent 
relaxation is normally mediated by NO in aorta in diabetes there is an up-regulation of non-
NO vasodilator mediators such as EDHF (Malakul et al., 2007). By contrast, there is no 
compensation for diabetes-induced impairment of endothelium-dependent relaxation in the 
carotid artery (Shi et al., 2006).  
Pieper and others (Hattori et al., 1991; Kitayama et al., 2006; Lund et al., 2000; 
Pieper, 1999; Wenzel et al., 2008) have clearly shown that endothelium-dependent relaxation 
is not impaired until at least 7 weeks after STZ treatment, however, it remains unclear as to 
how endothelium-dependent relaxation is maintained at earlier stages of diabetes. Therefore, 
we sought to verify whether short term diabetes will result in the up-regulation of 
compensatory mechanism(s) to preserve endothelium-dependent relaxation in response to 
hyperglycaemia in rat carotid artery. 
 
3.2 Methods 
3.2.1 Animals  
 Male 8-10 week old Sprague-Dawley rats (University of Melbourne Animal Facility, 
Melbourne, VIC, Australia) were randomly divided into two groups: normal and diabetic. 
Diabetes was induced by a single injection of STZ into the rat tail vein after fasting overnight. 
The control groups received an equivalent volume of the vehicle (0.1 M citrate buffer) alone. 
No animals in this study were treated with insulin. Six weeks after STZ or vehicle treatment, 
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the rats were euthanized with pentobarbitone sodium (325 mg/kg, i.p, Virbac, Melbourne, 
VIC, Australia). Blood samples were obtained from the left ventricle by cardiac puncture and 
the glucose concentration was measured using a one-touch glucometer (Roche, Sydney, 
NSW, Australia). Induction of diabetes was considered successful when the glucose level was 
higher than 20 mM.  None of the rats in this study were administered with insulin. In this 
chapter, all the diabetic rats were used for experimentation. All procedures involved were 
approved by the Animal Experimentation Ethics Committees of Melbourne and RMIT 
Universities and conformed to the Australian National Health and Medical Research Council 
code of practice for the care and use of animals for scientific purposes. 
 
3.2.2 Myograph experiments 
Carotid arteries were removed and placed in Krebs bicarbonate solution (118 mM 
NaCl, 4.7 mM KCl, 1.18 mM MgSO4, 1.2 mM KH2PO4, 25 mM NaHCO3, 11.1 mM D-
glucose, and 2.5 mM CaCl2, pH 7.4), bubbled with 5% CO2 in O2  at 37˚C. Vascular 
reactivity of carotid arteries were performed as described in Chapter 2.3. The effect of the 
treatment on relaxant responses was examined by cumulative concentration-response curves 
to ACh (0.1 nM-10 μM) and SNP (0.01 nM-10 μM). In addition, responses to ACh and SNP 
were examined after 20 min incubation with different combinations of L-NNA (100 μM or 1 
mM), a NO synthase inhibitor, indomethacin (10 μM), a COX inhibitor, ODQ (10 μM), an 
inhibitor of sGC, Hb (20 μM), scavenger of both NO and HNO, carboxy-PTIO (200 μM), a 
NO scavenger, L-cysteine (1 mM), a HNO scavenger,  TRAM-34 (1 μM), a selective blocker 
of IKCa, apamin (1 M), a SKCa inhibitor or cupric chloride (10 μM, 30 min), an agent that 
causes degradation of S-nitrosothiol (Singh et al., 1996).  
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3.2.3 Western Blot 
 Western blot analysis was performed as described in Chapter 2.6. To investigate 
eNOS homodimer formation in the tissue, a non-boiled sample was resolved by 6% SDS-
PAGE at 4°C (Chapter 2.6.5). 
 
3.2.4 Superoxide measurement 
Superoxide levels in the carotid artery were measured by the L-012-induced 
chemiluminescence assay as described in Chapter 2.4.1.  
 
3.2.5 Nitric oxide measurement 
Intracellular levels of NO in the carotid artery were measured by DAF-FM diacetate 
(Chapter 2.5).  
 
3.2.6 Drugs used 
 All drugs were purchased from Sigma-Aldrich (St Louis, MO, USA), except for 
acetylcholine perchlorate (BDH Chemicals, Poole, Dorset, UK), ODQ, carboxy-PTIO and 
U46619 (Cayman Chemical, Ann Arbor, MI, USA). All drugs were all dissolved in distilled 
water, with the exception of Hb, which was dissolved in Krebs solution, indomethacin, which 
was dissolved in 0.1 M sodium carbonate, L-NNA, which was dissolved in 0.1 M sodium 
bicarbonate, ODQ, carboxy-PTIO, DAF-FM diacetate, apocynin and TRAM-34, which were 
dissolved in DMSO, and U46619, which was dissolved in absolute ethanol as a 1 mM stock 
solution, and subsequent dilutions were in distilled water.  
 
3.2.7 Statistical analyses 
All results are expressed as the mean±s.e.m., n represents the number of animals per 
group. Concentration-response curves from rat isolated carotid arteries were computer fitted 
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to a sigmoidal curve using nonlinear regression (Prism version 4.0, GraphPad Software, San 
Diego, CA, USA) to calculate the sensitivity of each agonist (pEC50). Maximum relaxation 
(Rmax) to ACh or SNP was measured as a percentage of precontraction to PE/U46619. Group 
pEC50 and Rmax values were compared via one-way ANOVA with post-hoc Dunnett‟s test or 
Student‟s unpaired t-test as appropriate. Results from western analysis, DAF-FM and L-012 
were compared by either Student‟s unpaired t-test or one-way ANOVA with post-hoc 
Dunnett‟s test as appropriate. P<0.05 was considered statistically significant. 
 
3.3 Results 
3.3.1 Body weights and blood glucose 
 The body weights and blood glucose of the rats are shown in Table 3.1. Six weeks 
after treatment with STZ or vehicle, both groups of rats gained weight, however, the weight 
gained by normal rats was significantly greater than diabetic rats (Table 3.1). The blood 
glucose of diabetic rats was significantly greater than normal rats (Table 3.1).  
 
3.3.2 Effect of diabetes on superoxide generation. 
 The superoxide generation in carotid arteries from normal and diabetic rats measured 
using L-012 chemiluminescence is shown in Figure 3.1. The superoxide level in carotid 
arteries from diabetic rats was significantly higher than in normal rats. To examine whether 
uncoupled eNOS may contribute to superoxide production, a NOS inhibitor, L-NNA was 
used. L-NNA significantly decreased superoxide release from diabetic but not normal arteries. 
Apocynin, a ROS scavenger, attenuated the generation of superoxide to comparable levels in 
normal and diabetic rats (Figure 3.1). 
 
 
Chapter 3-Altered endothelial function in short term diabetes 
100 
 
Table 3.1 Body weights and blood glucose, before and 6 weeks after streptozotocin or 
vehicle treatment of male Sprague-Dawley rats. 
 Before treatment 6 weeks after treatment 
  Normal  Diabetic 
n 69 36 33 
Body weight (g) 236 ± 6 418 ± 14
*
 300 ± 11
*#
 
Blood glucose (mM) ND 11.1 ± 0.7 High (>33) 
 
A comparison of rat body weights and blood glucose, before and 6 weeks after streptozotocin 
(48 mg/kg) or vehicle treatment. n= the number of rats. * Significantly different from rats 
before treatment (Dunnett‟s test, p<0.05). # Significantly different from normal rats 6 weeks 
after streptozotocin injection (Student‟s unpaired t-test, p<0.05). Results are shown as 
mean±s.e.m. ND: Not determined. 
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Figure 3.1 Measurement of superoxide levels in carotid artery. Superoxide levels in 
carotid artery from normal (open bars) and diabetic (solid bars) rats in the absence or presence 
of either L-NNA (100 μM), a NOS inhibitor or apocynin (Apo, 300 μM), ROS scavenger. 
Arteries from diabetic rats had a significantly higher level of superoxide production compared 
to normal rats. In the presence of L-NNA, superoxide levels were significantly decreased in 
diabetic arteries. n= 7-13 experiments. Results are shown as mean±s.e.m. * Significantly 
different from normal rats (Student‟s unpaired t-test, p<0.05). # Significantly different from 
control within respective group (Student‟s unpaired t-test, p<0.05). 
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3.3.3 Effect of diabetes on relaxation to ACh and SNP 
The relaxant responses to ACh and SNP in carotid arteries from rats treated with STZ or 
vehicle are shown in Figure 3.2. The sensitivity and maximum relaxation to ACh and SNP 
were not significantly different between the normal and diabetic rats (Table 3.2).  
 
3.3.4 Effect of diabetes on the mechanism of relaxation to ACh and SNP  
 The relaxation to ACh in carotid arteries from normal and diabetic rats was not 
affected by indomethacin treatment (Figure 3.2, Table 3.2), suggesting that a cyclo-oxygenase 
product was not involved in endothelium-dependent relaxation in carotid arteries.  L-NNA 
(100 M) or ODQ (10 M) abolished responses to ACh in normal (Figure 3.2a, Table 3.2) but 
not in diabetic arteries (Figure 3.2b, Table 3.2). A 10-fold higher concentration of L-NNA did 
not cause a significantly greater reduction in the maximum relaxation to ACh (L-NNA (100 
M), Rmax= 34±6% vs. L-NNA (1 mM), Rmax= 33±4%, n=7, p>0.05) in diabetic arteries. 
The presence of indomethacin did not affect SNP-induced relaxation in carotid arteries 
from normal or diabetic rats. NOS inhibition tended to increase the sensitivity to SNP in 
arteries from normal rats, although the change in pEC50 was not statistically significant, and in 
diabetic rats L-NNA treatment significantly shifted the SNP concentration-response curve to 
the left (Figure 3.2d, Table 3.2). ODQ abolished the response to SNP in normal arteries 
(Figure 3.2c, Table 3.2) whereas SNP-induced relaxation (Figure 3.2d, Table 3.2) was 
attenuated but not abolished by ODQ in diabetic arteries. 
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Figure 3.2 Role of NO and PGI2 to endothelium-dependent relaxation in carotid arteries. 
Cumulative concentration response curves to ACh (a,b) or SNP (c,d) in the absence (control, 
■) or in the presence of L-NNA (●), ODQ (▲) or indomethacin (♦) in endothelium-intact 
carotid arteries isolated from (a,c) normal or (b,d) diabetic rats. The relaxation response to 
ACh in the presence of L-NNA or ODQ was abolished in arteries from normal rats (a), 
whereas in diabetic rats (b), a significant relaxation remained. The relaxation response to SNP 
in the presence of ODQ was abolished in arteries from normal rats (c), whereas in diabetic 
rats (d) a 31% maximal relaxation was observed. n= 6-7 experiments. Results were shown as 
mean±s.e.m. The pEC50 and Rmax values are shown in Table 3.2.  
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Table 3.2 Effect of L-NNA, indomethacin and ODQ on ACh- and SNP-induced 
relaxation of carotid arteries from normal and diabetic rats. 
 
A comparison of the sensitivity (pEC50) and maximum relaxation (Rmax) to ACh and SNP in 
the absence (control) or the presence of L-NNA (100 μM), indomethacin (10 μM) or ODQ 
(10 μM) in endothelium intact carotid arteries from normal and diabetic rats. n= the number 
of experiments. * Significantly different from corresponding control ACh/SNP response in 
the carotid arteries within normal/diabetic group (Dunnett‟s test, p<0.05). # Significantly 
different from normal group in the carotid arteries within the respective inhibitor group 
(Student‟s unpaired t-test, p<0.05). Results are shown as mean±s.e.m. ND: Not determined 
  
  Normal   Diabetic 
 n pEC50 Rmax (%) n pEC50 Rmax (%) 
ACh       
Control 6 7.26±0.23 94±3 7 7.21±0.28 94±3 
L-NNA 6 ND 4±4
*
 7 6.23±0.24 40±6
#*
 
ODQ 6 ND 4±4
*
 7 ND 23±3
#*
 
Indomethacin 6 7.12±0.12 93±2 7 6.83±0.25 95±3 
SNP       
Control 6 8.23±0.19 100±1 7 8.37±0.18 98±2 
L-NNA 6 8.86±0.24 100±0 7 9.01±0.14
*
 99±1 
ODQ 6 ND 4±4
*
 7 6.3±0.11
*
 31±8
#*
 
Indomethacin 6 8.37±0.14 100±1 7 8.31±0.20 97±2 
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3.3.5 Role of IKCa and SKCa in ACh and SNP-induced relaxation in diabetes 
 Having established that COX inhibition did not affect endothelium-dependent 
relaxation in normal or diabetic rats, further experiments to determine the potential 
contribution from a non-NO, non-prostanoid factor were all conducted in the presence of 
indomethacin. The presence of TRAM-34+apamin, blockers of IKCa and SKCa channels 
respectively, significantly reduced the maximum relaxation to ACh in diabetic arteries (Rmax 
76±4%) in comparison to normal arteries (Rmax 94±2%, Figure 3.3, Table 3.3). In arteries 
from diabetic rats, the presence of TRAM-34+apamin, abolished the residual ACh-induced 
relaxation which was apparent after L-NNA+ODQ treatment.  
There was similar relaxation to SNP in the presence of L-NNA+ODQ or L-
NNA+ODQ+TRAM-34+apamin in normal and diabetic arteries. TRAM-34+apamin alone 
had no effect on SNP-induced relaxation in either normal or diabetic rats (Table 3.3). 
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Figure 3.3 Role of NO and EDHF to endothelium-dependent relaxation in carotid 
arteries. Cumulative concentration response curves to ACh in the presence of indomethacin 
(■), indomethacin+L-NNA+ODQ (●), indomethacin+L-NNA+ODQ+TRAM-34+apamin (▲) 
or indomethacin+TRAM-34+apamin (♦) in endothelium-intact carotid arteries isolated from 
(a) normal or (b) diabetic rats. The relaxation response to ACh in the presence of 
indomethacin+L-NNA+ODQ was abolished in arteries from normal rats but not in diabetic 
rats, where significant relaxation was observed. Indomethacin+TRAM-34+apamin 
significantly reduced maximum relaxation in diabetic rats but not in normal rats. The presence 
of indomethacin+L-NNA+ODQ+TRAM-34+apamin abolished ACh-induced relaxation in 
both groups. n= 5-10 experiments. Results were shown as mean±s.e.m. The pEC50 and Rmax 
values determined from the data presented in these graphs are shown in Tables 3.3. 
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Table 3.3 Effect of L-NNA, indomethacin, ODQ, TRAM-34 and apamin on ACh- and 
SNP-induced relaxation of carotid arteries from normal and diabetic rats. 
 
 
A comparison of the sensitivity (pEC50) and maximum relaxation (Rmax) to ACh and SNP in 
the presence of indomethacin (10 μM) alone, or in the additional presence of L-NNA (100 
μM)+ODQ (10 μM), TRAM-34 (1 μM)+apamin (1 μM) or L-NNA (100 μM)+ODQ (10 
μM)+ TRAM-34 (1 μM) +apamin (1 μM) in endothelium intact carotid arteries from normal 
and diabetic rats. n= the number of experiments. * Significantly different from corresponding 
control ACh/SNP response in the carotid arteries within normal/diabetic group (Dunnett‟s 
test, p<0.05). # Significantly different from normal group in the carotid arteries within the 
respective inhibitor group (Student‟s unpaired t-test, p<0.05). Results are shown as 
mean±s.e.m. ND: Not determined 
 
 
 
  Normal   Diabetic 
 n pEC50 Rmax (%) n pEC50 Rmax (%) 
ACh       
Indomethacin 7 6.91±0.15 95±2 10 7.00±0.12 94±2 
Indomethacin + L-NNA + 
ODQ 
7 ND 4±4
*
 5 ND 25±5
*#
 
Indomethacin + TRAM-34 
+ apamin 
7 6.70±0.17 94±2 5 6.51±0.10 76±4
*#
 
Indomethacin + L-NNA + 
ODQ + TRAM-34 + 
apamin 
7 ND 3±3
*
 5 ND 3±3
*
 
SNP       
Indomethacin 7 8.41±0.20 101±1 5 8.49±0.17 100±2 
Indomethacin + L-NNA + 
ODQ 
7 ND 44±4
*
 5 ND 27±5
*
 
Indomethacin + TRAM-34 
+ apamin 
7 8.24±0.18 100±0 5 8.18±0.10 99±1 
Indomethacin + L-NNA + 
ODQ + TRAM-34 + 
apamin 
7 ND 40±6
*
 5 ND 31±5
*
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3.3.6 Characterization of L-NNA resistant relaxation in diabetes 
 The relaxation to ACh was abolished by indomethacin+L-NNA (100 M, 1 mM) in 
arteries from normal but not diabetic rats. To test whether the resistance to NOS inhibition in 
diabetic arteries may be due to an alternative source of NO such as nitrosothiols, NO 
scavengers and copper were used. The addition of Hb, a non-selective NO scavenger, 
abolished the residual ACh-induced relaxation after treatment with indomethacin+L-NNA 
(Dunnett‟s test, p<0.05, Figure 3.4, Table 3.4). Similarly, the residual ACh-induced relaxation 
was significantly attenuated by the addition of either carboxy-PTIO or L-cysteine which 
specifically scavenge NO and HNO respectively (Figure 3.4, Table 3.4).  
The presence of cupric chloride significantly decreased the sensitivity to ACh in 
diabetic arteries (indomethacin+ cupric chloride, pEC50= 6.71±0.08 vs. indomethacin, pEC50= 
7.05±0.12), n=5, p<0.05, Figure 3.5).The addition of cupric chloride to indomethacin+L-NNA 
significantly reduced the residual ACh-induced relaxation (indomethacin+L-NNA+ cupric 
chloride, Rmax= 9±3% vs. indomethacin+L-NNA, Rmax= 34±6%), n=7, p<0.05, Figure 3.5). 
The presence of Hb+indomethacin alone significantly attenuated the ACh-induced relaxation 
in both normal and diabetic rats (Table 3.4). 
The maximum relaxation to SNP in diabetic and normal arteries was not affected by 
L-NNA, Hb or the combination of the 2 inhibitors (Table 3.4). The sensitivity to SNP was 
significantly increased by indomethacin+L-NNA, and decreased by indomethacin+Hb or 
indomethacin+L-NNA+Hb in both normal and diabetic rats (Table 3.4).  
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Figure 3.4 Role of L-NNA resistant ACh-induced relaxation in diabetic carotid arteries. 
Cumulative concentration response curves to ACh in the presence of indomethacin+L-NNA 
(■), indomethacin+L-NNA+carboxy-PTIO (●), indomethacin+L-NNA+L-cysteine (▲) or 
indomethacin+L-NNA+Hb (♦) in endothelium-intact carotid arteries isolated from diabetic 
rats. The addition of either carboxy-PTIO or L-cysteine after indomethacin+L-NNA 
significantly reduced the maximum relaxation in diabetic rats. The presence of 
indomethacin+L-NNA+Hb abolished ACh-induced relaxation in the diabetic arteries. n= 5-10 
experiments. Results are shown as mean±s.e.m. The pEC50 and Rmax values determined from 
the data presented in these graphs are shown in Tables 3.4. 
  
Chapter 3-Altered endothelial function in short term diabetes 
110 
 
 
Figure 3.5 Role of nitrosothiol stores to endothelium-dependent relaxation in diabetic 
carotid arteries. Cumulative concentration response curves to ACh in the presence of 
indomethacin (■),cupric chloride (10 M) (●), indomethacin+L-NNA (100 M) (▲) or 
indomethacin+L-NNA+ cupric chloride (♦) in endothelium-intact carotid arteries isolated 
from diabetic rats. * pEC50 significantly different to indomethacin (Student‟s unpaired t-test, 
p<0.05), # Rmax significantly different to indomethacin+L-NNA. n= 5-7 experiments. Results 
were shown as mean±s.e.m. Refer to text for pEC50 and Rmax values 
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Table 3.4 Effect of L-NNA, indomethacin, carboxy-PTIO, L-cysteine and Hb on ACh- 
and SNP-induced relaxation of carotid arteries from normal and diabetic rats 
 
A comparison of the sensitivity (pEC50) and maximum relaxation (Rmax) to ACh and SNP in 
the presence of indomethacin (10 μM) alone, or in the additional presence of L-NNA (100 
μM), Hb (20 μM), L-NNA (100 μM)+carboxy-PTIO (200 μM), L-NNA (100 μM)+L-cysteine 
(1 mM)  or L-NNA (100 μM)+Hb (20 μM) in endothelium intact carotid arteries from normal 
and diabetic rats. n= the number of experiments. * Significantly different from corresponding 
control ACh/SNP response in the carotid arteries within normal/diabetic group (Dunnett‟s 
test, p<0.05). # Significantly different from normal treatment group in the carotid arteries 
within the “indomethacin + L-NNA” group (Student‟s unpaired t-test, p<0.05). Results are 
shown as mean±s.e.m. ND: Not determined 
  Normal   Diabetic  
 n pEC50 Rmax (%) n pEC50 Rmax (%) 
ACh       
Indomethacin 6 7.03±0.26 91±4 10 6.96±0.12 96±2 
Indomethacin + L-NNA  6 ND 4±4
*
 8 ND 48±6
*#
 
Indomethacin + Hb 6 ND 39±8
*
 5 ND 38±9
*
 
Indomethacin + L-NNA 
+ Hb 
6 ND 2±2
*
 5 ND 6±6
*
 
Indomethacin + L-NNA 
+ carboxy-PTIO 
   5 ND 17±5
*
 
Indomethacin + L-NNA 
+ L-cysteine 
   5 ND 12±4
*
 
SNP       
Indomethacin 6 8.35±0.11 101±1 3 8.63±0.05 101±1 
Indomethacin + L-NNA  6 8.84±0.07
*
 104±1 3 9.08±0.15 98±2 
Indomethacin + Hb 6 7.46±0.08
*
 102±1 3 7.87±0.29
*
 104±2 
Indomethacin + L-NNA 
+ Hb 
6 7.86±0.14
*
 104±1 3 7.87±0.11
*
 103±3 
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3.3.7 Effect of diabetes on nitric oxide production detected by DAF-FM fluorescence 
In normal arteries, stimulation with ACh caused a significant increase in DAF-FM 
fluorescent which was abolished by L-NNA. Diabetes had no effect on the basal release of 
DAF-FM fluorescent, but stimulation with ACh caused a significantly smaller increase 
compared to normal arteries. In the presence of L-NNA, the response to ACh was abolished in 
normal but only attenuated in diabetic arteries, suggesting a non-NOS source of NO (Figure 
3.6).  
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Figure 3.6 Measurement of DAF-FM-fluorescent levels in carotid arteries. DAF-FM 
fluorescent levels in carotid artery from normal (open bars) and diabetic (solid bars) rats in the 
absence or presence of either ACh (10 μM) or ACh (10 μM)+L-NNA (100 μM), a NOS 
inhibitor. Diabetes has a significantly lower level of DAF-FM fluorescent compared to 
normal rats. In the presence of L-NNA, nitric oxide levels were significantly increased in 
diabetic arteries. n= 7 experiments. Results are shown as mean±s.e.m. * Significantly 
different from normal rats (Student‟s unpaired t-test, p<0.05). # Significantly different from 
ACh within respective group (Dunnet‟s test, p<0.05). 
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3.3.8 Effect of diabetes on the expression of iNOS, eNOS, Nox2 and caveolin-1 in the 
carotid artery. 
 In diabetes, the expression of eNOS and Nox2, which is the catalytic subunit of 
NADPH oxidase, were significantly increased whereas caveolin-1 (Dudzinski et al., 2007), 
which is a modulator of eNOS activity, was significantly decreased in the rat carotid arteries 
when compared to normal rats (Figure 3.7a, c, d). Diabetes also significantly reduced the 
proportion of eNOS expressed as a dimer, indicating that eNOS was uncoupled (Figure 3.7b). 
Furthermore, there was no detectable expression of iNOS in the rat carotid arteries from either 
group, indicating that this does not replace eNOS as a source of vascular NO production (data 
not shown).   
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Figure 3.7 Western blot analysis of carotid arteries. Protein expression of (a) eNOS, (b) 
eNOS homodimer formation, (c) caveolin-1 and (d) Nox2 in the normal and diabetic rat 
carotid arteries determined by Western blot analysis. Diabetes significantly increased the 
expression of eNOS and Nox2, and decreased the expression of caveolin-1 in the rat carotid 
arteries. Diabetes also significantly reduced the proportion of eNOS expressed as the dimer. 
n= 6-7 experiments. Representative blots were shown on each corresponding graphs. Results 
are shown as mean±s.e.m. * Significantly different from normal rats (Student‟s unpaired t-
test, p<0.05). 
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3.4 Discussion 
This study demonstrated that, whilst 6 weeks of diabetes caused a significant increase 
in vascular superoxide production, it did not affect the sensitivity or maximum response to 
ACh, but there were marked changes in the mechanism of endothelium-dependent relaxation. 
Diabetes caused a resistance of ACh-induced relaxation to NOS inhibition and also revealed 
some sensitivity of endothelium-dependent relaxation to inhibition by potassium channel 
blockers in addition to the usual role for NO-induced stimulation of sGC. The NOS-
independent component of the response to ACh could be attenuated by scavengers of NO and 
HNO and by degradation of nitrosothiols with copper ions. Western blot analysis indicated 
that diabetes caused an increased expression of eNOS and decreased expression of caveolin-1 
protein but that it also significantly reduced the proportion of eNOS that is expressed as a 
dimer, indicating that eNOS was uncoupled and could in part be producing superoxide instead 
of NO. In the early stages of STZ-induced diabetes, despite marked hyperglycaemia, 
increased production of superoxide, and decreased NO synthesis detected by DAF-FM, 
endothelium-dependent relaxation was maintained possibly by a NOS-independent source of 
NO such as nitrosothiols. In diabetes, the nitrosothiol-derived NO-mediated relaxation 
involves the opening of potassium channels in addition to the activation of sGC. 
In the present study, the STZ-treated rats exhibited hyperglycaemia and a lower body 
weight than normal rats, demonstrating that diabetes was induced successfully. The 
observation that endothelium-dependent and –independent relaxation of the carotid arteries 
was not impaired 6 weeks after STZ treatment is consistent with others studies examining the 
time course of the vascular response to diabetes, as endothelial dysfunction was only observed 
at least 7 weeks after diabetes induction even though the animals were hyperglycaemic after 
STZ treatment (Hattori et al., 1991; Kitayama et al., 2006; Lund et al., 2000; Pieper, 1999; 
Wenzel et al., 2008). Although endothelium-dependent relaxation was maintained in the 
diabetic vessels, we demonstrated that superoxide production detected by L-012 was 
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increased and at the same time, ACh (10 M) stimulated NO release detected by DAF-FM 
was decreased in diabetes. The Nox2-dependent NADPH oxidase (Cai et al., 2000; 
Griendling et al., 2000) and uncoupled eNOS (Hink et al., 2001) have been shown to be 
amongst the major sources of vascular superoxide in disease, including in diabetes, and in this 
study the increased superoxide production in diabetic endothelium and VSMC (Cai et al., 
2005) was associated with increased expression of Nox2 in the carotid arteries, which could 
be due to vascular infiltration of macrophages (Mollnau et al., 2003). Previous studies have 
shown that diabetes could also cause eNOS uncoupling via multiple mechanisms, such as 
increased endothelial arginase activity (Ryoo et al., 2008) or depletion of the eNOS cofactor 
tetrahydrobiopterin by decreasing the expression of guanosine triphosphate cyclohydrolase I 
and/or dihydrofolate reductase (Cai et al., 2005; Ren et al., 2008; Wang et al., 2009c). We 
observed a decrease in caveolin-1 expression and an increase in eNOS expression but this was 
accompanied by a decreased proportion of the eNOS as the dimer indicating eNOS 
uncoupling and decreased NO synthesis in the diabetic carotid arteries, consistent with 
reported observations at a later stage of diabetes (Wenzel et al., 2008). Indeed, Zou et al., 
(2002) have demonstrated that the uncoupling of eNOS could be observed after peroxynitrite 
treatment for five min, suggesting a rapid effect of oxidant stress on eNOS dimerization (Zou 
et al., 2002a; Zou et al., 2002b).  
Despite eNOS uncoupling in diabetes, the amount of NO being produced was 
adequate to induce full relaxation as observed in our functional experiments where near 
maximum relaxation was obtained with less than 10 μM of ACh in both normal and diabetic 
arteries. This could possibly be due to an increased sensitivity of the sGC and/or the 
contribution of non-NOS derived NO to endothelium-dependent relaxation in diabetes. 
Indeed, we observed that in normal rats, SNP-induced relaxation was abolished in the 
presence of ODQ, whereas in diabetic rats, there was significant relaxation perhaps due to 
enhanced sGC activity. In addition, we observed that NO production detected by DAF-FM 
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was resistant to NOS inhibition in diabetes, suggesting a role for a non-NOS derived source of 
NO.  
Although endothelium-dependent relaxation was not impaired in the diabetic arteries, 
we demonstrated that the mechanism of endothelium-dependent relaxation was altered. In 
normal carotid arteries, endothelium-dependent relaxation was solely mediated by NO acting 
on sGC, as ACh-induced relaxation of arteries from normal rats was abolished by L-NNA 
and/or ODQ but was unaffected by indomethacin or KCa channel blockers. In contrast, in 
diabetes ACh-induced relaxation of the carotid arteries was in part resistant to inhibition of 
NOS and/or sGC. The resistance of ACh responses to NOS inhibition did not appear to be due 
to an inadequate inhibition of NOS as there was no greater inhibitory effect with a 10-fold 
higher concentration of L-NNA. This suggested a possible up-regulation of alternative 
mechanism(s) of endothelium-dependent relaxation. To investigate the possible role of 
prostanoids in endothelium-dependent relaxation, we used indomethacin, a non-selective 
COX inhibitor, but there was no evidence that a prostanoid made any contribution to 
endothelium-dependent relaxation in the carotid arteries. Alternative explanations for the 
resistance to NOS and sGC inhibition could be that diabetes stimulates the involvement of 
EDHF to endothelium-dependent relaxation or NO may act through a sGC-independent 
pathway to induce relaxation, such as by causing hyperpolarization through the opening of 
KCa channels (Bolotina et al., 1994; Mistry et al., 1998; Plane et al., 1998). 
To examine whether EDHF contributed to endothelium-dependent relaxation of 
carotid arteries in diabetes, the combination of TRAM-34 and apamin was used to block IKCa 
and SKCa channels respectively. Inhibition of endothelial KCa channels caused a reduction in 
endothelium-dependent relaxation in carotid arteries from diabetic, but not normal rats, 
suggesting the involvement of the opening of endothelial KCa channels in relaxation during 
diabetes. Whilst this supports the possible release of an EDHF, the observation could also be 
explained by NO causing relaxation through activation of KCa channels. Therefore, to 
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examine this possibility, we increased the NO inhibition by the addition of NO scavengers 
(Hb, carboxy-PTIO and L-cysteine) and demonstrated that ACh-induced relaxation was 
abolished with the addition of NO scavengers in the diabetic rat. Hence, the ability of NO 
scavengers to abolish endothelium-dependent relaxation in the presence of indomethacin+L-
NNA from diabetic arteries perhaps argues against a role for EDHF. Rather, it is possible that 
there is a non-NOS source of NO in diabetes consistent with our observation that ACh-
induced DAF-FM fluorescence in the presence of L-NNA is higher in diabetic compared to 
normal arteries. Taken together, our data suggests that in diabetes there is an additional action 
of NO acting through a sGC-independent pathway, causing opening of the IKCa and SKCa 
channels to induce relaxation.  
We postulated that to maintain vascular relaxation in the carotid artery during the early 
stages of diabetes, NO derived from a NOS-independent source such as nitrosothiols may be 
involved. To address the role of nitrosothiols in modulating endothelium-dependent relaxation 
in diabetes, we used a nitrosothiol degrading agent, cupric chloride (Foster et al., 2003; 
Gandley et al., 2005; Singh et al., 1996) in the presence of indomethacin+L-NNA. Brief 
exposure to copper ions has been demonstrated to not affect endothelial function in normal 
arteries (Chiarugi et al., 2002), but our studies demonstrated that in diabetic arteries, the 
sensitivity to ACh responses was decreased, suggesting that nitrosothiols contribute to 
endothelium-dependent relaxation. In addition, copper was able to abolish the residual 
relaxation in the presence of the NOS inhibitor. Furthermore, in our functional experiments, 
we also demonstrated that specific NO scavengers, carboxy-PTIO and L-cysteine (scavengers 
of NO and HNO respectively) (Favaloro et al., 2009; Irvine et al., 2008; Pino et al., 1994; 
Yuill et al., 2011) were able to significantly attenuate ACh-induced relaxation in the presence 
of L-NNA (plus indomethacin) in the diabetic rat, further supporting the possibility that NO-
derived from nitrosothiols was responsible for maintaining vascular function. Indeed, 
nitrosothiols have been shown to release both NO and HNO in response to several agonists, 
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including ACh (Arnelle et al., 1995b; Ellis et al., 2000b; Manukhina et al., 2006; Ng et al., 
2007b), to cause vascular relaxation through the endothelial IKCa and SKCa channels 
(Batenburg et al., 2004). Our results suggest that in diabetes, as has previously been shown in  
hypertension (Kubaszewski et al., 1994), where NO production/activity is impaired, 
nitrosothiol-derived NO may serve as a compensatory source of vascular NO supply.  
Previous studies have suggested that NO may activate large-conductance calcium-
activated K
+
 channels (maxi KCa) which are found on VSMC to cause relaxation (Bolotina et 
al., 1994; Mistry et al., 1998; Plane et al., 1998), rather than opening the endothelial IKCa and 
SKCa channels suggested by our data. Those studies, however, used charybdotoxin which 
inhibits both  maxi KCa and IKCa channels (Ledoux et al., 2006) and these results were 
inconsistent as to whether the responses were also sensitive to selective blockade of maxi KCa 
using iberiotoxin (Bolotina et al., 1994; Mistry et al., 1998; Plane et al., 1998), leaving it 
uncertain as to whether NO was acting on channels in the VSMC, endothelial cells or both. In 
this study, we used the combination of TRAM-34+apamin to selectively block the endothelial 
IKCa and SKCa channels respectively without affecting potassium channels on VSMC. Thus, a 
role of maxi KCa on VSMC is unlikely but it is not possible to conclude which of the IKCa and 
SKCa channels are involved in NO activity within the vasculature as the inhibitors were not 
tested individually. Taken together, the results demonstrate that the resistance to NOS and 
sGC inhibition in diabetes was due to a role of non-NOS source of NO and subsequent 
activation of KCa channels, and perhaps an increase in sensitivity of sGC due to the decrease 
in eNOS derived NO production.  
Previous studies have demonstrated that acute hyperglycaemia (Hoshiyama et al., 
2003; Qian et al., 2006; Tesfamariam et al., 1992a; Tsubouchi et al., 2005) or diabetes for 7 
or more weeks (Ding et al., 2007b; Wenzel et al., 2008) reduces endothelial NO synthesis 
accompanied by both an increase in superoxide production and eNOS expression, and 
impaired endothelium-dependent relaxation.  This study, at 6 weeks of diabetes, also noted 
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the increase in superoxide, decrease in NO production and eNOS expression/uncoupling but 
endothelium-dependent relaxation was preserved.  Taken together, these results suggest that 
hyperglycaemia acutely increases oxidative stress but nitrosothiols may serve as a 
compensatory vascular NO supply which can maintain endothelium-dependent relaxation.  It 
is proposed that with prolonged diabetes, the compensatory mechanisms may fail and 
endothelium-dependent relaxation is impaired. This is a likely explanation for the differences 
between these observations and those of Shi et al. (2006) who also studied the effects of STZ-
induced diabetes on the mechanism of endothelium-dependent relaxation in rat carotid 
arteries. In that study it was reported that after 12 weeks of diabetes NO-mediated 
endothelium-dependent relaxation was impaired in carotid arteries but there was no evidence 
of compensation by any change in alternative dilator mechanisms. 
In conclusion, after 6 weeks of STZ-induced diabetes, NO, not only from NOS 
activity but perhaps also from nitrosothiol stores, may be acting in part through a sGC-
independent mechanism, particularly by the opening of the IKCa and SKCa channels, in order 
to preserve endothelial function in the presence of diabetes-induced vascular oxidant stress.  
Therefore, these results suggest that the additional role of nitrosothiol at this early stage of 
diabetes in the rat carotid artery is an adaptive mechanism to counteract the inactivation of 
NO by superoxide to maintain vascular relaxation in response to hyperglycaemia. 
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Chapter 4 
 
Endothelium-dependent nitroxyl-mediated 
relaxation is resistant to superoxide 
scavenging and preserved in diabetic rat 
aorta. 
 
4.1 Introduction 
The endogenous production of NO is well recognized as an important contributor to 
vascular homeostasis. The vascular action of NO predominantly involves the activation of 
sGC, which catalyses the conversion of GTP to cGMP, leading to vasodilatation (Moncada et 
al., 1991).  NO may not be the only endothelium-derived nitrogen species, with HNO, the one 
electron reduced and protonated form of NO, likely to have a role in modulating vascular tone 
as there is evidence that it is formed endogenously and contributes to endothelium-dependent 
relaxation in both conduit (Ellis et al., 2000a; Wanstall et al., 2001) and resistance vessels 
(Andrews et al., 2009).  
HNO can be produced by several distinct pathways in the vascular endothelium. 
Biochemical studies indicate that HNO can be synthesized via endothelial NO synthase 
(eNOS)-dependent and independent pathways (Irvine et al., 2008). HNO can be synthesized 
by eNOS itself as an intermediate product during the conversion of L-arginine to NO. 
Subsequently, HNO is oxidized to NO by superoxide dismutase (Hobbs et al., 1994). 
Moreover, the production of HNO by eNOS could occur under the conditions of reduced 
levels of the eNOS cofactor, BH4 (Rusche et al., 1998), oxidation of NOS intermediates, N-
hydro-L-arginine (Pufahl et al., 1995) and hydroxylamine (Donzelli et al., 2008). 
Furthermore, HNO can be produced from NOS-independent sources, including the reduction 
of NO by mitochondrial cytochrome c (Sharpe et al., 1998) and xanthine oxidase (Saleem et 
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al., 2004). Finally, S-nitrosothiols are also known to generate HNO via S-thiolation, a 
reaction between S-nitrosothiols with other thiol species (Arnelle et al., 1995a).  
Like NO, HNO has the ability to cause vascular relaxation via the accumulation of 
cGMP but HNO also has distinct pharmacological actions in comparison to NO (Bullen et al., 
2011a). For example, Miranda and coworkers demonstrated that unlike NO the HNO donor, 
Angeli‟s salt does not react with superoxide to form peroxynitrite (Miranda et al., 2002), 
suggesting that HNO-mediated vasodilatation could be preserved when there is oxidative 
stress. Despite these, Ellis and colleagues reported that Angeli‟s salt-induced relaxation was 
significantly attenuated by the presence of a superoxide generator, pyrogallol, in the rat aorta 
(Ellis et al., 2001), suggesting that HNO does react with superoxide anions. Thus, it remains 
unclear whether HNO-induced vascular relaxation is affected by superoxide anions in the 
vasculature. 
It is well established that the overproduction of ROS is associated with diabetes, 
leading to impaired NO synthesis/activity and endothelial dysfunction (De Vriese et al., 2000; 
Fatehi-Hassanabad et al., 2010). It is not known, however, whether the vascular action of 
endothelium-derived HNO is affected under oxidative stress. Thus, the aim of the study was 
to investigate the effects of pyrogallol-induced superoxide production on HNO-induced 
relaxation in rat isolated aorta. Importantly, we also evaluated the vascular actions of 
endothelium-derived HNO in diabetes where there is chronic oxidative stress.  
 
4.2 Methods 
All procedures were approved by the Animal Experimentation Ethics Committee of 
RMIT University and conformed to the National Health and Medical Research Council of 
Australia code of practice for the care and use of animals for scientific purposes. 
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4.2.1 Induction of diabetes  
 Briefly, male Sprague-Dawley rats weighing approximately 200g (Animal Resource 
Centre, Perth, WA, Australia) were randomly divided into two groups: normal and diabetic. 
Diabetes was induced by a single injection of STZ into the tail vein after the rats were fasted 
overnight. In events where the diabetic rats exhibited weight loss (approximately 5% weight 
loss from the initial weight), these rats were treated with a low dose of insulin (4-5 IU, 
Protaphane, Novo Nordisk, NSW, Australia) to promote weight gain and reduce mortality. 
The control groups were not treated with insulin. In this chapter, all of the diabetic rats were 
used for experimentation. Ten weeks after STZ, rats were asphyxiated by CO2 inhalation, 
followed by decapitation, at which point blood was collected. Blood glucose was measured 
using a one touch glucometer (Roche, Sydney, NSW, Australia). Induction of diabetes was 
considered successful when the glucose level was higher than 20 mM.  
 
4.2.2 Preparation and equilibration of rat aortic rings  
Rats were asphyxiated by CO2 inhalation, followed by decapitation, and their chests 
opened to isolate the thoracic aortae. After the removal of superficial connective tissues, the 
aorta was cut into ring segments of approximately 2-3 mm in length. The aortic rings were 
then mounted between two stainless steel wires, one of which was linked to an isometric force 
transducer (model FT03, Grass Medical Instruments, Quincy, MA, USA) connected to a 
MacLab/8 (model MKIII, AD Instrument Co., Sydney, Australia), and the other anchored to a 
glass rod submerged in a standard 10 mL organ bath. The organ bath was filled with Krebs-
bicarbonate solution [composition (mM): NaCl, 118.0; KCl, 4.7; KH2PO4, 1.2; MgSO4.7H2O, 
1.2; D-glucose, 11.0; NaHCO3, 25.0; CaCl2.2H2O, 2.5;] containing 0.026 mM EDTA to 
prevent degradation of HNO to NO (Irvine et al., 2003). The bath medium was maintained at 
37°C, pH 7.4 and continuously aerated with 95% O2, 5% CO2. Aortic rings were equilibrated 
and endothelium integrity was tested to as described in Chapter 2.3. 
Chapter 4-HNO-mediated relaxation is preserved in diabetes 
126 
 
4.2.3 Functional experiments  
To examine the effect of superoxide on NO and HNO-mediated relaxation, responses 
to the HNO donor, Angeli‟s salt, NO donor, DEANONOate or ACh were examined in the 
presence of pyrogallol. Aortic rings were isolated from male Sprague-Dawley rats (~8 weeks 
of age, 250-300 g) and mounted in standard 10 mL organ baths containing Krebs-bicarbonate 
solution as described above. After aortic rings were equilibrated, the maximum responses 
established, and the endothelium integrity tested, rings were incubated for 20 min with 
pyrogallol (100 μM), a superoxide generator, HXC (100 μM), a selective NO scavenger or L-
cysteine (3 mM, which was incubated for 3 min), a selective HNO scavenger or a 
combination of these compounds. After establishing a stable precontraction using PE (0.01-
0.3 μM), cumulative concentration-response curves to ACh (0.1 nM-10 μM) were determined. 
In some experiments, cumulative concentration-response curves to either Angeli‟s salt (0.1 
nM-10 μM) or DEANONOate (0.1 nM-10 μM) were determined either in the absence or 
presence of pyrogallol (30 μM and 100 μM). 
To examine the effect of diabetes on endothelium-derived NO and HNO-mediated 
relaxation, aortic rings were isolated from normal and diabetic rats. The effect of the 
treatment on relaxant responses was determined by cumulative concentration-response curves 
to ACh (0.1 nM-10 μM). In addition, responses to ACh were examined after 20 min 
incubation with different combinations of L-NNA, (100 μM), a non-selective NOS inhibitor, 
ODQ, (10 μM), a sGC inhibitor, HXC (100 μM), and L-cysteine (3 mM, which was incubated 
for 3 min). 
 
4.2.4 Reagents 
 All drugs were purchased from Sigma-Aldrich (St Louis, MO, USA), except for 
acetylcholine perchlorate (BDH Chemicals, Poole, Dorset, UK), ODQ (Cayman Chemical, 
Ann Arbor, MI, USA), Angeli‟s salt (Cayman Chemical, Ann Arbor, MI, USA) and 
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DEANONOate (Cayman Chemical, Ann Arbor, MI, USA). All drugs were dissolved in 
distilled water, with the exception of L-NNA, which was dissolved in 0.1 M sodium 
bicarbonate and ODQ, which was dissolved in dimethyl sulfoxide (DMSO). Both Angeli‟s 
salt and DEANONOate were dissolved in 0.01 M sodium hydroxide. Subsequent dilutions of 
Angeli‟s salt and DEANONOate were in 0.01 M sodium hydroxide. 
 
4.2.5 Statistical analyses 
All results are expressed as the mean±s.e.m, n represents the number of animals per 
group. Concentration-response curves from rat isolated aortae were computer fitted to a 
sigmoidal curve using nonlinear regression (Prism version 5.0, GraphPad Software, San 
Diego, CA, USA) to calculate the sensitivity of each agonist (pEC50). Maximum relaxation 
(Rmax) to ACh, Angeli‟s salt and DEANONOate were measured as a percentage of 
precontraction to PE. Group pEC50 and Rmax values were compared using Student‟s unpaired 
t-test or one-way ANOVA with post-hoc analysis using either Newman Keul‟s test or 
Dunnett‟s test as appropriate. P<0.05 was considered statistically significant. 
 
4.3 Results 
4.3.1 Effects of superoxide on DEANONOate-induced NO and Angeli’s salt-induced 
HNO relaxation in rat aorta 
 The effect of the superoxide generator, pyrogallol on NO and HNO-mediated 
relaxation is shown in Figure 4.1. The presence of pyrogallol caused a concentration-
dependent reduction in the sensitivity to the NO donor, DEANONOate (Figure 4.1a).  The 
sensitivity to DEANONOate in the aorta was significantly reduced by the presence of 100 µM 
of pyrogallol (pEC50: control, 8.03±0.10 vs. 100 µM pyrogallol, 7.48±0.09, n=6, p<0.01) but 
not 30 µM of pyrogallol (pEC50: control, 8.03±0.09 vs. 30 µM pyrogallol, 7.89±0.13, n=6, 
p>0.05). The maximum relaxation to DEANONOate (Rmax: control, 106±2%) was not 
Chapter 4-HNO-mediated relaxation is preserved in diabetes 
128 
 
affected by the presence of either concentration of pyrogallol (Rmax: 30 µM pyrogallol, 
112±3% and 100 µM pyrogallol, 108±2%).  In contrast the maximum relaxation or the 
sensitivity to the HNO donor, Angeli‟s salt was not affected by the presence of either 30 µM 
(pEC50: control, 7.30±0.15 vs. 30 µM pyrogallol, 7.44±0.06, n=5-6, p>0.05) or 100 µM 
pyrogallol (pEC50: control, 7.30±0.15 vs. 100 µM pyrogallol, 7.31±0.08, n=5-6, p>0.05) 
(Figure 4.1b).  
 
4.3.2 Relative contribution of NO and HNO to endothelium-dependent relaxation in rat 
aorta 
In the rat aorta, the sensitivity and maximum relaxation to ACh were significantly 
inhibited by the NO scavenger, HXC and the HNO scavenger, L-cysteine, indicating that both 
NO and HNO contributed to endothelium-dependent relaxation. In the combined presence of 
both NO and HNO scavengers, endothelium-dependent relaxation was abolished (Figure 4.2a, 
Table 4.1).  
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Figure 4.1 Vascular responses to NO and HNO donors. Cumulative concentration-
response curves to DEANONOate (a) or Angeli‟s salt (b) in the absence (control, ■) or 
presence of 30 µM pyrogallol (●) or 100 µM pyrogallol (▼) in endothelium-intact rat isolated 
aorta. n=5-6 experiments. Results are shown as mean±s.e.m. See text for pEC50 and Rmax 
values and statistical analysis.  
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4.3.3 Effects of superoxide on endothelium-derived NO and HNO-mediated relaxation in 
rat aorta 
 The sensitivity and maximum relaxation to ACh in the aorta were significantly 
reduced by the presence of the superoxide generator, pyrogallol. The residual relaxation was 
resistant to the additional presence of HXC but could be significantly attenuated by the 
addition of L-cysteine (Figure 4.2, Table 4.1). When the contribution of NO was eliminated 
by the presence of HXC, the residual HNO-mediated relaxation was not affected by the 
presence of pyrogallol, indicating that superoxide had no effect on HNO-mediated relaxation 
(Figure 4.2b, Table 4.1). Conversely, when the contribution of HNO was inhibited by L-
cysteine, the remaining NO-mediated relaxation was significantly reduced by the addition of 
pyrogallol (Figure 4.2c, Table 4.1). 
 
4.3.4 Body weights and blood glucose in normal and diabetic rats 
The body weight in normal rats was significantly greater than in diabetic rats (normal, 
501±24 g vs. diabetic, 340±16 g, n=8-9, p<0.0001) at the end of the experimental period. 
Similarly, the blood glucose level of diabetic rats was significantly greater than normal rats 
(normal, 8.6±0.9 mM vs. diabetic, >33 mM, n=8-9).  
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Figure 4.2 Role of NO and HNO to endothelium-dependent relaxation in the presence of 
pyrogallol. Cumulative concentration-response curves to ACh in the absence (control, ■) or 
(a) presence of 100 µM HXC (●), 3 mM L-cysteine (▼) or 100 µM HXC+ 3 mM L-cysteine 
(□), (b) presence of 100 µM HXC (●), 100 µM pyrogallol (∆) or 100 µM pyrogallol + 100 
µM HXC (▲) or (c) presence of 100 µM pyrogallol (∆), 3mM L-cysteine (▼) or 100 µM 
pyrogallol+ 3mM L-cysteine (♦) in endothelium-intact rat isolated aorta. n=4-7 experiments. 
Results are shown as mean±s.e.m. See Table 4.1 for pEC50 and Rmax values and statistical 
analysis.   
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Table 4.1 Effect of superoxide on ACh-induced NO- and HNO-mediated relaxation in 
rat isolated aorta. 
 
 
 
 
 
 
 
 
 
 
A comparison of the sensitivity (pEC50) and maximum relaxation (Rmax) to ACh in the 
absence (control), or presence of L-cysteine (3 mM), HXC (100 μM), L-cysteine (3 
mM)+HXC (100 μM) , pyrogallol (100 μM), pyrogallol (100 μM)+ L-cysteine (3 mM) or 
pyrogallol (100 μM)+ HXC (100 μM) in endothelium-intact rat aorta. n= the number of 
experiments. Results are shown as mean±s.e.m. ND: Not determined 
* Significantly different to control (Newman-Keul‟s test, p<0.05).  
† Significantly different to L-cysteine (Newman-Keul‟s test, p<0.05).  
‡ Significantly different to HXC (Newman-Keul‟s test, p<0.05).  
# Significantly different to pyrogallol (Newman-Keul‟s test, p<0.05).  
 
  
ACh n pEC50 Rmax (%) 
Control 7 7.55±0.10 100±1 
L-cysteine 7 6.95±0.08
*
 83±4
*
 
HXC 7 6.71±0.12
*
 80±2
*
 
HXC + L-cysteine 4 ND 9±9
*†‡
 
Pyrogallol 6 6.79±0.07
*
 59±3
*
 
Pyrogallol  + L-cysteine 6 6.48±0.44
*
 45±7
*†#
 
Pyrogallol  + HXC 7 6.82±0.15
*
 67±7
*
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4.3.5 Effect of diabetes on endothelial function 
 Diabetes significantly reduced the sensitivity, but not the maximum relaxation, to ACh 
in the aorta (Figure 4.3a, Table 4.2), indicating that diabetes caused endothelial dysfunction. 
In aorta from normal and diabetic rats, the combination of L-cysteine and HXC, a HNO 
scavenger and NO scavenger respectively abolished relaxation to ACh (Table 4.2), indicating 
that endothelium-dependent relaxation in the normal and diabetic aorta was mediated by NO 
and HNO. 
 
4.3.6 Effect of diabetes on NO and HNO-mediated relaxation 
In the presence of HXC, the relaxant response to ACh is mediated by HNO. When the 
contribution of NO was eliminated by HXC, the sensitivity and maximum relaxation to ACh 
were not significantly different between normal and diabetic aorta, suggesting that diabetes 
had no effect on the contribution of HNO to endothelium-dependent relaxation (Figure 4.3b, 
Table 4.2).  
In the presence of L-cysteine, the relaxant response to ACh is mediated by NO. If the 
responses to ACh in the presence of L-cysteine were compared between aorta from normal 
and diabetic rats, it was apparent that diabetes decreased both the sensitivity and maximum 
relaxation to ACh (Figure 4.3c, Table 4.2), indicating that diabetes impairs the contribution of 
NO to endothelium-dependent relaxation.  
  
Chapter 4-HNO-mediated relaxation is preserved in diabetes 
134 
 
NO & HNO
-10 -9 -8 -7 -6 -5
0
25
50
75
100
Normal
Diabetic
Log [ACh] M
R
e
la
x
a
ti
o
n
 (
%
)
HNO
-10 -9 -8 -7 -6 -5
0
25
50
75
100
Log [ACh] M
R
e
la
x
a
ti
o
n
 (
%
)
NO
-10 -9 -8 -7 -6 -5
0
25
50
75
100
Log [ACh] M
R
e
la
x
a
ti
o
n
 (
%
)
a)
b)
c)
 
Figure 4.3 Role of NO and HNO to endothelium-dependent relaxation in normal and 
diabetic aorta. Cumulative concentration-response curves to ACh in the absence (a) or 
presence of either 100 µM HXC (b) or 3 mM L-cysteine (c) in endothelium-intact aorta 
isolated from normal (■) or diabetic (●) rats. n=8-9 experiments. Results are shown as 
mean±s.e.m. See Table 4.2 for pEC50 and Rmax values and statistical analysis.  
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Table 4.2 Effect of NO and HNO on ACh-induced relaxation in aorta isolated from 
normal and diabetic rats 
 
A comparison of the sensitivity (pEC50) and maximum relaxation (Rmax) to ACh in the 
absence (control), or presence of L-cysteine (3 mM), HXC (100 μM), L-cysteine (3 mM)+ 
HXC (100 μM) , L-NNA (100 μM), L-NNA (100 μM)+ L-cysteine (3 mM) or ODQ (10 μM) 
in endothelium-intact rat aorta. n= the number of experiments. Results are shown as 
mean±s.e.m. ND: Not determined 
* Significantly different to corresponding control ACh response within the same treatment 
group (Newman-Keul‟s test, p<0.05).  
† Significantly different to L-NNA response within the same treatment groups (Newman-
Keul‟s test, p<0.05).  
‡ Significantly different to HXC response within the same treatment groups (Newman-Keul‟s 
test, p<0.05).  
# Significantly different to normal treatment group within the respective inhibitor group 
(Student‟s unpaired t-test, p<0.05).   
  Normal   Diabetic 
ACh n pEC50 Rmax (%) n pEC50 Rmax (%) 
Control 8 7.44±0.08 99±1 9 6.92±0.09
#
 97±3 
L-cysteine 7 7.01±0.04
*
 90±3 8 6.72±0.10
#
 78±4
*#
 
HXC 8 6.63±0.20
*
 55±7
*
 9 6.45±0.15
*
 60±8
*
 
HXC + L-cysteine 7 ND 10±6
*‡
 7 ND 6±6
*‡
 
L-NNA  8 ND 16±7
*
 8 ND 40±3
*#
 
L-NNA+L-cysteine    8 ND 16±5
*†
 
ODQ 7 ND 4±4
*
 6 ND 14±5
*
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4.3.7 Sources of NO and HNO-mediated relaxation in normal and diabetic aorta 
 In normal aorta, responses to ACh could be abolished either by the presence of a NOS 
inhibitor, L-NNA or a soluble guanylate cyclase inhibitor, ODQ (Figure 4.4a, Table 4.2). In 
contrast in the diabetic aorta, maximum relaxation to ACh was significantly attenuated by L-
NNA, but was abolished by ODQ (Figure 4.4b, Table 4.2). If the responses to ACh in the 
presence of L-NNA were compared between aorta from normal and diabetic rats, it is 
apparent that ACh caused a greater relaxation in the diabetic arteries (diabetic, 40±3% vs. 
normal, 16±7%, n=8, p<0.01). This residual relaxation was sensitive to the HNO scavenger, 
L-cysteine (diabetic, L-NNA+L-cysteine 14±5%, n=8, p<0.05), indicating a role of NOS-
independent source of HNO-mediated relaxation in the diabetic aorta.  
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Figure 4.4 Sources of NO and HNO in normal and diabetic aorta. Cumulative 
concentration-response curves to ACh in the absence (control, ■) or presence of L-NNA (●), 
ODQ (♦) or L-NNA+L-cysteine (▲) in endothelium-intact aorta isolated from normal (a) or 
diabetic (b) rats. n=7-9 experiments. Results are shown as mean±s.e.m. See Table 4.2 for 
pEC50 and Rmax values and statistical analysis. 
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4.4 Discussion 
This study has provided functional pharmacological evidence that vascular relaxation 
to the NO donor, DEANONOate was significantly attenuated by the presence of superoxide 
anions. In contrast, vascular relaxation to the HNO donor, Angeli‟s salt was not affected by 
the presence of superoxide anions. This study also demonstrated that HNO is produced 
endogenously and contributes to endothelium-dependent relaxation in the rat aorta. Whilst 
both NO and HNO contribute to endothelium-dependent relaxation in the aorta, the 
component of HNO-mediated relaxation was resistant to scavenging by pyrogallol-induced 
superoxide production. Similarly, in a model of chronic oxidative stress, endothelial 
dysfunction is evident in the diabetic rat aorta which is due to a decreased contribution of NO 
to endothelium-dependent relaxation. Consistent with our earlier finding in this study, the 
contribution of HNO-mediated relaxation to endothelium-dependent relaxation is preserved in 
the diabetic aorta. Furthermore, HNO appeared to be derived wholly from eNOS in normal 
aorta, whereas in the diabetic aorta it may in addition also arise from an eNOS-independent 
source. 
 
4.4.1 Role of NO and HNO-mediated relaxation in the presence of superoxide anions 
To distinguish between the NO and HNO-mediated relaxation that may contribute to 
endothelium-dependent relaxation in the aorta, we employed well-established 
pharmacological tools, i.e. a selective HNO scavenger, L-cysteine (Favaloro et al., 2009; Pino 
et al., 1994), and the selective NO scavenger, HXC (Li et al., 1993). In the present study, we 
provide evidence that NO is not the only endothelium-derived nitrogen species that 
contributes to vascular relaxation. In addition, there is a contribution of endothelium-derived 
HNO to endothelium-dependent relaxation. These observations are consistent with several 
other studies that have demonstrated that both NO and HNO contribute to endothelium-
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dependent relaxation in either large conduit (Ellis et al., 2000a; Wanstall et al., 2001) or 
resistance vessels (Andrews et al., 2009).  
Despite reports suggesting that HNO has distinct pharmacological actions and 
therapeutic advantage over NO, including having little or no reactivity with superoxide anions 
(Bullen et al., 2011a; Irvine et al., 2008), some doubt remains as to whether HNO-induced 
relaxation is affected by oxidant stress (Ellis et al., 2001; Miranda et al., 2002). In this study, 
it was demonstrated that vascular relaxation to the NO donor DEANONOate was significantly 
attenuated by the presence of the superoxide generator pyrogallol. In contrast, vascular 
relaxation to the HNO donor, Angeli‟s salt was not affected by the presence of pyrogallol. 
These observations indicated that HNO was resistant to scavenging by superoxide thus 
resulting in preserved vascular relaxation. Therefore, our finding is in agreement with 
Miranda et al., (2002) providing further evidence that HNO has no reactivity with superoxide 
anions. In addition, we also examined the contribution of HNO to endothelium-dependent 
relaxation in the presence of the superoxide generator, pyrogallol. Our results indicated that 
pyrogallol caused an impairment of endothelium-dependent relaxation, which is likely to be 
due to the scavenging of NO as the HNO component of relaxation is not affected by the 
presence of pyrogallol. Once again, this observation is in agreement with Miranda et al., 
(2002) who reported that HNO does not react with superoxide anion to form peroxynitrite 
(Miranda et al., 2002). Thus, in the present study, it was demonstrated that both endothelium-
derived HNO and Angeli‟s salt-mediated relaxation were not affected by the acute exposure 
to superoxide anions. It is not known, however, whether HNO-mediated relaxation is 
preserved under pathophysiological condition such as diabetes, where chronic oxidative stress 
is evident. 
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4.4.2 Effects of diabetes on NO and HNO-mediated relaxation 
It has been well documented by us (Chapter 3) and others (De Vriese et al., 2000; 
Fatehi-Hassanabad et al., 2010; Malakul et al., 2007; Woodman et al., 2009; Woodman et al., 
2008) that diabetes increases the level of vascular superoxide production and causes 
endothelial dysfunction but little is known about the effects of diabetes on the relative 
contribution of NO and HNO to endothelium-dependent relaxation. To investigate the role of 
NO, we assessed endothelium-dependent relaxation in the presence of L-cysteine to scavenge 
HNO. In the presence of L-cysteine, the sensitivity and maximum relaxation to ACh were 
decreased in diabetic aorta when compared to normal aorta, indicating an impairment of the 
contribution of a NO-mediated relaxation. These observations were consistent with several 
other studies (Cai et al., 2005; Guzik et al., 2002; Malakul et al., 2011). Conversely, in order 
to evaluate HNO-mediated relaxation, the NO-mediated relaxation was inhibited by the NO 
scavenger, HXC. This confirmed a preserved action of HNO in the presence of HXC, the 
sensitivity and maximum relaxation to ACh were not different in the diabetic aorta in 
comparison to normal aorta. This observation is consistent with our earlier findings in this 
study that HNO-mediated relaxation was not affected by the presence of pyrogallol-induced 
superoxide production. Similarly, recent studies have also demonstrated that HNO-mediated 
relaxation was preserved in arteries from hypertensive and hypercholesterolemic mice where 
chronic oxidative stress were also evident (Bullen et al., 2011b; Wynne et al., 2011). Taken 
together, diabetes-induced endothelial dysfunction in the aorta is due to selective impairment 
of NO-mediated relaxation. In addition, we have shown that HNO-mediated relaxation was 
preserved in the diabetic aorta which may be due to resistance to scavenging by superoxide 
anions. 
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4.4.3 Sources of HNO in diabetes  
Endogenous HNO may be derived from eNOS-dependent and independent sources 
(Arnelle et al., 1995a; Hobbs et al., 1994; Pufahl et al., 1995; Rusche et al., 1998; Saleem et 
al., 2004; Sharpe et al., 1998). In normal aorta, responses to ACh could be abolished by the 
presence of a NOS-inhibitor, L-NNA, indicating that HNO is derived predominantly from a 
NOS-dependent source. In contrast, in the diabetic aorta, there is a component of relaxation 
remaining after NOS inhibition. This is likely due to an augmented contribution of other 
compensatory vasorelaxant mechanisms rather than an inadequate blockade of NOS by L-
NNA as this was not affected by increasing the concentration of L-NNA by 10-fold (Chapter 
3). This NOS-resistant component of relaxation has also been reported by others studies 
(Malakul et al., 2011; Malakul et al., 2007) in diabetic conduit arteries. 
 An alternative possibility is that diabetes may have caused an increased contribution 
of EDHF as a compensatory mechanism in response to diminished NO synthesis (Malakul et 
al., 2007; Shi et al., 2006) which could account for the NOS-resistant component of 
relaxation. In the present study, however, responses to ACh were abolished either by the 
combination of the NO scavenger, HXC, and HNO scavenger, L-cysteine, or the sGC 
inhibitor, ODQ in both normal and diabetic aorta, which argues against a role for EDHF in the 
diabetic aorta. The NOS-resistant component of relaxation is likely to be S-nitrosothiol-
dependent as we have previously shown that there was a role for a S-nitrosothiol component 
of relaxation in the diabetes (Chapter 3). S-nitrosothiols are reported to release an 
undetermined redox species of NO as it was sensitive to both selective and non-selective NO 
and HNO scavengers (carboxy-PTIO, L-cysteine and haemoglobin) (Chauhan et al., 2003; Ng 
et al., 2007a). Indeed, in the present study, the NOS-resistant component of relaxation was 
sensitive to the addition of L-cysteine, suggesting that HNO may, in addition, arise from 
NOS-independent sources in the diabetic aorta, possibly from S-nitrosothiols. Furthermore, 
diabetes is known to cause the uncoupling of eNOS due to the reduction of BH4 (Cai et al., 
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2005; Hink et al., 2001) levels, which could be a potential source for eNOS-dependent HNO 
production in the diabetic aorta. Thus, all these observations support a role of eNOS-
dependent source and, at least in part, an additional role of S-nitrosothiol derived HNO 
production in diabetes.  
 
4.4.4 Conclusion 
The endogenous production of HNO will not be proven conclusively until direct 
detection methods for HNO production in intact blood vessels have been developed (Kemp-
Harper, 2011). Based on our functional pharmacological analysis of HNO production, we 
confirmed that both NO and HNO contributes to endothelium-dependent relaxation in the rat 
aorta. Whilst NO-mediated relaxation is impaired in the presence of oxidative stress (exposure 
to pyrogallol and diabetes), the HNO component of relaxation remains preserved under those 
conditions, indicating that HNO is serving as a compensatory vasorelaxant when NO 
bioavailability is impaired. The potential for preserved HNO bioavailability under conditions 
of oxidative stress indicate that HNO donors may have a potential for the treatment of 
vascular diseases that are associated with oxidative stress such as hypertension, 
atherosclerosis and diabetes.  
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Chapter 5 
 
Investigation of macrovascular and 
microvascular function in rats that are 
selectively bred for high and low exercise 
capacity. 
 
5.1 Introduction 
 The metabolic syndrome is defined as a clustering of hyperglycaemia/insulin 
resistance, obesity, hypertension and dyslipidemia. According to the National Cholesterol 
Education Program Adult Treatment Panel III (NCEP ATP III), metabolic syndrome is 
diagnosed if three or more of the following five criteria are met: waist circumference over 40 
inches (men) or 35 inches (women), blood pressure over 130/85 mmHg, fasting triglyceride 
level over 150 mg/dl, fasting high-density lipoprotein cholesterol level less than 40 mg/dl 
(men) or 50 mg/dl (women) and fasting blood glucose over 100 mg/dl (Huang, 2009). The 
metabolic syndrome is dramatically increasing and is strongly linked to cardiovascular 
diseases (Lakka et al., 2002). The presence of cardiovascular risk factors that constitute the 
metabolic syndrome is negatively correlated to the levels of aerobic capacity and endothelial 
function, which are demonstrated by studies, showing that both aerobic capacity and 
endothelial function are strong and independent predictors of lower mortality (Halcox et al., 
2002; Myers et al., 2002).  
Koch and Britton (2001) developed a novel rodent model for intrinsic aerobic capacity 
where rats were artificially selected for low-capacity runners (LCR) and high-capacity runners 
(HCR) (Koch et al., 2001). The selectively bred rats exhibit phenotypes emulating the 
physiological profiles of sedentary and exercise-trained individuals. Using these novel rodent 
models, studies have shown that LCR animals exhibited decreased whole-body insulin 
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sensitivity and impaired metabolic health in comparison to their HCR counterparts (Lessard et 
al., 2009; Rivas et al., 2011). The impairment of metabolic health in the LCR rats was 
associated with impaired β-adrenergic signal transduction in the skeletal muscle (Lessard et 
al., 2009; Lessard et al., 2011). One of the important functions of β-adrenoceptors is the 
regulation of blood pressure and vascular smooth muscle tone. Activation of β-adrenergic 
receptors in the peripheral vasculature leads to vascular smooth muscle relaxation (Kozłowska 
et al., 2003), which is manifested as a hypotensive blood pressure response. It is not known, 
however, whether β-adrenoceptor-mediated relaxation is affected in the LCR animals or 
whether such an effect could increase the risk for cardiovascular diseases such as 
hypertension.   
In addition to the impairment of metabolic parameters in the LCR animals, these 
animals have impaired endothelial function indicative of abnormal cardiovascular function 
(Wisløff et al., 2005). The vascular endothelium can release both relaxing and contracting 
factors to modulate the tone of the underlying smooth muscle. Endothelium-dependent 
relaxation is mediated by multiple factors including NO (Furchgott et al., 1980; Palmer et al., 
1988), PGI2 (Moncada et al., 1976) and EDHF (Busse et al., 2002). Different vascular beds, 
exposed to varying local or external stimuli, exhibit a marked heterogeneity in the relative 
contribution of these factors to alterations in tone (Chen et al., 1988; Clark et al., 1997). For 
example, in a large vessel such as the aorta, endothelium-dependent relaxation is largely 
mediated by NO with little or no contribution of EDHF, whereas in small resistance vessels, 
the contribution of EDHF to endothelium-dependent relaxation increases while the 
contribution of NO decreases (Luksha et al., 2009). Whilst it is clear that endothelial function 
was decreased in the LCR rats, it is not established whether NO and/or EDHF are affected in 
the LCR animals.  
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Therefore, our aims were to compare the contribution of NO and EDHF to 
endothelium-dependent relaxation from HCR and LCR rats. In addition, we aimed to verify 
whether β-adrenoceptor-mediated relaxation was affected in the LCR animals.  
 
5.2 Methods 
5.2.1 Animals 
Rats with high and low aerobic capacity were bred from genetically heterogeneous 
N:NIH stock rats by artificial selection for low and high treadmill running capacity as 
previously reported (Koch et al., 2001). Animals were phenotyped for intrinsic running 
capacity at 11 weeks of age using an incremental treadmill running test, and their running 
capacity in meters was recorded. Female rats from generations 16, 20, and 22 were used for 
analysis in the present study. Animals were killed by CO2 asphyxiation followed by 
exsanguination. Blood samples were obtained from the left ventricle via cardiac puncture and 
the glucose concentration was measured using a one touch glucometer (Roche, Sydney, NSW, 
Australia). All animal experimental procedures were carried out with the approval of animal 
ethics committees from the University of Melbourne, RMIT University, and University of 
Michigan.  
 
5.2.2 Isolation of blood vessels 
 After the rats were killed, the aorta and mesenteric arcade were isolated and 
immediately placed in ice cold Krebs bicarbonate solution. In some experiments, the Krebs 
buffer contained indomethacin (10 μM), a non-selective COX inhibitor, to inhibit the 
synthesis of prostanoids. Aortic rings and third-order branch mesenteric arteries (internal 
diameter ~200-300 m) were isolated and prepared as described in Chapter 2.2. 
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5.2.3 Vascular reactivity 
 Reactivity of the vessels was assessed as previously described (Chapter 2.3). Briefly, 
after establishing maximum contraction and assessment of the integrity of the endothelium, 
arteries were precontracted with PE (0.1-3 μM) to achieve similar active tension and 
cumulative concentration-response curves to ACh (0.1 nM-10 μM), isoprenaline (1 nM-10 
μM), fenoterol (1 nM-10 μM) or SNP (0.01 nM-10 μM) were evaluated. In some experiments, 
responses to ACh was examined after 20 min incubation with different combinations of L-
NNA (100 μM), a non-selective NOS inhibitor, ODQ (10 μM), a sGC inhibitor, TRAM-34 (1 
μM), a selective blocker of IKCa and apamin (1 μM), a SKCa inhibitor. Similarly, in some 
experiments, responses to isoprenaline were examined after 30 min incubation with ICI 
118551, a selective β2- adrenoceptor blocker and/or CGP 20712, a selective β1- adrenoceptor 
blocker. 
 
5.2.4 Superoxide measurement 
Superoxide production in the aorta and heart were measured using lucigenin-enhanced 
chemiluminescence assay as described in Chapter 2.7.1.  
 
5.2.5 Reagents 
 All drugs were purchased from Sigma-Aldrich (St Louis, MO, USA), except for 
acetylcholine perchlorate (BDH Chemicals, Poole, Dorset, UK) and ODQ (Cayman 
Chemical, Ann Arbor, MI, USA). All drugs were dissolved in distilled water, with the 
exception of indomethacin, which was dissolved in 0.1 M sodium carbonate and ODQ and 
TRAM-34, which were dissolved in DMSO. 
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5.2.6 Statistical analyses 
All results are expressed as the mean±s.e.m., n represents the number of animals per 
group. Concentration-response curves from rat isolated arteries were computer fitted to a 
sigmoidal curve using nonlinear regression (Prism version 5.0, GraphPad Software, San 
Diego, CA, USA) to calculate the sensitivity of each agonist (pEC50). Maximum relaxation 
(Rmax) to ACh or SNP was measured as a percentage of precontraction to PE. Group pEC50 
and Rmax values were compared via one-way ANOVA with post-hoc analysis using Dunnett‟s 
test or Student‟s unpaired t-test as appropriate. P<0.05 was considered statistically significant. 
 
5.3 Results 
5.3.1 Body weights and blood glucose of HCR and LCR rats. 
The average body weights for the LCR rats were significantly higher in comparison to 
HCR rats (body weight gained LCR 246±8g vs. HCR 202±9g, n=22, Student‟s t test, 
p=0.001). Similarly, fasting blood glucose levels were found to be significantly (P=0.003, 
Student‟s t test) higher in the LCR (4.87±0.18 mM, n=10) compared to the HCR (3.87± 0.22 
mM, n=10) rats. 
 
5.3.2 Vascular reactivity of blood vessels 
 The cumulative concentration response curves to the endothelium-dependent relaxant, 
ACh, the endothelium-independent relaxant, SNP, isoprenaline, non-selective β receptor 
agonist and fenoterol, a selective β2-adenoceptor agonist, in the aorta and mesenteric arteries 
were shown in Figure 5.1 and 5.2 respectively. The sensitivity or maximum relaxation to ACh 
(Figure 5.1a), SNP (Figure 5.1b) and fenoterol (Figure 5.1d) were not significantly different 
in the aorta from LCR or HCR rats (Table 5.1). In contrast, the sensitivity to isoprenaline 
(Figure 5.1c) but not maximum relaxation was significantly different in the aorta between 
Chapter 5-Vascular function in LCR and HCR animals 
148 
 
LCR and HCR rats. In the presence of L-NNA, the maximum relaxation to fenoterol was 
significantly attenuated in aorta from either HCR or LCR rats (Table 5.1). 
 In the mesenteric arteries, the sensitivity to ACh (Figure 5.2a) and fenoterol (Figure 
5.2d) but not maximum relaxation was significantly different between LCR and HCR rats. 
However, the sensitivity or maximum relaxation to SNP (Figure 5.2b) and isoprenaline 
(Figure 5.2c) were not significantly different in the mesenteric arteries from either LCR or 
HCR rats (Table 5.2). 
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Figure 5.1 Vascular function of aorta. Cumulative concentration-response curves to ACh 
(a), SNP (b), isoprenaline (c) or fenoterol (d) in endothelium-intact aorta isolated from HCR 
(●) or LCR (▲) rats. Results are shown as mean±s.e.m. * pEC50 significantly different from 
HCR rats (Student‟s unpaired t-test, p<0.05). See Table 5.1 for pEC50 and Rmax values. 
  
Chapter 5-Vascular function in LCR and HCR animals 
150 
 
Table 5.1 Isoprenaline, fenoterol, ACh and SNP responses in aortae isolated from HCR 
and LCR rats. 
 
A comparison of the sensitivity (pEC50) and maximum relaxation (Rmax) to ACh, SNP, 
fenoterol and isoprenaline in the absence (control), or presence of L-NNA, ICI 118551 or ICI 
118551+CGP 20712 in endothelium-intact aorta isolated from HCR and LCR rats. n= the 
number of experiments. Results are shown as mean±s.e.m. ND: Not Determined * 
Significantly different to corresponding control response within the same treatment group 
(Bonferroni‟s test, p<0.05).  # Significantly different to corresponding ICI 118551 response 
within the same treatment groups (Bonferroni‟s test, p<0.05).  ‡ Significantly different to 
HCR group (Student‟s t-test, p<0.05). 
  
  HCR   LCR  
Isoprenaline n pEC50 Rmax (%) n pEC50 Rmax (%) 
Control 11 6.96±0.08 97±1 11 6.60±0.08
‡
 96±1 
L-NNA 6 6.49±0.12
*
 86±5 6 6.42±0.09 73±8
*
 
ICI 118551 10 6.09±0.05
*
 92±1 12 5.97±0.06
*
 92±2 
ICI 118551 + CGP 20712  9 5.32±0.05
*#
 67±7
*#
 12 5.48±0.09
*#
 62±6
*#
 
Fenoterol       
Control 10 6.53±0.10 88±3 10 6.41±0.11 89±2 
L-NNA 12 ND 32±11
*
 12 ND 20±7
*
 
ACh       
 11 6.90±0.07 97±1 12 7.04±0.05 97±1 
SNP       
 6 8.11±0.11 103±2 6 8.02±0.07 100±1 
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Figure 5.2 Vascular function of mesenteric arteries. Cumulative concentration-response 
curves to ACh (a), SNP (b), isoprenaline (c) or fenoterol (d) in endothelium-intact mesenteric 
arteries isolated from HCR (●) or LCR (▲) rats. Results are shown as mean±s.e.m. * pEC50 
significantly different from HCR rats (Student‟s unpaired t-test, p<0.05). See Table 5.2 for 
pEC50 and Rmax values.  
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Table 5.2 Isoprenaline, fenoterol, ACh and SNP responses in mesenteric arteries isolated 
from HCR and LCR rats. 
 
 
A comparison of the sensitivity (pEC50) and maximum relaxation (Rmax) to ACh, SNP, 
fenoterol and isoprenaline in the absence (control), or presence of ICI 118551 or ICI 
118551+CGP 20712 in endothelium-intact mesenteric arteries isolated from HCR and LCR 
rats. n= the number of experiments. Results are shown as mean±s.e.m. ND: Not Determined * 
Significantly different to corresponding control response within the same treatment group 
(Bonferroni‟s test, p<0.05).  # Significantly different to corresponding ICI 118551 response 
within the same treatment groups (Bonferroni‟s test, p<0.05).  ‡ Significantly different to 
HCR group (Student‟s t-test, p<0.05).  
  
  HCR   LCR  
Isoprenaline n pEC50 Rmax (%) n pEC50 Rmax (%) 
Control 10 7.27±0.11 98±1 8 7.22±0.12 99±1 
ICI 118551 10 6.55±0.08
*
 98±1 6 6.77±0.10 100±0 
ICI 118551 + CGP 20712  11 5.39±0.24
*#
 94±3 7 4.65±0.44
*#
 94±3 
Fenoterol       
 8 7.05±0.18 99±1 7 6.51±0.09
‡
 98±2 
ACh       
 9 7.62±0.09 98±1 6 7.05±0.16
‡
 96±2 
SNP       
 4 8.54±0.16 100±0 4 8.30±0.11 100±0 
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5.3.3 Role of β-adrenoceptor-mediated relaxation in aorta 
 The sensitivity to isoprenaline, but not the maximum relaxation, in aortic rings from 
HCR (Figure 5.3a, Table 5.1) and LCR rats (Figure 5.3b, Table 5.1) was significantly 
attenuated by the presence of a β2-adrenoceptor blocker, ICI 118551. In the presence of ICI 
118551, the addition of a β1-adrenoceptor blocker, CGP 20712, caused a further decrease in 
the sensitivity and maximum relaxation to isoprenaline in aorta isolated from both HCR 
(Figure 5.3a, Table 5.1) and LCR rats (Figure 5.3b, Table 5.1). In HCR rats, the sensitivity, 
but not the maximum relaxation, to isoprenaline in aortic rings (Figure 5.3a, Table 5.1) was 
significantly attenuated by the presence of a NOS inhibitor, L-NNA. In contrast, the presence 
of L-NNA significantly decreased the maximum relaxation, but not sensitivity, to isoprenaline 
in the aorta from LCR rats (Figure 5.3b, Table 5.1).  
 
5.3.4 Role of β-adrenoceptor-mediated relaxation in mesenteric arteries 
The sensitivity, but not the maximum relaxation, to isoprenaline in mesenteric arteries 
from HCR rats (Figure 5.4a, Table 5.2) was significantly attenuated by the presence of a β2-
adrenoceptor blocker, ICI 118551. In contrast, the presence of ICI 118551 had no effect on 
either the sensitivity or maximum relaxation to isoprenaline in mesenteric arteries from LCR 
rats (Figure 5.4b, Table 5.2). In the presence of ICI 118551, the addition of a β1-adrenoceptor 
blocker, CGP 20712 caused a further decrease in the sensitivity, but not the maximum 
relaxation, to isoprenaline in both HCR (Figure 5.4a, Table 5.2) and LCR rats (Figure 5.4b, 
Table 5.2). 
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Figure 5.3 Role of β1-adrenoceptors and β2-adrenoceptors-mediated responses in the 
aorta. Cumulative concentration-response curves to isoprenaline in the absence (control, ■) 
or presence of L-NNA (●), ICI 118551 (▲) or ICI 118551+CGP 20712 (▼) in endothelium-
intact aorta isolated from HCR (a) or LCR (b) rats. n=7-10 experiments. Results are shown as 
mean±s.e.m. See Table 5.1 for pEC50 and Rmax values.  
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Figure 5.4 Role of β1-adrenoceptors and β2-adrenoceptors-mediated responses in the 
mesenteric arteries. Cumulative concentration-response curves to isoprenaline in the absence 
(control, ■) or presence of ICI 118551 (▲) or ICI 118551+CGP 20712 (▼) in endothelium-
intact mesenteric arteries isolated from HCR (a) or LCR (b) rats. n=7-10 experiments. Results 
are shown as mean±s.e.m. See Table 5.2 for pEC50 and Rmax values.  
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5.3.5 Role of NO-mediated relaxation in aorta and mesenteric arteries 
 The relaxant responses to ACh in aortic rings from LCR and HCR rats were abolished 
by the presence of the NOS inhibitor, L-NNA, indicating that endothelium-dependent 
relaxation was entirely NO-dependent in the aorta.  
In the mesenteric arteries, the presence of L-NNA+ODQ had no effect on either the 
sensitivity or maximum relaxation to ACh in either group of rats (Figure 5.5, Table 5.3). 
When the contribution of EDHF was eliminated by the presence of KCa channel inhibitors, the 
sensitivity and maximum relaxation to ACh were comparable in both groups of rats, 
indicating that the NO-mediated component of relaxation was not affected in LCR animals 
(Table 5.3).  
 
5.3.6 Role of EDHF-type relaxation in mesenteric arteries 
In the mesenteric arteries, the presence of KCa channel inhibitors significantly 
decreased the sensitivity to ACh but had no effect on the maximum relaxation in either group 
of rats (Figure 5.5, Table 5.3). When the contribution of NO was eliminated by the presence 
of L-NNA+ODQ, the sensitivity to ACh was significantly different between HCR and LCR 
rats, indicating that EDHF-type relaxation was impaired in LCR animals (Table 5.3). The 
maximal response of EDHF-type relaxation was similar in both groups of rats. The addition 
of KCa channel inhibitors to L-NNA+ODQ significantly decreased ACh-induced relaxation in 
mesenteric arteries from both HCR and LCR rats (Figure 5.5, Table 5.3). 
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Figure 5.5 Role of NO and EDHF to endothelium-dependent relaxation in the 
mesenteric arteries. Cumulative concentration-response curves to ACh in the absence 
(control, ●) or presence of L-NNA+ODQ (■), TRAM-34+apamin (▲) or L-NNA+ODQ+ 
TRAM-34+apamin (▼) in endothelium-intact aorta isolated from HCR (a) or LCR (b) rats. 
n=5-10 experiments. Results are shown as mean±s.e.m. See Table 5.3 for pEC50 and Rmax 
values.  
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Table 5.3 Effect of L-NNA, ODQ, TRAM-34, and apamin on ACh-induced relaxation of 
mesenteric arteries from HCR and LCR rats in the presence of indomethacin. 
 
A comparison of the sensitivity (pEC50) and maximum relaxation (Rmax) to ACh in the 
absence (control) or presence of L-NNA + ODQ, TRAM-34 + apamin or L-NNA + ODQ+ 
TRAM-34 + apamin in endothelium intact mesenteric arteries isolated from HCR and LCR 
rats. n= the number of experiments. Results are shown as mean±s.e.m. ND: Not Determined * 
Significantly different to corresponding control response within the same treatment group 
(Dunnett‟s test, p<0.05).  ‡ Significantly different to HCR group (Student‟s t-test, p<0.05).  
 
  
  HCR  LCR 
ACh n pEC50 Rmax (%) n pEC50 Rmax (%) 
Control 10 7.86±0.14 98±1 8 7.31±0.13
‡
 95±2 
L-NNA + ODQ 8 7.66±0.07 98±1 6 7.00±0.20
‡
 96±2 
TRAM-34 + apamin 6 6.84±0.31
*
 73±13 4 6.66±0.12
*
 73±14 
L-NNA + ODQ + TRAM-
34 + apamin 
6 ND 61±14
*
 5 ND 37±14
*
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5.3.7 Superoxide measurement in aorta and heart 
 Superoxide levels in the aorta and heart were determined by lucigenin-enhanced 
chemiluminescence. Superoxide levels in the aorta (LCR 1375±151 counts/mg tissue vs. HCR 
1358±225 counts/mg tissue, n=14-17, p=0.95) and heart (LCR 536±78 counts/mg tissue vs. 
HCR 528±75 counts/mg tissue, n=11-15, p=0.94) were not significantly different between 
groups.  
 
5.4 Discussion 
It is proposed that altered β-adrenergic signal transduction contributes to metabolic 
disease such as type II diabetes (Blaak et al., 2004). Defects to whole body and skeletal 
muscle metabolism that occur following artificial selection for LCR was similar to the 
impairments observed in individuals at risk of developing type II diabetes (Mootha et al., 
2003). In the present study, using an animal model that was artificially selected for LCR and 
HCR (Koch et al., 2001), we demonstrated that β-adrenoceptor-mediated relaxation was 
significantly attenuated in both macro- and microvasculature of LCR animals. In the LCR 
microvasculature, the impairment of β-adrenergic signal transduction was, at least in part, 
contributed to by the loss of β2-adrenergic responses. In addition, impaired microvascular 
endothelial function was also evident in the LCR phenotype which was caused by diminished 
EDHF-mediated relaxation.  
 Using an animal model based on selection for low and high aerobic capacity (Koch et 
al., 2001), studies have shown that LCR animals exhibited decreased whole-body insulin 
sensitivity, increased blood pressure, increased blood glucose and body weights in 
comparison to their HCR counterparts (Lessard et al., 2009; Rivas et al., 2011; Wisløff et al., 
2005). In agreement with these observations, the LCR animals from this study also have 
increased blood glucose levels and body weights in comparison with HCR animals, 
suggesting that LCR animals are predisposed to impaired metabolic function. 
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5.4.1 Role of β-adrenoceptor-mediated relaxation 
Previous studies have reported that the impaired metabolic function in the LCR rats 
was associated with an impaired β-adrenergic signal transduction in the skeletal muscle 
(Lessard et al., 2009; Lessard et al., 2011), however, it remains unknown whether β-
adrenoceptors-mediated relaxation (Kozłowska et al., 2003) was affected in the LCR animals. 
The data presented here demonstrates that vascular responses to the non-selective β-
adrenoceptor agonist, isoprenaline, were significantly attenuated in the aorta isolated from the 
LCR animals in comparison to HCR animals. The diminished β-adrenoceptor-mediated 
relaxation was not due to the decrease in β2-adrenoceptor signaling as the responses to the 
selective β2-adrenoceptor agonist, fenoterol, were not different between the HCR and LCR 
animals, suggesting that diminished isoprenaline-induced relaxation observed in the aorta 
isolated from the LCR animals is likely to be due to a non-β2-adrenergic receptor pathway. 
The β-adrenoceptor-induced vascular relaxation in isolated blood vessels were predominantly 
mediated by the β1-adrenoceptor subtype and to a lesser extent mediated by both β2- and β3-
adrenoceptor subtypes (Briones et al., 2005; Chruscinski et al., 2001). Thus, it is likely that 
the β1-adrenoceptor signaling pathway is decreased in the aorta from LCR animals.  
In contrast to the aorta, vascular responses to the non-selective β-adrenoceptor agonist, 
isoprenaline, were not different between the HCR and LCR animals in the mesenteric arteries. 
Although the responses to isoprenaline were not different between the HCR and LCR 
animals, the contribution of the β-adrenoceptor subtypes to cause vascular relaxation were 
altered in the mesenteric arteries isolated from the LCR animals. In mesenteric arteries from 
the LCR animals, the selective- β2-adrenoceptor antagonist, ICI 118551, had no effect on 
isoprenaline-induced relaxation, indicating that the β2-adrenoceptor did not contribute to 
vascular relaxation in the LCR animals. Consistent with earlier observations in the mesenteric 
arteries isolated from the LCR animals, responses to the selective β2-adrenoceptor agonist 
fenoterol were also diminished in comparison to the HCR counterparts. The mechanism(s) 
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underlying β-adrenoceptor-mediated vascular relaxation are complex, however evidence 
suggests the potential involvement of multiple intracellular signalling pathways for β-
adrenoceptor-mediated vascular relaxation such as cAMP/protein kinase A, endothelium-
derived factors such as NO and EDHF or direct VSMC hyperpolarization (Al Zubair et al., 
2008; Dessy et al., 2004; Kang et al., 2007; Matsushita et al., 2006).  
Recent evidence demonstrated that selective stimulation of β1, β2 and β3-adrenoceptors 
caused NO production and cGMP accumulation in the mesenteric arteries, which were 
inhibited by either endothelium removal or NOS inhibition (Figueroa et al., 2009). This 
suggested that β-adrenoceptor-mediated relaxation was in part endothelium-dependent. In this 
study, the selective β2-adrenoceptor agonist, fenoterol-induced relaxation which was impaired 
in the mesenteric arteries isolated from the LCR. This is consistent with observations from 
other studies in skeletal muscles where an impairment of the β2-adrenergic signalling pathway 
was observed (Lessard et al., 2009; Lessard et al., 2011). In this study, experiments were 
conducted in the presence of endothelium so it was not possible to conclude whether the 
diminished response to β2-adrenoceptor agonist was associated with endothelial dysfunction. 
Therefore, the precise mechanism underlying the impairment of β2-adrenergic-mediated 
relaxation in the mesenteric arteries from LCR animals remains to be elucidated. In the aorta, 
however, the decreased β-adrenergic signalling in the LCR animals appears to be independent 
of the β2-adrenoceptor. 
 
5.4.2 Role of NO-mediated and EDHF-type relaxation 
The presence of cardiovascular risk factors that constitute the metabolic syndrome is 
linked to the level of aerobic fitness and endothelial function (Wisløff et al., 2005). This 
notion is further supported by studies showing that both aerobic fitness and endothelial 
function are strong and independent predictors of mortality (Halcox et al., 2002; Myers et al., 
2002). It has been reported that endothelium-dependent relaxation was impaired in carotid 
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arteries isolated from the LCR animals in comparison to the HCR animals (Wisløff et al., 
2005). An important contributor to endothelial dysfunction in metabolic disease is the 
overproduction of superoxide (Fatehi-Hassanabad et al., 2010) which rapidly reacts with NO 
to produce toxic peroxynitrite and limit the beneficial actions of NO, thus the level of oxidant 
stress in tissues isolated from both LCR and HCR animals were evaluated. The results 
indicated that the level of superoxide production in the aorta and heart were not significantly 
different between HCR and LCR animals. This observation is consistent with a study by 
Morris et al., (2009) who also reported comparable levels of superoxide production in the 
kidneys from both HCR and LCR animals (Morris et al., 2009), suggesting that endothelial 
dysfunction in the LCR animals is independent of oxidant stress. In this study, we have shown 
that endothelium-dependent relaxation was impaired in the small mesenteric arteries but not 
in the aorta from the LCR animals in comparison to the HCR animals, suggesting that NO-
dependent relaxation is not affected in the LCR animals. Thus, endothelial function in the 
aorta was similar between the LCR and HCR animals.  
Different vascular beds exhibit a marked heterogeneity in the relative contribution of 
NO and EDHF to the alterations in vascular tone (Chen et al., 1988; Clark et al., 1997). For 
example, in the aorta, endothelium-dependent relaxation is predominantly mediated by NO 
whereas, in a smaller vessels such as the mesenteric arteries, there is a contribution of both 
NO and EDHF to endothelium-dependent relaxation (Luksha et al., 2009). Whilst it has been 
reported that endothelial function was impaired in LCR animals (Wisløff et al., 2005), it has 
not previously been investigated whether the microvascular endothelial function was 
impaired, in particular the contribution of EDHF to endothelium-dependent relaxation. In this 
study, endothelium-dependent relaxation in the small mesenteric arteries was resistant to the 
combination of NOS and soluble guanylate cyclase inhibitors, L-NNA and ODQ respectively, 
indicating that endothelium-dependent relaxation in the small mesenteric arteries from the 
HCR and LCR rats are predominantly caused by EDHF. In the presence of L-NNA and ODQ, 
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endothelium-dependent relaxation in the small mesenteric arteries from the LCR rats were 
significantly decreased in comparison to their HCR counterparts, indicating that EDHF-type 
relaxation is significantly impaired in mesenteric arteries from LCR animals.  
The chemical identity of EDHF remains unknown but the physiological actions of 
EDHF can be classified into two broad categories (Edwards et al., 2010). The classical EDHF 
pathway involves the opening of endothelial IKCa and SKCa channels and subsequent 
hyperpolarization and relaxation of smooth muscle cells by either downstream microdomain 
signaling pathways (Absi et al., 2007; Dora et al., 2008; Sandow et al., 2006) or 
myoendothelial gap junctions (Edwards et al., 1999). The second category of EDHF does not 
involve endothelial hyperpolarization, but involves the release of endothelium-derived factors 
such as NO, HNO, H2O2 and EETs to cause smooth muscle hyperpolarization by acting on 
the potassium channels located on the smooth muscle cells (Edwards et al., 2010). Therefore, 
the exact pathway underlying the impairment of EDHF-type relaxation in the 
microvasculature of the LCR animals remains to be clarified. 
 
5.4.3 Conclusion 
 In animals that were artificially selected for HCR and LCR, vascular responses to β-
adrenergic stimulation and an endothelium-dependent vasodilator were differentially affected 
in the LCR animals. The impairment to β-adrenergic stimulation was observed in the aorta 
from the LCR animals. In constrast in the mesenteric arteries, β2-adrenergic stimulation and 
endothelial function was reduced in the LCR animals. The impairment of endothelial function 
was likely due to the decreased contribution of EDHF to endothelium-dependent relaxation in 
the mesenteric arteries from LCR animals. The microvasculature plays an important role in 
the regulation of blood pressure hence a reduction in β2-adrenergic stimulation and 
endothelial function in the microvasculature may in part contribute to the increased 
cardiovascular risk associated with LCR animals.  
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Chapter 6 
 
Impairment of both nitric oxide-mediated 
and EDHF-type relaxation in small 
mesenteric arteries from rats with 
streptozotocin-induced diabetes. 
 
6.1 Introduction 
 Endothelial cells can release both relaxing and contracting factors to modulate the tone 
of the underlying smooth muscle. Endothelium-dependent relaxation is mediated by multiple 
factors including NO (Furchgott et al., 1980; Palmer et al., 1988), PGI2 (Moncada et al., 
1976) and EDHF (Busse et al., 2002). There are two broad categories of EDHF responses. 
The classical EDHF pathway involves the opening of endothelial IKCa and SKCa channels and 
subsequent hyperpolarization and relaxation of smooth muscle cells by either downstream 
microdomain signaling pathways (Absi et al., 2007; Dora et al., 2008; Sandow et al., 2006) or 
myoendothelial gap junctions (Edwards et al., 1999). The second category of EDHF does not 
involve endothelial hyperpolarization, but involves the release of endothelium-derived factors 
such as NO, HNO, H2O2 and EETs to cause smooth muscle hyperpolarization by acting on 
the potassium channels located on the smooth muscle cells (Edwards et al., 2010). Different 
vascular beds, exposed to varying local or external stimuli, exhibit a marked heterogeneity in 
the relative contribution of these factors to alterations in tone (Chen et al., 1988; Clark et al., 
1997). For example, in the rat mesenteric artery, endothelium-dependent relaxation is 
mediated by both NO, the classical EDHF pathway and there is also a role for the non-
classical EDHF pathway (HNO) (Andrews et al., 2009; McCulloch et al., 1998). The relative 
contribution of each pathway may be altered in vascular disease (Nishikawa et al., 2000b; 
Sofola et al., 2002). 
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 Diabetes mellitus is characterized by hyperglycaemia resulting from a defective 
secretion or action of endogenous insulin. It is well established that diabetes often causes 
macro- and microvascular complications in human and animal models of diabetes, and several 
lines of evidence suggest that endothelial dysfunction could play a critical and initiating role 
in the development of these complications (Vanhoutte et al., 2009). The relative contribution 
of endothelium-derived factors to relaxation in the presence of diabetes-induced endothelial 
dysfunction remains poorly understood especially in the smaller arteries, such as the 
mesenteric artery, where both NO and EDHF contribute to endothelium-dependent relaxation 
(De Vriese et al., 2000; McCulloch et al., 1998; Shi et al., 2006; Wigg et al., 2001). For 
example, Shi et al.,(2006) reported an augmented contribution of EDHF and reduced 
contribution of NO to endothelium-dependent relaxation in the mesenteric artery. In contrast, 
Wigg et al.,(2001) reported a selective impairment of the EDHF component of relaxation and 
preserved NO-mediated relaxation in the mesenteric artery. Hence, it is not established 
whether diabetes affects the contribution to relaxation of either or both NO and EDHF. In 
addition, other studies using mesenteric arteries focused on the effect of diabetes on EDHF-
dependent relaxation as experiments were conducted in the presence of NO synthase and 
COX inhibitors (Fukao et al., 1997; Matsumoto et al., 2003b; Matsumoto et al., 2005).
 Therefore, the aim of the present study was to evaluate the mechanism of 
endothelium-dependent relaxation of small mesenteric arteries in rats with type I diabetes. In 
particular, we sought to verify the relative contribution of NO-mediated and EDHF-type 
relaxation to endothelium-dependent responses in normal and diabetic vessels. 
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6.2 Methods 
6.2.1 Animals  
 Male 8-10 week old Sprague-Dawley rats (University of Melbourne animal facility, 
Melbourne, Vic, Australia) were randomly divided into two groups: normal and diabetic. 
Type I diabetes was induced by a single injection of STZ into the rat tail vein after fasting 
overnight. The control groups received an equivalent volume of the vehicle (0.1 M citrate 
buffer) alone. In events where the diabetic rats exhibited weight loss (approximately 5% 
weight loss from the initial weight), these rats were treated with a low dose of insulin (4-5 IU, 
Protaphane, Novo Nordisk, NSW, Australia) to promote weight gain and reduce mortality. 
The control groups were not treated with insulin. In this chapter, approximately 5-10% of the 
diabetic animals died before they were due for experimentation. Ten weeks after STZ or 
vehicle treatment, the rats were euthanized with pentobarbitone sodium (325 mg.kg
-1
, i.p, 
Virbac, Australia). Blood samples were obtained from the left ventricle via cardiac puncture 
and the glucose concentration and HbA1c were measured using a one touch glucometer 
(Roche, Sydney, NSW, Australia) and Micromat HbA1c analyser (Biorad, Sydney, NSW, 
Australia) respectively. Induction of diabetes was considered successful when the glucose 
level and HbA1c was higher than 20 mM and 6.5% respectively. All procedures involved 
were approved by the Animal Experimentation Ethics Committee of RMIT University and 
conformed to the Australian National Health and Medical Research Council code of practice 
for the care and use of animals for scientific purposes. 
 
6.2.2 Isolation of mesenteric arteries 
 After the rats were euthanized, the mesenteric arcades were isolated and immediately 
placed in ice cold Krebs bicarbonate solution (118 mM NaCl, 4.7 mM KCl, 1.18 mM MgSO4, 
1.2 mM KH2PO4, 25 mM NaHCO3, 11.1 mM D-glucose, and 2.5 mM CaCl2). Small 
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mesenteric arteries (third-order branch of the superior mesenteric artery, internal diameter 
~300 m) were isolated and set up as described in Chapter 2.2.3. 
 
6.2.3 Functional experiments 
 Thirty min after normalization, vessels were maximally contracted with 123 mM 
KPSS (normal ∆14.9±0.39 mN vs. diabetic ∆15.3±0.53 mN, p>0.05). Endothelium integrity 
and vascular reactivity of mesenteric arteries were evaluated as described in Chapter 2.3. 
Briefly, arteries were precontracted to ~50% KPSS response using PE (0.1-3 μM) or in some 
cases 45 mM K
+
. The effect of the treatment on relaxant responses was determined by 
cumulative concentration-response curves to the endothelium-depedent relaxant, ACh (0.1 
nM-10 μM) and the endothelium-independent relaxant, SNP (0.01 nM-10 μM). In addition, 
responses to ACh and SNP were examined after 20 min incubation with different 
combinations of L-NNA (100 μM), a non-selective NOS inhibitor, ODQ (10 μM), a sGC 
inhibitor, tempol (100 μM), a cell permeable SOD mimetic, HXC (200 μM), a NO scavenger, 
TRAM-34 (1 μM), a selective blocker of the IKCa, Ibtx (100 nM), a selective blocker of maxi 
KCa) and apamin (1 μM), a SKCa inhibitor. 
 To evaluate the constrictor reactivity, cumulative concentration-response curves to 
ET-1 (0.1 nM-0.1 μM) were constructed in the absence of indomethacin. In another set of 
experiments, the effect of diabetes on basal levels of NO release was also examined in the 
absence of indomethacin through the addition of L-NNA (100 μM) in endothelium-intact 
rings precontracted with PE (10-100 nM) to approximately 20% KPSS as described in 
Chapter 2.3.2.  
 
6.2.4 Western Blot 
 First order, second order and third order mesenteric arteries from 3 animals from the 
same treatment group were pooled, and considered as n=1. Western blots were performed as 
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described as decribed in Chapter 2.6. To investigate eNOS homodimer formation in the tissue, 
a non-boiled sample was resolved by 6% SDS-PAGE at 4°C (Chapter 2.6.5). 
 
6.2.5 Superoxide measurement in mesentery artery 
 Superoxide production in the mesenteric artery was measured by using L-012 and 
lucigenin enhanced-chemiluminescence as described in Chapter 2.4.1 or Chapter 2.7.2 
respectively.  
 
6.2.6 Drugs used 
 All drugs were purchased from Sigma-Aldrich (St Louis, MO, USA), except for 
acetylcholine perchlorate (BDH Chemicals, Poole, Dorset, UK) and ODQ (Cayman 
Chemical, Ann Arbor, MI, USA). All drugs were all dissolved in distilled water, with the 
exception of indomethacin, which was dissolved in 0.1 M sodium carbonate, L-NNA, which 
was dissolved in 0.1 M sodium bicarbonate, ODQ and TRAM-34, which were dissolved in 
DMSO. 
 
6.2.7 Statistical analyses 
All results are expressed as the mean±s.e.m., n represents the number of animals per 
group or the number of assays when tissue from animals was pooled. Concentration-response 
curves from rat isolated mesenteric arteries were computer fitted to a sigmoidal curve using 
nonlinear regression (Prism version 5.0, GraphPad Software, San Diego, CA, USA) to 
calculate the sensitivity of each agonist (pEC50). Maximum relaxatio Group pEC50 and Rmax 
values were compared via one-way ANOVA with post-hoc analysis using Bonferroni‟s test or 
Student‟s unpaired t-test as appropriate. P<0.05 was considered statistically significant. 
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6.3 Results 
6.3.1 Body weights and blood glucose 
 The body weight gained, blood glucose and HbA1c levels of the rats are shown in 
Table 6.1. Ten weeks after treatment with STZ or vehicle, the body weight gained in normal 
rats was significantly greater than in diabetic rats (Table 6.1). The blood glucose and HbA1c 
level of diabetic rats were significantly greater than normal rats (Table 6.1).  
 
6.3.2 Superoxide production in diabetes 
 The superoxide level in intact mesenteric arteries from diabetic rats was significantly 
higher than in normal rats (Figure 6.1a). Treatment with tempol, a cell permeable SOD 
mimetic, attenuated the generation of superoxide to comparable levels in normal and diabetic 
rats. NADPH oxidase-driven superoxide production from mesenteric homogenates was also 
significantly increased in diabetes (Figure 6.1b). In the presence of DPI, the NADPH oxidase-
driven superoxide production was attenuated to comparable level in mesenteric homogenates 
from both normal and diabetic animals.  
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Table 6.1 Body weight gained, blood glucose and HbA1c levels of male Sprague-Dawley 
rats treated with either streptozotocin or vehicle. 
  10 weeks after vehicle or STZ treatment 
 n Normal  n Diabetic 
Body weight gained (g) 19 324 ± 13 19 135 ± 15
*
 
Blood glucose (mM) 19 9.5 ± 0.5 19 High (>33) 
HbA1c (%) 4 4.6 ± 0.5 6 12.3 ± 1.2
*
 
 
A comparison of rat body weight gained, blood glucose and HbA1c from STZ or vehicle 
treated rats. n= the number of rats. * Significantly different from normal rat (Student‟s 
unpaired t-test, p<0.05). Results are shown as mean±s.e.m.  
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6.3.3 Effect of indomethacin on vascular function in normal and diabetic arteries 
  The presence of the non-selective COX inhibitor, indomethacin, had no significant 
effect on the sensitivity to ACh in either normal (control, 7.58±0.12 vs. indomethacin, 
7.74±0.09, n=4-11, p>0.05) or diabetic (control, 6.52±0.12 vs. indomethacin, 6.77±0.14, n=4-
10, p>0.05) mesenteric arteries (Figure 6.2). Similarly, the maximum relaxation to ACh was 
also not affected by the presence of indomethacin in normal (control, 100±0 vs. indomethacin, 
100±0, n=4-11, p>0.05) and diabetic (control, 100±0 vs. indomethacin, 98±2, n=4-10, 
p>0.05) rats (Figure 6.2). Thus, all following experiments were conducted in the presence of 
indomethacin to exclude the role of prostanoid synthesis.   
 
6.3.4 Effect of diabetes on vascular function 
 Diabetes significantly reduced the sensitivity, but not the maximum relaxation, to ACh 
in mesenteric arteries (Figure 6.3, Table 6.2), however, the sensitivity (diabetic, 8.48±0.10 vs. 
normal, 8.18±0.14, n=5, p>0.05) and maximum relaxation (diabetic, 97±2% vs. normal, 
100±0%, n=5, p>0.05) to SNP were not affected. In addition, the diabetic arteries also showed 
a significant increase in sensitivity to ET-1 (diabetic, 8.46±0.25 vs. normal, 7.99±0.06, n=4, 
p<0.05), without affecting the maximum contraction (Figure 6.3). 
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Figure 6.1 Mesurement of superoxide levels in mesenteric arteries. Superoxide levels in 
intact superior mesenteric arteries (a) and mesenteric homogenates (b) from normal (solid 
bars) and diabetic (open bars) rats. Diabetes has a significantly higher level of superoxide 
production in either intact or mesenteric homogenates compared to normal rats. Superoxide 
levels could be attenuated either by the presence of tempol (100 μM), a cell permeable SOD 
mimetic (a) or DPI (5 μM), a flavoprotein inhibitor that inhibits NADPH oxidase (b). n=5-6 
experiments. Results are shown as mean±s.e.m. * Significantly different from normal rats 
(Student‟s unpaired t-test, p<0.05). # Significantly different from control within respective 
group (Student;s unpaired t-test, p<0.05). 
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Figure 6.2 Contribution of PGI2 to endothelium-dependent relaxation in mesenteric 
arteries. Cumulative concentration-response curves to ACh in endothelium-intact mesenteric 
arteries isolated from normal rats in the absence (□) or presence of indomethacin (■) and 
diabetic rats in the absence (∆) or presence of indomethacin (▲). Results are shown as 
mean±s.e.m. See results section for pEC50 and Rmax values. 
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Figure 6.3 Vascular function of mesenteric arteries. Cumulative concentration-response 
curves to ACh (a), SNP (b) or ET1 (c) in endothelium-intact mesenteric arteries isolated from 
normal (●) or diabetic (■) rats. All experiments were conducted in the presence of 
indomethacin except for (c). Results are shown as mean±s.e.m. * pEC50 significantly different 
from normal rats (Student‟s unpaired t-test, p<0.05). See Table 6.2 or results section for 
pEC50 and Rmax values.  
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6.3.5 Role of EDHF-type relaxation in diabetic mesenteric arteries  
 The sensitivity to ACh in normal mesenteric arteries was significantly reduced by the 
presence of L-NNA+ODQ (Figure 6.4a, Table 6.2). In contrast, in arteries from diabetic rats, 
the sensitivity to ACh was unaffected by the presence of L-NNA+ODQ (Figure 6.3b, Table 
6.2). When the contribution of NO was eliminated by L-NNA+ODQ, the sensitivity to ACh 
was significantly lower in the diabetic compared to the normal arteries (diabetic, 6.68±0.12 
vs. normal, 7.08±0.11, n=11-12, p<0.05), indicating that diabetes impairs the contribution of a 
non-NO and non-prostanoid factor to endothelium-dependent relaxation. The maximum 
relaxation to ACh was unaffected by the presence of L-NNA+ODQ in normal or diabetic 
arteries.  
 To determine the individual roles of IKCa and SKCa in EDHF-type relaxation, we 
examined responses to ACh in the presence of either TRAM-34 or apamin respectively in 
addition to NOS inhibition (L-NNA+ODQ). In normal arteries, the addition of either TRAM-
34 or apamin caused a further significant decrease in the sensitivity to ACh, without affecting 
the maximum relaxation (Table 6.2). In comparison, in diabetic arteries, the addition of 
TRAM-34 significantly decreased the sensitivity to ACh, whereas the addition of apamin 
caused a significant reduction in the maximum relaxation to ACh (Table 6.2). When the 
contribution of IKCa was eliminated by L-NNA+ODQ+TRAM-34, the sensitivity to ACh was 
significantly lower in the diabetic compared to the normal arteries (Table 6.2). Conversely, 
when the contribution of SKCa was eliminated by L-NNA+ODQ+apamin, the maximum 
relaxation to ACh was significantly reduced in the diabetic compared to the normal arteries 
(Table 6.2), indicating that diabetes impairs both the IKCa- and SKCa-mediated relaxation.  
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Figure 6.4 Role of NO and EDHF to endothelium-dependent relaxation in the 
mesenteric arteries from normal and diabetic animals. Cumulative concentration-response 
curves to ACh in the absence (control,●) or presence of L-NNA+ODQ (■), TRAM-
34+Apamin (▲) or L-NNA+ODQ+TRAM-34+Apamin (▼) in endothelium-intact mesenteric 
arteries isolated from normal (a) or diabetic (b) rats. All the experiments were conducted in 
the presence of indomethacin. In each group of experiments, mesenteric arteries were 
precontracted with PE to similar levels: (a) 54±1, (b) 56±2 %KPSS.  n=9-15 experiments. 
Results are shown as mean±s.e.m. * pEC50 significantly different from control (Bonferroni‟s 
test, p<0.05). # Rmax significantly different from control (Bonferroni‟s test, p<0.05). See Table 
6.2 for values.  
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Table 6.2 Role of EDHF on ACh-induced relaxation of mesenteric arteries from normal 
and diabetic rats in the presence of indomethacin. 
 
 
A comparison of the sensitivity (pEC50) and maximum relaxation (Rmax) to ACh in the 
absence (control), or presence of L-NNA+ODQ, L-NNA+ODQ+apamin, L-
NNA+ODQ+TRAM-34, L-NNA+ODQ+TRAM-34+apamin, L-NNA+ODQ+TRAM-34 
+apamin+Ibtx or L-NNA+ODQ+45 mM K
+
 in endothelium intact mesenteric arteries from 
normal and diabetic rats. All experiments were conducted in the presence of indomethacin. n= 
the number of experiments. * Significantly different from corresponding control ACh 
response in the mesenteric arteries within the same treatment group (Bonferroni‟s test, 
p<0.05). † Significantly different from corresponding “L-NNA+ODQ” ACh response in the 
mesenteric arteries within the same treatment group (Bonferroni‟s test, p<0.05). # 
Significantly different from normal treatment group in the mesenteric arteries within the 
respective inhibitor group (Student‟s unpaired t-test, p<0.05). Results are shown as 
mean±s.e.m. ND: Not determined 
  
  Normal   Diabetic 
 n pEC50 
Rmax 
(%) 
n pEC50 Rmax (%) 
ACh       
Control 15 7.66±0.09 99±0 14 6.72±0.12
#
 98±1 
L-NNA + ODQ 11 7.08±0.11
*
 99±1 12 6.68±0.12
#
 96±3 
L-NNA + ODQ + apamin 4 6.19±0.13
*†
 96±2 4 ND 28±6
*†#
 
L-NNA+ODQ+TRAM-34  4 6.28±0.17
*†
 96±3 4 5.79±0.15
*†#
 89±9
*
 
L-NNA + ODQ + TRAM-
34 + apamin 
10 ND 58±8
*†
 9 ND 9±7
*†#
 
L-NNA + ODQ + TRAM-
34 + apamin+Ibtx 
7 ND 29±9
*†
 6 ND 0±0
*†#
 
45 mM K
+
 + L-NNA + 
ODQ 
4 ND 0±0
*†
 4 ND 0±0
*†
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The addition of TRAM-34+apamin, in the presence of L-NNA+ODQ, abolished ACh-
induced relaxation in diabetic arteries but in normal arteries ACh continued to cause a 
maximum relaxation of almost 60% (Table 6.2). The additional presence of Ibtx, to block 
maxi KCa, caused a further significant reduction in relaxation to ACh in normal arteries 
(Figure 6.4a, Table 6.2), suggesting an additional role of other endothelium-derived factors to 
relaxation in normal arteries, but not in diabetes. 
To investigate the contribution of NO to the maxi KCa component of relaxation, 
responses to ACh were tested in the presence of a NO scavenger, HXC, in addition to KCa 
channel inhibitors (TRAM-34+apamin or TRAM-34+apamin+Ibtx). In normal arteries, the 
addition of HXC to TRAM-34+apamin significantly decreased the sensitivity to ACh without 
affecting the maximum relaxation (Table 6.3), whereas the addition of HXC to TRAM-
34+apamin+Ibtx caused a significant reduction (~50%) of the maximum relaxation to ACh. In 
contrast, in diabetic arteries, the addition of HXC to TRAM-34+apamin (Table 6.3) caused a 
significant reduction (~60%) in the maximum relaxation, which was abolished by the 
additional presence of Ibtx (Table 6.3). If the responses to ACh in the presence of TRAM-
34+apamin+HXC or TRAM-34+apamin+Ibtx+HXC are compared between arteries from 
normal and diabetic rats, it is apparent that diabetes also significantly reduced the remaining 
maximum relaxation to ACh.  
 
6.3.6 Role of NO-mediated relaxation in diabetic mesenteric arteries 
 In normal arteries, the presence of either apamin alone or the combination of TRAM-
34+apamin, significantly reduced the sensitivity but not the maximum relaxation to ACh 
(Figure 6.4a, Table 6.3). The presence of TRAM-34 alone had no effect on the sensitivity or 
maximum relxation to ACh in normal arteries (Table 6.3). In contrast, in diabetic arteries, the 
sensitivity to ACh was unaffected, while the maximum relaxation to ACh was significantly 
reduced (Figure 6.4b, Table 6.3) by the combination of the IKCa and SKCa blockers in 
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comparison to control. In arteries from normal and diabetic rats, the addition of Ibtx, a blocker 
of maxi KCa, in the presence of TRAM-34+apamin, significantly reduced the sensitivity and 
maximum relaxation to ACh (Figure 6.5, Table 6.3).  
If the responses to ACh in the presence of TRAM-34+apamin or TRAM-
34+apamin+Ibtx are compared between arteries from normal and diabetic rats, it is apparent 
that diabetes decreased both the sensitivity (diabetic 6.74±0.11 vs. normal, 7.19±0.11, n=9-10, 
p<0.05) and maximum relaxation (diabetic 74±7 vs. normal, 96±1, n=9-10, p<0.05) to ACh in 
the presence of TRAM-34+apamin, and maximum relaxation (diabetic 17±5 vs. normal, 
81±5, n=8-9, p<0.0001) in the presence of TRAM-34+apamin+Ibtx, suggesting that diabetes 
impaired the contribution of NO to endothelium-dependent relaxation. In addition, in arteries 
precontracted with a depolarizing solution of 45 mM K
+
, to eliminate any contribution of the 
opening of potassium channels, ACh-induced relaxation was significantly attenuated and in 
comparison to normal arteries the Rmax was significantly lower in diabetic rats (Figure 6.5). 
The additional presence of L-NNA+ODQ in arteries that were precontracted with 45 mM K
+
, 
abolished ACh-induced relaxation in normal and diabetic rats (Table 6.2).  
The basal level of NO release was assessed by measuring the contraction induced by 
L-NNA in arteries with a low level of PE-induced tone (Judkins et al., 2010; Miller et al., 
2010; Woodman et al., 2004b). The L-NNA-induced contraction was significantly greater in 
arteries from normal rats compared with diabetic rats (normal, 44±4% vs. diabetic, 30±3%, 
n=4-6, p<0.05), indicating that diabetes impaired the basal release of NO (Figure 6.6). 
 
Chapter 6-Mechanism of endothelial dysfunction in diabetes 
181 
 
 
Figure 6.5 Role of NO-mediated relaxation in mesenteric arteries from normal and 
diabetic animals. Cumulative concentration-response curves to ACh in the absence (control, 
●) or presence of 45 mM K+ (□), L-NNA+ODQ+TRAM-34+Apamin+Ibtx (∆) or TRAM-
34+Apamin+Ibtx (♦) in endothelium-intact mesenteric arteries isolated from normal (a) or 
diabetic (b) rats. All the experiments were conducted in the presence of indomethacin. In each 
group of experiments, mesenteric arteries were precontracted with PE or depolarizing solution 
to similar levels: (a) 53±2, (b) 56±2 %KPSS. n=7-15 experiments. Results are shown as 
mean±s.e.m. * pEC50 significantly different from control (Bonferroni‟s test, p<0.05). # Rmax 
significantly different from control (Bonferroni‟s test, p<0.05). See Table 6.2 and Table 6.3 
for values. 
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Table 6.3 Role of NO on ACh-induced relaxation of mesenteric arteries from normal 
and diabetic rats in the presence of indomethacin. 
 
A comparison of the sensitivity (pEC50) and maximum relaxation (Rmax) to ACh in the 
absence (control), or presence of apamin, TRAM-34, TRAM-34 +apamin, TRAM-
34+apamin+Ibtx, TRAM-34+apamin+HXC, TRAM-34+apamin+Ibtx+HXC or 45 mM K
+
 in 
endothelium intact mesenteric arteries from normal and diabetic rats. All experiments were 
conducted in the presence of indomethacin. n= the number of experiments. * Significantly 
different from corresponding control ACh response in the mesenteric arteries within the same 
treatment group (Bonferroni‟s test, p<0.05). † Significantly different from corresponding 
“TRAM-34+apamin” ACh response in the mesenteric arteries within the same treatment 
group (Bonferroni‟s test, p<0.05). # Significantly different from normal treatment group in 
the mesenteric arteries within the respective inhibitor group (Student‟s unpaired t-test, 
p<0.05). Results are shown as mean±s.e.m. ND: Not determined 
 
  
  Normal   Diabetic 
 n pEC50 
Rmax 
(%) 
n pEC50 Rmax (%) 
ACh       
Control 15 7.66±0.09 99±0 14 6.72±0.12
#
 98±1 
apamin 4 6.80±0.09
*
 98±1 4 6.41±0.08
#
 96±1
†
 
TRAM-34  4 7.23±0.22 99±1 4 6.45±0.15
#
 98±1
†
 
TRAM-34 + apamin 10 7.19±0.11
*
 96±1 9 6.74±0.11
#
 74±7
*#
 
TRAM-34 + apamin+Ibtx 9 6.56±0.19
*†
 81±5
*†
 8 ND 17±5
*†#
 
TRAM-34 + apamin+HXC 4 6.47±0.13
†
 96±3 4 ND 41±6
*†#
 
TRAM-34 + 
apamin+Ibtx+HXC 
4 ND 47±8
*†
 4 ND 0±0
*#
 
45 mM K
+
  7 6.61±0.08
*
 50±5
*†
 8 6.61±0.10 27±5
*#
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Figure 6.6 Basal NOS activity in mesenteric arteries from normal and diabetic rat. 
Contractile responses to L-NNA in mesenteric arteries from normal (solid bars) and diabetic 
(open bars) rats which is taken to reflect basal NO release. Diabetes had a significantly lower 
basal NO level in mesenteric arteries compared to normal rats. n=4-6 experiments. Results are 
shown as mean±s.e.m. * Significantly different from normal rats (Student‟s unpaired t-test, 
p<0.05).  
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6.3.7 Role of oxidative stress in diabetic mesenteric arteries 
 In normal arteries, the presence of tempol had no effect on either the sensitivity 
(normal 7.64±0.10 vs. normal+tempol 7.86±0.09, n=4, p>0.05) or maximum relaxation to 
ACh. In contrast, in diabetic arteries (Figure 6.7), tempol significantly improved the 
sensitivity (diabetic 6.85±0.08 vs. diabetic+tempol 7.55±0.05, n=4, p<0.05) to ACh, but had 
no effect on the maximum relaxation. This effect was eliminated by the additional presence of 
L-NNA+ODQ (L-NNA+ODQ 6.57±0.15 vs. L-NNA+ODQ+tempol 6.68±0.18, n=4 p>0.05), 
indicating that tempol improves NO-dependent relaxation. 
 
6.3.8 Effect of diabetes on the expression of Nox2 and NOS related proteins expression.  
Diabetes did not change the expression of total eNOS (Figure 6.8a) in the mesenteric 
arteries but significantly decreased the proportion of eNOS expressed as a dimer (Figure 
6.8d). The expression of total Akt was not changed but phosphorylation of the ser
473
 residue 
was significantly decreased in the diabetic arteries (Figure 6.8e) The expression of Nox2 was 
significantly increased in diabetic arteries compared to normal arteries (Figure 6.8f). Diabetes 
had no effect on the expression of caveolin-1 and calmodulin in the mesenteric arteries 
(Figure 6.8b, c) and inducible-NOS expression was not detected from either group (data not 
shown).  
 
6.3.9 Effect of diabetes on the expression of KCa channels 
Diabetes did not change the expression of maxi KCa in the mesenteric arteries (Figure 
6.9a) but significantly increased the expression of SKCa (SKCa2.3) and IKCa (Figure 6.9b, c).  
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Figure 6.7 Role of oxidative stress on endothelial function in diabetic mesenteric 
arteries. Cumulative concentration-response curves to ACh in the absence (control, ●) or 
presence of tempol (○), L-NNA+ODQ (■) or L-NNA+ODQ+tempol (□) in endothelium-
intact mesenteric arteries isolated from diabetic rats. All the experiments were conducted in 
the presence of indomethacin. n=4 experiments. Results are shown as mean±s.e.m. * pEC50 
significantly different from control (Bonferroni‟s test, p<0.05). See results section for pEC50 
and Rmax values. 
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Figure 6.8 Western blot analysis of mesenteric arteries from normal and diabetic rats. 
Protein expressions of eNOS (a), caveolin-1 (b), calmodulin (c) eNOS homodimer (d) 
formation and pAkt/Akt (e) and Nox2 (f) in the normal and diabetic mesenteric arteries 
determined by western blot analysis. Diabetes significantly reduced the proportion of eNOS 
expressed as the dimer, decreased the phosphorylation of Akt Ser
473
 and increased the 
expression of Nox2. n= 5-7 experiments. Representative blots are shown on each of the 
corresponding graphs. Results are shown as mean±s.e.m. * Significantly different from 
normal rats (Student‟s unpaired t-test, p<0.05). 
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Figure 6.9 Western blot analysis of mesenteric arteries from normal and diabetic rats. 
Protein expression of maxi KCa (a), SKCa2.3 (b) and IKCa (c) in the normal and diabetic 
mesenteric arteries determined by western blot analysis. Diabetes significantly increased the 
expression of IKCa and SKCa2.3. n= 5-7 experiments. Representative blots are shown on each 
of the corresponding graphs. Results are shown as mean±s.e.m. * Significantly different from 
normal rats (Student‟s unpaired t-test, p<0.05). 
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6.4 Discussion 
 This study demonstrated that, after 10 weeks of diabetes, endothelial dysfunction was 
evident in the rat small mesenteric artery, which was due to a decreased contribution of both 
NO-mediated and EDHF-type relaxation to endothelium-dependent relaxation. Diabetes also 
caused an increased superoxide production in mesenteric arteries associated with an increase 
in Nox2 expression. Western blot analysis also indicated that diabetes significantly decreased 
the proportion of eNOS expressed as a dimer and decreased the activation of eNOS by 
decreasing the level of phosphorylation of Akt, actions that would decrease NO synthesis 
(Fulton et al., 1999; Hink et al., 2001). Uncoupled eNOS may also contribute to the increase 
in superoxide production (Hink et al., 2001). Furthermore, the basal level of NO release was 
also decreased. In contrast, diabetes caused a significant increase in the expression of the 
endothelial KCa channels, suggesting that, rather than a decrease in channels expression, the 
impairment of the EDHF-type relaxation may be attributed to defective downstream processes 
such as microdomain signaling or myoendothelial gap junction pathways (Edwards et al., 
2010).  
 
6.4.1 Endothelial dysfunction in diabetes 
In the present study, diabetes increased the level of vascular superoxide production, 
associated with an increase in Nox2 expression which was abolished by the presence of DPI, 
and endothelial dysfunction, as observed by an impairment of endothelium-dependent 
relaxation without affecting endothelium-independent relaxation. Endothelial dysfunction 
could be acutely reversed by decreasing the activity of superoxide with the cell permeable 
SOD mimetic, tempol, which restored the NO-mediated responses. These observations are 
consistent with several other studies that have demonstrated that diabetes causes vascular 
oxidant stress and causes endothelial dysfunction in either large conduit or resistance 
vasculature (De Vriese et al., 2000; Xu et al., 2009). Despite the many reports of diabetes 
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induced endothelial dysfunction the mechanism(s) of that effect remain poorly understood 
(Shi et al., 2006; Wigg et al., 2001), in particular the relative contribution of NO and EDHF 
in the presence of diabetes-induced endothelial dysfunction of resistance vessels.  
 
6.4.2 Role of EDHF-type relaxation in diabetic mesenteric arteries 
To investigate the role of EDHF, we assessed endothelium-dependent relaxation in the 
presence of L-NNA and ODQ to inhibit NO synthesis and sGC activity respectively. In the 
presence of L-NNA+ODQ (and indomethacin), the sensitivity to ACh was decreased in 
diabetic arteries when compared to normal arteries, indicating an impairment of the 
contribution of a EDHF-type relaxation, although it is important to note that the non-NO, non-
prostanoid effect was able to maintain the maximal response to ACh. These observations were 
consistent with several other studies (Fukao et al., 1997; Matsumoto et al., 2003b; Matsumoto 
et al., 2005). To further investigate the individual KCa channels (IKCa and SKCa) involved in 
the classical type of EDHF-type relaxation in the diabetic mesenteric arteries, responses to 
ACh were assessed in the presence of either TRAM-34 or apamin, blockers of IKCa or SKCa 
respectively. Addition of either TRAM-34 or apamin to L-NNA+ODQ, significantly 
attenuated the remaining relaxation in diabetic arteries in comparison with normal arteries, 
indicating that diabetes impairs both IKCa and SKCa-mediated EDHF-type relaxation. 
Consistent with this observation, when the combination of IKCa and SKCa blockers were 
added to L-NNA+ODQ, endothelium- dependent relaxation was abolished in diabetic arteries, 
but only significantly attenuated in normal arteries. This suggests that in normal mesenteric 
artery, there is a role of a non-classical type of EDHF-type relaxation i.e. endothelium-derived 
factor that caused smooth muscle cell hyperpolarization and relaxation that is independent of 
IKCa and SKCa (Edwards et al., 2010). Endothelium-derived factors such as EETs, HNO or 
H2O2 could contribute to the non-classical EDHF-type relaxation observed in normal 
mesenteric arteries. However, in the diabetic mesenteric arteries, the role of the non-classical 
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EDHF-type relaxation was abolished, suggesting that the endothelium-derived factors could 
be a NOS-dependent source and perhaps argues against a role for EETs or H2O2 in diabetes.  
One possible NOS-derived factor could be HNO which has recently been shown to be 
involved in endothelium-dependent relaxation in normal mesenteric arteries (Andrews et al., 
2009) and can be formed endogenously by uncoupled NOS or from nitrosothiols (Irvine et al., 
2008). The hyperpolarizing and relaxing effect of HNO could be partially inhibited by either 
Ibtx or 4-aminopyridine, suggesting the involvement of both maxi KCa and Kv channels 
(Andrews et al., 2009; Zeller et al., 2009; Zygmunt et al., 1996). Indeed, our results have 
shown that the addition of Ibtx to L-NNA+ODQ+TRAM-34+apamin caused a significant 
reduction (~30%) to the maximum relaxation to ACh as has been previously reported by 
(Ellis et al., 2009). Andrews et al.,(2009) have provided evidence that the remaining 
relaxation could be significantly attenuated by either 4-aminopyridine or L-cysteine, a HNO 
scavenger. Interestingly, in the diabetic mesenteric arteries, a HNO-mediated relaxation was 
not observed in the presence of L-NNA+ODQ+TRAM-34+apamin, which suggests that in 
diabetic arteries HNO could be solely derived from uncoupled NOS and without any 
contribution from nitrosothiols. Our results show that there was an increase in superoxide 
production in diabetic mesenteric arteries, which has been shown to degrade biological 
nitrosothiols (Aleryani et al., 1996). Similarly, we have demonstrated eNOS uncoupling in the 
diabetic mesenteric arteries, which could be a source of HNO in diabetes. When we examined 
relaxant responses to ACh with the addition of a NO scavenger, HXC, in the presence of 
TRAM-34+apamin or TRAM-34+apamin+Ibtx, the maximum relaxation to ACh was 
significantly reduced in diabetic arteries in comparison to normal arteries, indicating that 
diabetes also impairs HNO-mediated relaxation.  
Whilst our functional experiments demonstrated an impairment of IKCa and SKCa-
mediated EDHF-type relaxation, the results from our western blot analysis have shown an 
increased expression of IKCa and SKCa in diabetes. This phenomenon could be a compensatory 
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response to diabetes in order to maintain both EDHF and NO-mediated relaxation (Sheng et 
al., 2009). Indeed, many studies have shown that diabetes causes compensatory changes in 
endothelial function. For example, we (Chapter 3) and others (Cai et al., 2005) have 
demonstrated that in the large vessels, NO synthesis was significantly impaired in diabetes but 
eNOS expression was significantly increased. Therefore, in this study, despite the increased 
expression of IKCa and SKCa, the impairment of IKCa and SKCa-mediated EDHF-type 
relaxation may be due to the impairment of downstream microdomain signaling and/or 
myoendothelial gap junction pathways (Weston et al., 2010; Young et al., 2008). 
 
6.4.3 Role of NO-mediated relaxation in diabetic mesenteric arteries 
In order to evaluate NO-mediated relaxation, the EDHF-type relaxation was inhibited 
either by the endothelial KCa channel blockers or by the presence of a depolarizing high K
+
 
solution. This confirmed an impaired release of NO as the maximum relaxation to ACh was 
decreased in the diabetic mesenteric arteries in comparison to normal arteries. In addition to 
stimulated NO release, basal release of NO was also decreased in diabetic mesenteric arteries 
demonstrated by impaired contraction in response to NOS inhibition. Hence, endothelial 
dysfunction in the diabetic mesenteric arteries was partly attributed to the impairment of NO 
activity.  
Our functional results demonstrated an impairment of NO-mediated relaxation in 
diabetic mesenteric arteries.  We found that the expression of total eNOS was unaffected by 
diabetes, but we observed eNOS uncoupling, demonstrated by the decreased proportion of 
eNOS expressed as a dimer in the diabetic mesenteric vasculature without affecting the total 
expression of eNOS, suggesting that in the diabetic rats eNOS is producing more superoxide 
and less NO (Hink et al., 2001) (Chapter 3), than the normal rats. The activation of eNOS is 
regulated by several protein kinases (Dudzinski & Michel, 2007), including the protein kinase 
Akt (Fulton et al., 1999), hence we investigated the level of phosphorylation of Akt in the 
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diabetic mesenteric arteries. We observed that the level of phosphorylation of Akt on Ser
473
 
was decreased in diabetes, without affecting the total expression of Akt. This observation is 
consistent with a recent study where it has been demonstrated that diabetes was able to 
decrease the  phosphorylation of Akt on Ser
473
 (Hamamdzic et al., 2010). A further possible 
explanation for decreased NO activity could be the increased expression of Nox2 which could 
contribute to the elevated vascular superoxide production evident in diabetic mesenteric 
arteries, which could then promote an increased degradation of NO by superoxide resulting in 
the formation of peroxynitrite. Indeed, endothelium-dependent relaxation was restored with 
the antioxidant, tempol, presumably due to acute enhancement of NO activity resulting from 
decreased inactivation by superoxide. Taken together, we have shown that several diabetes-
induced changes could contribute to the decrease in NO activity that is the decrease in 
phosphorylation of Akt, uncoupling of eNOS and increased vascular superoxide levels, at 
least in part, due to increased NADPH oxidase-driven superoxide production. 
 
6.4.4 Conclusion 
At 10 weeks of diabetes, hyperglycaemia increased superoxide production, causing 
endothelial dysfunction which was due to the impairment of both NO and EDHF-type 
relaxation. The impairment of NO-mediated relaxation could be, at least in part, due to 
increased superoxide production, eNOS uncoupling and decreased activation of eNOS via the 
protein kinase Akt.  The impairment of EDHF-type relaxation did not involve a decrease in 
channel expression, rather it may arise from the disruption of downstream pathways of IKCa 
and SKCa channels. The degree of impairment in NO activity appears to be greater than the 
reduction in EDHF activity as EDHF is able to elicit maximum relaxation when NO is 
inhibited, suggesting that NO is more susceptible to impairment by diabetes. Therefore, 
pharmacological intervention that aimed to improve the bioavailability of NO could be useful 
in the prevention of diabetic microvascular diseases 
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Chapter 7 
 
3’,4’-dihydroxyflavonol restores 
endothelium-dependent relaxation in small 
mesenteric artery from rats with type I and 
type II diabetes. 
 
7.1 Introduction 
Diabetes mellitus is characterized by hyperglycaemia which is associated with 
oxidative stress and abnormal function of the vascular endothelium and it is proposed that 
these defects contribute to the underlying vasculopathies (Fatehi-Hassanabad et al., 2010). 
This suggestion has sparked a number of studies examining the effects of vitamin antioxidants 
on endothelial function in various animal models of diabetes (Alper et al., 2006; Cinar et al., 
2001; Jariyapongskul et al., 2007; Sridulyakul et al., 2006; Wigg et al., 2004). Although a 
number of studies showed a beneficial effect of antioxidants in preventing diabetes-induced 
endothelial dysfunction in the aorta (Alper et al., 2006; Cinar et al., 2001; Sena et al., 2008), 
whether there is benefit in the resistance vasculature is less certain (Belin de Chantemèle et 
al., 2009; Dhein et al., 2003; Jariyapongskul et al., 2007; Lu et al., 2005; Palmer et al., 1998; 
Sridulyakul et al., 2006; Wigg et al., 2004). For example, Wigg et al.,(2004) reported that 
vitamin E supplementation could restore impaired endothelial function in the mesenteric 
arteries, whereas Palmer et al.,(1998) reported that supplementation of vitamin E to diabetic 
rats caused a further impairment to endothelial function in comparison to untreated diabetic 
rats. In contrast to these two studies, Dhein et al.,(2003) suggested that vitamin E 
supplementation was effective in preserving endothelial function during the early stages of 
diabetes, but was ineffective at a later stage of diabetes. In all of these studies (Dhein et al., 
2003; Palmer et al., 1998; Wigg et al., 2004), there is a lack of direct evidence that vitamin E 
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was exerting an antioxidant effect. Thus, it remains uncertain as to whether the antioxidant 
effect of vitamin E is responsible for improving or impairing endothelial function in the 
diabetic microvasculature. 
Previous studies have demonstrated that a synthetic flavonol, DiOHF is significantly 
more potent than a number of natural flavones and flavonols in its antioxidant ability 
(Woodman et al., 2005). DiOHF has been shown to be effective in preventing oxidant stress-
induced cardiovascular dysfunction, resulting from ischaemia/reperfusion injury in rats (Chan 
et al., 2003) and sheep (Wang et al., 2004; Wang et al., 2009a). Furthermore, DiOHF has 
been shown to preserve endothelial function in the presence of oxidative stress (Qin et al., 
2008) and in diabetic aortae (Woodman et al., 2009), however, it is not known whether the 
antioxidant effect of DiOHF restores endothelial function in the diabetic resistance vessels, i.e 
the rat mesenteric artery. 
As diabetes-induced impairment of endothelium-dependent relaxation in the 
mesenteric arteries is associated with oxidative stress (Chapter 6), the aim of the present study 
was to investigate whether the acute presence of DiOHF restores microvascular endothelial 
function in arteries from type I and type II diabetic rats. In addition, the effects of DiOHF 
were compared with well-known antioxidants i.e SOD mimetics (MnTMPyP and tempol), 
which have previously been shown to preserve endothelial function in diabetes (Duncan et al., 
2007; Retailleau et al., 2010; Romanko et al., 2009; Woodman et al., 2008). 
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7.2 Methods 
7.2.1 Animals 
All procedures were approved by the Animal Experimentation Ethics Committee of 
RMIT University and conformed with the Australian National Health and Medical Research 
Council of Australia code of practice for the care and use of animals for scientific purposes. 
 
7.2 Type I diabetes 
 Male 8-10 week old Sprague-Dawley rats (Animal Resource Center, Perth, WA, 
Australia) were randomly divided into two groups: normal and diabetic. Type I diabetes was 
induced by a single injection of STZ into the rat tail vein after fasting overnight. The control 
groups received an equivalent volume of the vehicle (0.1 M citrate buffer) alone. In events 
where the diabetic rats exhibited weight loss (approximately 5% weight loss from the initial 
weight), these rats were treated with a low dose of insulin (4-5 IU, Protaphane, Novo Nordisk, 
NSW, Australia) to promote weight gain and reduce mortality. The control groups were not 
treated with insulin. In this chapter, approximately 5-10% of the diabetic animals died before 
they were due for experimentation. Ten weeks after STZ or vehicle treatment, the rats were 
euthanized with pentobarbitone sodium (325 mg/kg, i.p, Virbac, Australia). Blood samples 
were obtained from the left ventricle via cardiac puncture and the glucose concentration was 
measured using a one touch glucometer (Roche, Sydney, NSW, Australia). Induction of 
diabetes was considered successful when the glucose level was higher than 20 mM.  
 
7.2.3 Type II diabetes 
Male 25-week-old obese Zucker Rats and age-matched control lean Zucker rats 
(Monash Animal Service, Melbourne, VIC, Australia) were used. Rats were asphyxiated by 
CO2 inhalation, followed by decapitation, at which point blood was collected. Blood glucose 
was measured as described above.  
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7.2.4 Isolation of mesenteric arteries 
 After the rats were euthanized, the mesenteric arcade was isolated and immediately 
placed in ice cold Krebs bicarbonate solution (118 mM NaCl, 4.7 mM KCl, 1.18 mM MgSO4, 
1.2 mM KH2PO4, 25 mM NaHCO3, 11.1 mM D-glucose, and 2.5 mM CaCl2). Small 
mesenteric arteries (third-order branch of the superior mesenteric artery, internal diameter 
~300 m) were isolated and prepared as described in Chapter 2.2.3. 
 
7.2.5 Functional experiments 
 Endothelium integrity and vascular reactivity were evaluated as described in Chapter 
2.3. Briefly, arteries were precontracted to ~50% of the KPSS response using PE (0.1-3 μM). 
The effect of the treatment on relaxant responses was determined by cumulative 
concentration-response curves to the endothelium-dependent relaxant, ACh (0.1 nM-10 μM). 
In addition, responses to ACh were examined after 30 min incubation with DiOHF (1 μM) or 
the SOD mimetics MnTMPyP (10 μM) and tempol (100 μM).   
 
7.2.6 Superoxide measurement in mesenteric artery 
 Superoxide production in the mesenteric artery was measured using L-012 induced-
chemiluminescence as described in Chapter 2.4.1.  
 
7.2.7 Reagents 
 All drugs were purchased from Sigma-Aldrich (St Louis, MO, USA), except for 
acetylcholine perchlorate (BDH Chemicals, Poole, Dorset, UK), MnTMPyP (Alexis 
Chemicals, Farmingdale, NY, USA) and DiOHF (Indofine Chemicals, Hillsborough, NJ, 
USA). All drugs were all dissolved in distilled water, with the exception of DiOHF, which 
was dissolved in DMSO. 
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7.2.8 Statistical analyses 
All results are expressed as the mean±s.e.m., n represents the number of animals per 
group. Concentration-response curves from rat isolated mesenteric arteries were computer 
fitted to a sigmoidal curve using nonlinear regression (Prism version 5.0, GraphPad Software, 
San Diego, CA, USA) to calculate the sensitivity of each agonist (pEC50). Maximum 
relaxation (Rmax) to ACh was measured as a percentage of precontraction to PE. Group pEC50 
and Rmax values were compared using Student‟s unpaired t-test or one-way ANOVA with 
post-hoc analysis using Dunnett‟s test as appropriate. P<0.05 was considered statistically 
significant. 
 
7.3 Results 
7.3.1 Body weights and blood glucose 
 Over a 10 week period, the STZ-treated diabetic rats gained significantly less weight 
compared to vehicle-treated normal rats (body weight gained normal 356±16g vs. STZ 
diabetic 167±12g, n=9-11, Student‟s t test, P<0.0001). Similarly, the blood glucose level in 
STZ-treated rats was significantly higher than vehicle-treated normal rats (blood glucose 
normal 10.5±0.6 mM vs. STZ diabetic >33 mM). For the type II model of diabetes, the 
average body weight for the obese rats was significantly higher in comparison to their lean 
littermate controls (body weight gained obese 474±5g vs. lean 386±9g, n=6-8, Student‟s t test, 
P<0.0001). Blood glucose level was found to be significantly (P<0.0001, Student‟s t test) 
higher in the obese (8.8±0.6 mM, n=8) compared to the lean (4.5± 0.2 mM, n=6) Zucker rats. 
 
7.3.2 Superoxide production in diabetes 
 The superoxide generation from type I and type II diabetic rats is shown in Figure 7.1. 
The superoxide level in mesenteric arteries from STZ-treated (Figure 7.1a) or obese (Figure 
7.1b) rats was significantly higher than their respective control rats (normal or lean). 
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Treatment with either DiOHF or SOD mimetics (MnTMPyP or tempol) attenuated superoxide 
levels to comparable levels in mesenteric arteries from either type I or type II diabetic rats. 
 
7.3.3 Effect of diabetes on endothelial function  
The relaxant responses to ACh in mesenteric arteries from type I or type II diabetic 
rats are shown in Figure 7.2. The sensitivity to ACh in mesenteric arteries from STZ-treated 
rats was significantly reduced in comparison to normal rats, without affecting the maximum 
relaxation (Figure 7.2a, Table 7.1). Similarly, mesenteric arteries from obese rats also showed 
a significant decrease in sensitivity but had no effect on the maximum relaxation to ACh in 
comparison to lean rats (Figure 7.2b, Table 7.2). 
 
7.3.4 Effect of antioxidants on endothelial function in type I and type II diabetic rats. 
The acute presence of DiOHF or SOD mimetics (MnTMPyP or tempol) had no 
significant effect on either the sensitivity or maximum relaxation to ACh in mesenteric 
arteries from either normal (Figure 7.3a, Table 7.1) or lean Zucker rats (Figure 7.4a, Table 
7.2). In contrast, the acute presence of DiOHF or SOD mimetics (MnTMPyP or tempol) 
significantly increased the sensitivity to ACh in STZ-treated mesenteric arteries to level that is 
comparable to normal arteries (Figure 7.3b, Table 7.1). Similarly, the acute treatment with 
DiOHF or SOD mimetics (MnTMPyP or tempol) significantly increased the sensitivity to 
ACh in mesenteric arteries from obese rats to level that is comparable to lean mesenteric 
arteries (Figure 7.4b, Table 7.2).  
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Figure 7.1 Measurement of superoxide levels in mesenteric arteries. Superoxide levels in 
superior mesenteric arteries from normal (open bars) and type I diabetic (stripe bars) rats (a) 
and lean (open bars) and obese (stripe bars) Zucker rats (type II diabetes) (b). Both type I and 
type II diabetic rats had a significantly higher level of superoxide production in mesenteric 
arteries compared to their respective control rats. Superoxide levels could be attenuated by the 
presence of DiOHF or SOD mimetics (tempol, MnTMPyP) in mesenteric arteries from either 
groups. n=5-8 experiments. Results are shown as mean±s.e.m. * Significantly different from 
respective non-diabetic control rats (Student‟s unpaired t-test, P<0.05). # Significantly 
different from L-012 within respective group (Dunnest‟s test, P<0.05). 
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Figure 7.2 Vascular responses to ACh in mesenteric arteries type I and type II diabetic 
rat model. Cumulative concentration-response curves to ACh in endothelium-intact 
mesenteric arteries isolated from normal (●) or type I diabetic (■) rats (a) or lean (●) or obese 
(■) Zucker rats (b). In each group of experiments (a, b), mesenteric arteries were 
precontracted with PE to similar levels: (a) normal 56±2 vs. diabetic 58±4, (b) lean 55±3 vs. 
obese 52±2 %KPSS. n=6-11 experiments. Results are shown as mean±s.e.m. * pEC50 
significantly different from respective non-diabetic control rats. See Table 7.1 or Table 7.2 for 
pEC50 and Rmax values.  
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Table 7.1 Effect of DiOHF, tempol and MnTMPyP on ACh-induced relaxation of 
mesenteric arteries from normal and STZ-induced diabetic rats. 
 
A comparison of the sensitivity (pEC50) and maximum relaxation (Rmax) to acetylcholine in 
the absence (control), or presence of DiOHF (1 μM), tempol (100 μM) or MnTMPyP (10 μM) 
in endothelium intact mesenteric arteries from normal and STZ-diabetic rats. n= the number 
of experiments. 
* 
Significantly different from corresponding control ACh response in the 
mesenteric arteries within the same treatment group (Dunnett‟s test, P<0.05). # Significantly 
different from normal treatment group in the mesenteric arteries within the respective 
inhibitor group (Student‟s unpaired t-test, P<0.05). Results are shown as mean±s.e.m. ND: 
Not determined 
  
  Normal   STZ-diabetes 
 n pEC50 Rmax (%) n pEC50 Rmax (%) 
ACh       
Control 11 7.75±0.08 100±0 9 6.57±0.13
#
 98±1 
DiOHF 8 7.75±0.16 100±0 7 7.42±0.18
*
 98±2 
Tempol 5 7.86±0.10 96±3 6 7.22±0.15
*
 97±1 
MnTMPyP 7 7.72±0.15 100±0 5 7.23±0.13
*
 98±1 
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Figure 7.3 Effect of antioxidants on endothelial function in type I diabetic model. 
Cumulative concentration-response curves to ACh in the absence (control,●) or presence of 
DiOHF (■), Tempol (▲) or MnTMPyP (▼) in endothelium-intact mesenteric arteries isolated 
from normal (a) or type 1 diabetic (b) rats. In each group of experiments, mesenteric arteries 
were precontracted with PE to similar levels: normal 52±2 vs. diabetic 55±2 %KPSS.  n=5-11 
experiments. Results are shown as mean±s.e.m. See Table 7.1 for values and statistical 
comparison.  
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Figure 7.4 Effect of antioxidants on endothelial function in type II diabetic model. 
Cumulative concentration-response curves to ACh in the absence (control,●) or presence of 
DiOHF (■), Tempol (▲) or MnTMPyP (▼) in endothelium-intact mesenteric arteries isolated 
from lean (a) or obese (b) Zucker rats. In each group of experiments, mesenteric arteries were 
precontracted with PE to similar levels: lean 54±2 vs. obese 50±1 %KPSS. n=6-8 
experiments. Results are shown as mean±s.e.m. See Table 7.2 for values and statistical 
comparison 
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Table 7.2 Effect of DiOHF, tempol and MnTMPyP on ACh-induced relaxation of 
mesenteric arteries from lean and obese rats. 
 
A comparison of the sensitivity (pEC50) and maximum relaxation (Rmax) to ACh in the 
absence (control), or the presence of DiOHF (1 μM), tempol (100 μM) or MnTMPyP (10 μM) 
in endothelium intact mesenteric arteries from lean and obese rats. n= the number of 
experiments. 
*
 Significantly different from corresponding control acetylcholine response in 
the mesenteric arteries within the same treatment group (Dunnett‟s test, P<0.05).  
#
 Significantly different from normal treatment group in the mesenteric arteries within the 
respective inhibitor group (Student‟s unpaired t-test, P<0.05). Results are shown as 
mean±s.e.m. ND: Not determined 
 
  
  Lean  Obese 
 n pEC50 Rmax (%) n pEC50 Rmax (%) 
ACh       
Control 6 7.42±0.12 97±2 8 6.79±0.16
#
 92±3 
DiOHF 6 7.51±0.08 93±3 7 7.67±0.11
*
 91±5 
Tempol 6 7.24±0.24 96±2 6 7.44±0.10
*
 95±2 
MnTMPyP 6 7.62±0.18 99±1 6 7.53±0.09
*
 97±1 
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7.4 Discussion 
Although there is evidence that oxidant stress contributes to the impairment of 
endothelium-dependent relaxation in the microvasculature, it has not been clearly 
demonstrated that antioxidants are able to reverse microvascular endothelial dysfunction. This 
study has demonstrated that the synthetic flavonol DiOHF acutely reduced the levels of 
oxidative stress and improved endothelium-dependent relaxation in mesenteric arteries from 
both type I and type II diabetic rats. In addition, the presence of DiOHF ex vivo is as effective 
as SOD mimetics in reducing vascular oxidative stress and improving microvascular 
endothelial function.  
In the present study, in a STZ-model of type I and the obese Zucker model of type II 
diabetes, there was an elevation in blood glucose levels and an increase in superoxide 
production in the mesenteric arteries together with an impairment of endothelium-dependent 
relaxation, as we (Chapter 6) and others have previously observed (De Vriese et al., 2000; 
Young et al., 2008). The level of superoxide production and the degree of impairment of 
endothelial function were comparable in type I and type II diabetes, which is consistent with 
the possibility that hyperglycaemia-induced oxidative stress was responsible for the 
impairment of endothelium-dependent relaxation in the mesenteric arteries. It is, however, 
important to note that degree of hyperglycaemia between the STZ and obese Zucker model of 
diabetes were different. For example, in this study the STZ-induced diabetes causes chronic 
hyperglycaemia (blood glucose >33mM) whereas the obese Zucker model exhibit mild 
hyperglycaemia (blood glucose 8.8 mM). Besides exhibiting mild hyperglycaemia, the obese 
Zucker rat is also associated with insulin resistance, obesity, hyperlipidaemia, 
hyperinsulinaemia and moderate hypertension, which could all acting in synergy and 
contributes to vascular oxidative stress (Contreras et al., 2010; Mingorance et al., 2009; 
Serpillion et al., 2009; Srinivasan et al., 2007). The role of hyperglycaemia-induced oxidative 
stress has gained considerable attention since the emergence of the proposed „unifying 
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mechanism‟ for the pathogenesis of diabetic complications, i.e. the overproduction of 
superoxide by the mitochondrial electron transport chain (Brownlee, 2001). This is followed 
by the activation of four downstream pathways: increased polyol pathway flux, increased 
formation of advanced glycosylation end products, activation of protein kinase C, and 
increased hexosamine pathway flux (Nishikawa et al., 2000a). 
In the resistance vessels, such as the rat mesenteric artery, endothelium-dependent 
relaxation is mediated by multiple factors including NO and EDHF (Edwards et al., 2010). 
Hyperglycaemia-induced oxidative stress has been associated with the impairment of both 
NO- and EDHF-mediated relaxation (Chapter 6) (De Vriese et al., 2000). An increase in 
superoxide anions can impair endothelium-dependent relaxation through a number of 
mechanisms. NO rapidly reacts with superoxide to form peroxynitrite, simultaneously 
reducing the availability of NO for relaxation and increasing peroxynitrite-induced toxicity. 
For example, peroxynitrite has been reported to uncouple endothelial NO synthase, thus 
further promoting the synthesis of superoxide (Zou et al., 2004), and to cause protein nitration 
of the calcium-activated potassium channels which are responsible for EDHF responses (Liu 
et al., 2002a; Liu et al., 2002b). In addition to peroxynitrite, superoxide alone has recently 
been shown to cause impairment to EDHF responses in the mesenteric arteries, which could 
be reversed by the presence of antioxidant treatment (Ma et al., 2008). 
Structure-activity relationship studies have demonstrated that the synthetic flavonol 
DiOHF has a structure predicted to enhance antioxidant activity over that of natural flavonols 
(Woodman et al., 2005). We have previously reported that DiOHF reduced the detection of 
superoxide in a cell-free system, where xanthine/xanthine oxidase or pyrogallol generate 
superoxide, suggesting that DiOHF could rapidly scavenge superoxide and significantly 
improve endothelium-dependent relaxation in rat isolated aorta. Alternatively, DiOHF has 
been shown to inhibit enzymatic sources of oxygen radicals such as NADPH oxidase (Jiang et 
al., 2008). Taken together,  DiOHF is able to preserve endothelial function in the presence of 
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the oxygen radical, demonstrating the potential for DiOHF to rapidly react with superoxide to 
preserve NO activity and possibly EDHF responses (Ma et al., 2008). In this study we 
demonstrated that the application of DiOHF acutely reduced the detection of superoxide and 
improved endothelium-dependent relaxation in mesenteric arteries from type I and type II 
diabetic rats without affecting arteries from control rats. Similarly, the application of SOD 
mimetics acutely reduced the detection of superoxide and improved endothelium-dependent 
relaxation in diabetic mesenteric arteries to the same extent as DiOHF, suggesting that 
hyperglycaemia-induced oxidant stress is responsible for impairing endothelial function in the 
mesenteric arteries.  
In conclusion, we have demonstrated that the synthetic flavonol DiOHF restored 
endothelial function, determined by relaxant responses to ACh in mesenteric arteries from 
STZ-induced type I diabetic and the obese Zucker type II diabetic rats. The flavonol is able to 
acutely scavenge superoxide anions to reduce inactivation of NO and thus maintain 
endothelium-dependent relaxation. The protective actions of DiOHF may occur through at 
least two mechanisms, i.e direct scavenging of free radicals and inhibiting the enzymatic 
source of radical production, in comparison to the sole radical scavenging activity of SOD 
mimetics. The beneficial effect of DiOHF found in this study indicates that it has potential as 
a therapeutic agent for use in the prevention of the microvascular complications of diabetes 
and that investigation of its potential to improve vascular function when administered to 
diabetic subjects is warranted.  
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Chapter 8 
 
3’,4’-dihydroxyflavonol reduces superoxide 
and improves nitric oxide function in 
diabetic rat mesenteric arteries. 
 
8.1 Introduction 
Endothelial dysfunction, characterized by the impairment of endothelium-dependent 
relaxation, is recognised as an early phenomemon during the development of diabetes-
induced vascular complications (De Vriese et al., 2000; Fatehi-Hassanabad et al., 2010). Oral 
hypoglycaemic agents and insulin have been used to treat diabetes but they do not prevent the 
development of diabetic vascular complications (Brown et al., 2010; Holman et al., 2008; The 
Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and 
Complications (DCCT/EDIC) Study Research Group, 2005). In diabetes, hyperglycaemia-
induced oxygen radical generation, mainly superoxide anion radicals, play a key role in the 
pathogenesis of vascular complications (Brownlee, 2001; Forstermann, 2008; Nishikawa et 
al., 2000a). Despite this, clinical trials with antioxidants have failed to clearly demonstrate 
any beneficial effect on vascular function (Lonn et al., 2002; Song et al., 2009). More 
effective antioxidants, acting perhaps by targeting the specific sources of ROS, might prove 
more beneficial than direct scavenging strategies (Forstermann, 2008; Johansen et al., 2005; 
Willcox et al., 2008). Potential targets for pharmacological therapies include NADPH 
oxidase, eNOS and mitochondria all of which have been reported to be sources of ROS 
production in diabetes (Fatehi-Hassanabad et al., 2010; Hink et al., 2001). 
 Flavonols are one class of a large family of plant-derived polyphenolic compounds 
known as flavonoids. They exhibit a variety of biological actions such as antithrombotic, anti-
inflammatory, antioxidant and vasorelaxant effects (Woodman et al., 2004a; Yap et al., 
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2010). There is growing evidence that consumption of a flavonoid-rich diet reduces the risk of 
cardiovascular disease states associated with overproduction of ROS (Engler et al., 2006; 
Geleijnse et al., 2002). In addition, a number of studies have shown that, in animal models of 
diabetes, chronic treatment with the flavonol quercetin preserved endothelial function 
(Machha et al., 2007), reduced pancreatic beta-cell death (Coskun et al., 2005) and protected 
against diabetic nephropathy (Anjaneyulu et al., 2004).  
 Structure-activity relationship studies have demonstrated that a synthetic flavonol, 
DiOHF was significantly more potent than a number of natural flavones and flavonols in its 
antioxidant ability (Chan et al., 2000; Woodman et al., 2005). In addition, the antioxidant 
ability of DiOHF has been shown to preserve endothelial function in the aorta in the presence 
of oxidative stress (Chan et al., 2003; Qin et al., 2008). Furthermore, DiOHF effectively 
reduces oxidative stress related impairment of cardiovascular function after 
ischaemia/reperfusion in rats (Chan et al., 2003) and sheep (Wang et al., 2004; Wang et al., 
2009a) and in diabetic aorta (Woodman et al., 2009). In the earlier chapter, we have shown 
the acute antioxidant activity of DiOHF is able to restore endothelial function in the diabetic 
microvasculature (Chapter 7) but it is not known whether treatment with DiOHF is able to 
inhibit the sources of ROS production (Mladenka et al., 2010) in the diabetic 
microvasculature to improve endothelial function.  
Diabetes-induced endothelial dysfunction is due to the impairment of both NO-
mediated and EDHF-type relaxation, which is accompanied by an increase in Nox2-derived 
superoxide production and eNOS uncoupling in the mesenteric artery (Chapter 6). Therefore, 
the aim of the present study was to investigate whether short term in vivo treatment with 
DiOHF preserves microvascular endothelial function in mesenteric artery from type I diabetic 
rats and, if so, whether it acts via direct scavenging of ROS and/or by inhibiting the sources of 
ROS production in the diabetic microvasculature. In addition, we also sought to verify 
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whether the antioxidant activity of DiOHF treatment would have any effect on NO-mediated 
relaxation and/or EDHF-type relaxation in the diabetic arteries. 
 
8.2 Methods 
All procedures were approved by the Animal Experimentation Ethics Committee of 
RMIT University and conformed to the National Health and Medical Research Council of 
Australia code of practice for the care and use of animals for scientific purposes. 
 
8.2.1 Induction of diabetes  
 Male 6-8 week old Wistar rats weighing approximately 200g (Animal Resource 
Centre, Perth, WA, Australia) were randomly divided into two groups: normal and diabetic. 
Type I diabetes was induced as described in Chapter 2.1.1. Once the rats were rendered 
diabetic (blood glucose > 20 mM) the following week after STZ injection, all diabetic rats 
were maintained on a low insulin dose (4-5 IU, s.c., 3 injections per week, Protaphane, Novo 
Nordisk, NSW, Australia) to promote weight gain and reduce mortality. In this chapter, 
approximately 20% of the diabetic animals died before they were due for experimentation. At 
the end of the experimental period, blood samples were obtained from the left ventricle and 
the glucose concentration and HbA1c were measured using a one touch glucometer (Roche, 
Sydney, NSW, Australia) and Micromat HbA1c analyser (Biorad, Sydney, NSW, Australia) 
respectively. 
 
8.2.2 DiOHF treatment 
After seven weeks of STZ-induced diabetes, the 2 groups of rats were further divided 
(Normal, Normal+DiOHF, Diabetic, Diabetic+DiOHF) receiving either vehicle (10% 
DMSO+90% peanut oil) or (DiOHF, 1mg/kg s.c. per day) for a period of 7 days. The last 
dose of DiOHF was administered at least 24 hr prior to the start of experimentation. 
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8.2.3 Isolation of mesenteric arteries 
 Eight weeks after STZ treatment, the rats were killed with pentobarbitone sodium (325 
mg/kg, i.p, Virbac, Australia). Small mesenteric arteries (third-order branch of the superior 
mesenteric artery, internal diameter ~300 m) were isolated and prepared as described in 
Chapter 2.2.3. 
 
8.2.4 Assessment of vascular reactivity 
 Vascular reactivity of mesenteric arteries was evaluated as described in Chapter 2.3. 
Briefly, arteries were precontracted to a similar level using PE (0.1-3 μM) or in some cases 30 
mM K
+
, and cumulative concentration-response curves to ACh (0.1 nM/l-10 μM) and SNP 
(0.01 nM-10 μM) were determined. In addition, responses to ACh and SNP were examined 
after 20 min incubation with different combinations of L-NNA (100 μM), a non-selective 
NOS inhibitor, ODQ (10 μM), a sGC inhibitor, TRAM-34 (1 μM), a selective blocker of IKCa, 
ibtx (100 nM), a selective blocker of maxi KCa and apamin (1 μM), a SKCa inhibitor. 
 To evaluate the constrictor reactivity, cumulative concentration-response curves to 
ET-1 (0.1 nM-0.1 μM) were constructed in the absence of indomethacin.  
 
8.2.5 Assessment of basal release of NO in mesenteric arteries  
In another separate set of experiments, the effect of diabetes on basal levels of NO 
release was also examined as described in Chapter 2.3.2.  
 
8.2.6 Western Blot 
 Endothelium-intact mesenteric arteries from 2 animals from the same treatment group 
were pooled and considered as n=1. Western blot analysis was performed as described in 
Chapter 2.6. To investigate eNOS homodimer formation in the tissue, a non-boiled sample 
was resolved by 6% SDS-PAGE at 4°C (Chapter 2.6.5). 
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8.2.7 Measurement of ROS in mesenteric artery 
 Two different methods of ROS measurement were employed. ROS in the mesenteric 
artery was measured using either L-012 or DCFDA as described in Chapter 2.4.  
 
8.2.8 NADPH oxidase activity 
NADPH oxidase-driven superoxide production in the mesenteric artery was measured 
using lucigenin-enhanced chemiluminescence as described in Chapter 2.7.1.  
 
8.2.9 Reagents 
 All drugs were purchased from Sigma-Aldrich (St Louis, MO, USA), except for 
acetylcholine perchlorate (BDH Chemicals, Poole, Dorset, UK), DiOHF (Indofine Chemicals, 
Hillsborough, NJ, USA) and ODQ (Cayman Chemical, Ann Arbor, MI, USA). All drugs were 
all dissolved in distilled water, with the exception of indomethacin, which was dissolved in 
0.1 M sodium carbonate, L-NNA, which was dissolved in 0.1 Ml sodium bicarbonate, ODQ 
and TRAM-34, which were dissolved in DMSO. 
 
8.2.10 Statistical analyses 
All results are expressed as the mean±s.e.m., n represents the number of animals per 
group or the number of assays when tissue from animals was pooled. Concentration-response 
curves from rat isolated mesenteric arteries were computer fitted to a sigmoidal curve using 
nonlinear regression (Prism version 5.0, GraphPad Software, San Diego, CA, USA) to 
calculate the sensitivity of each agonist (pEC50). Maximum relaxation (Rmax) to ACh or SNP 
was measured as a percentage of precontraction to PE. Group pEC50 and Rmax values were 
compared by one-way ANOVA with post-hoc analysis using Dunnett‟s test or Bonferroni‟s 
selected comparison test (normal vs. normal+DiOHF, normal vs. diabetic, normal+DiOHF vs. 
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diabetic+DiOHF and diabetic vs. diabetic+DiOHF) as appropriate. P<0.05 was considered 
statistically significant. 
 
8.3 Results 
8.3.1 Body weights and blood glucose 
 The body weight gained, blood glucose and HbA1c levels of the rats are shown in 
Table 8.1. Eight weeks after treatment with STZ or vehicle, the body weight gained in normal 
rats was significantly greater than in diabetic rats. The blood glucose and HbA1c level of 
diabetic rats were significantly greater than normal rats. Treatment with DiOHF had no 
significant effect on body weight gain, blood glucose or HbA1c levels in normal rats, but 
significantly increased the body weight gain in diabetic rats. In comparison to DiOHF-treated 
normal rats, the diabetic rats that were treated with DiOHF had significantly lower body 
weight gain, and greater blood glucose and HbA1c level (Table 8.1).  
 
8.3.2 Effect of DiOHF on ROS production  
 The ROS level in mesenteric arteries was measured by L-012 chemiluminescence and 
DCFDA fluorescence. The superoxide and DCFDA-induced fluorescence levels from diabetic 
rats were significantly higher than in normal rats (Figure 8.1). Seven days treatment with 
DiOHF attenuated the generation of superoxide (Figure 8.1a) and DCFDA-induced 
fluorescence levels (Figure 8.1b) in diabetic rats, but had no effect in normal arteries. The 
presence of L-NNA attenuated the generation of superoxide in diabetic arteries, but had no 
effect in either normal or DiOHF-treated arteries. Apocynin (300 µM), a ROS scavenger, 
attenuated the production of superoxide in arteries from all groups (Figure 8.1a). 
The level of NADPH oxidase-driven superoxide production detected by L-012-
enhanced chemiluminescence in mesenteric arteries from diabetic rats was significantly 
increased in comparison to normal rats (Figure 8.1c). DiOHF treatment of the rats did not 
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affect superoxide production by mesenteric arteries from normal rats but significantly reduced 
levels generated by diabetic mesenteric arteries to levels observed from normal rats. In all 
groups, NADPH oxidase-driven superoxide production from mesenteric arteries was inhibited 
by DPI (5 µM), a flavoprotein inhibitor that inhibits NADPH oxidase (Figure 8.1c). 
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Table 8.1 Mean body weight gained, blood glucose and HbA1C levels at the end of the experiment of normal and diabetic rats with or without 
DiOHF (1 mg/kg s.c. daily for 7 days) treatment. 
 8 weeks after vehicle or STZ treatment 
 n Normal n Normal+DiOHF n Diabetic n Diabetic+DiOHF 
Body weight gained (g) 22 307 ± 12 19 286 ± 5 19 126 ± 10
*
 20 177 ± 10
†‡
 
Blood glucose (mM) 22 8.3 ± 0.6 19 7.3 ± 0.6 19 32.4 ± 0.3
*
 20 30.2 ± 0.9
‡
 
HbA1c (%) 8 6.1 ± 0.2 7 5.8 ± 0.2 10 13.5 ± 0.5
*
 10 12.6 ± 0.6
‡
 
 
n= the number of rats. * Significantly different from normal group (Bonferroni‟s test, p<0.05), † Significantly different to diabetic group, p<0.05, 
Bonferroni‟s test. ‡ Significantly different to Normal+DiOHF group, p<0.05, Bonferroni‟s test. Results are shown as mean±s.e.m.  
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Figure 8.1 ROS measurement in intact mesenteric arteries. Superoxide (a), DCFDA-
induced flurorescence levels (b) and NADPH-oxidase activity (c) was increased in diabetic 
arteries which were reduced with DiOHF treatment. Superoxide levels (a) in diabetic arteries 
were attenuated by the presence of L-NNA (100 μM), indicating eNOS uncoupling. n=9-10 
experiments. * p<0.05, ** p<0.01, *** p<0.001. 
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8.3.3 Effect of DiOHF on vascular function 
 The level of the reference contraction to KPSS (123 mM), was not affected by 
diabetes or DiOHF treatment (Figure 8.2). Diabetes significantly reduced the sensitivity, but 
not the maximum relaxation, to ACh in mesenteric arteries (Figure 8.3a, Table 8.2), whereas 
the sensitivity (diabetic, 7.96±0.20 vs. normal, 7.89±0.16, n=5-6, p>0.05) and maximum 
relaxation (diabetic, 100±0% vs. normal, 99±1%, n=5-6, p>0.05) to SNP were not affected 
(Figure 8.3b). Treatment of normal rats with DiOHF (1 mg/kg s.c.) for 7 days did not affect 
responses to ACh, however, in mesenteric arteries from diabetic rats treated with DiOHF, the 
sensitivity to ACh was significantly increased in comparison to the response in mesenteric 
arteries from untreated diabetic rats (Figure 8.3, Table 8.2). DiOHF treatment did not affect 
responses to SNP in normal rats (pEC50 8.18±0.18, Rmax 100±0%, n=9) or diabetic rats (pEC50 
7.84±0.18, Rmax 99±1%, n=6).  
The diabetic arteries also showed a significant increase in sensitivity to ET-1 (diabetic, 
8.46±0.07 vs. normal, 8.19±0.06, n=7-8, p<0.05), without affecting the maximum contraction. 
Treatment with DiOHF had no effect in normal arteries (normal+DiOHF, 8.16±0.03, n=7), 
but significantly reduced the sensitivity to ET-1 in diabetic arteries in comparison to untreated 
diabetic arteries (diabetic, 8.46±0.07 vs. diabetic+DiOHF, 8.20±0.07, n=7-8, p<0.05), (Figure 
8.3c).  
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Figure 8.2 KPSS induced maximum contraction in mesenteric arteries. Exposure of 
mesenteric arteries from normal and diabetic rats with or without DiOHF (1 mg/kg s.c. daily 
for 7 days) treatment to KPSS (123 mM). The contraction to KPSS was not affected by 
diabetes or DiOHF treatment. Results are shown as mean±s.e.m. NS= Not significant. 
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Figure 8.3 Vascular function in mesenteric arteries. Cumulative concentration-response 
curves to ACh (a), SNP (b), ET1 (c) and basal NO release (d) in endothelium-intact 
mesenteric arteries. In each group of experiments (a, b), mesenteric arteries were 
precontracted with PE to similar levels: (a) normal 59±3, normal+DiOHF 59±3, diabetic 
62±2, diabetic+DiOHF 60±3, (b) normal 58±2, normal+DiOHF 57±3, diabetic 61±3, 
diabetic+DiOHF 59±4 %KPSS, n=5-12 experiments. Results are shown as mean±s.e.m. * 
p<0.05, ** p<0.01. See Table 8.2 or results section for pEC50 and Rmax values.  
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Table 8.2 Effect of L-NNA, ODQ and potassium channel blockers on ACh-induced relaxation of mesenteric arteries from normal and diabetic 
rats with or without DiOHF (1 mg/kg s.c. daily for 7 days) treatment in the presence of indomethacin 
A comparison of the sensitivity (pEC50) and maximum relaxation (Rmax) to ACh in the absence (control), or presence of TRAM-34 (1 μM)+apamin (1 
μM), TRAM-34 (1 μM)+apamin (1 μM) +Ibtx (100 nM), 30 mM K+, L-NNA (100 μM)+ODQ (10 μM), L-NNA (100 μM)+ODQ (10 μM)+TRAM-34 
(1 μM)+apamin (1 μM) or L-NNA (100 μM)+ODQ (1 μM)+TRAM-34 (1 μM)+apamin (1 μM)+Ibtx (100 nM)  in endothelium intact mesenteric 
arteries. All experiments were conducted in the presence of indomethacin (10 μM). n= the number of experiments. * Significantly different to control 
within each group, p<0.05, Dunnet‟s test, † Significantly different to normal within inhibitor group, p<0.05, Bonferroni‟s test. ‡ Significantly different 
to normal+DiOHF within inhibitor group, p<0.05, Bonferroni‟s test. §Significantly different to diabetic within inhibitor group, p<0.05, Bonferroni‟s 
test. Results are shown as mean±s.e.m, ND= Not determined. 
  Normal   Normal + DiOHF  Diabetic  Diabetic + DiOHF 
 n pEC50 Rmax (%) n pEC50 Rmax (%) n pEC50 Rmax (%) n pEC50 Rmax (%) 
Control 12 7.94±0.13 100±0 10 7.78±0.16 100±0 11 6.86±0.12
†
 97±3 11 7.49±0.13
§
 100±0 
TRAM-34 + apamin 12 7.26±0.19
*
 91±3 9 6.93±0.22
*
 92±2 11 6.86±0.16 66±8
*†
 11 7.04±0.11
*
 86±3
*§
 
TRAM-34 + 
apamin+Ibtx 
10 6.83±0.15
*
 68±10
*
 9 6.84±0.19
*
 71±11
*
 10 ND 31±9
*†
 11 6.98±0.12
*
 69±6
*§
 
30 mM K
+
 8 6.91±0.10
*
 78±4
*
 9 7.28±0.11
*†
 73±4
*
 8 6.35±0.07
*†
 52±5
*†
 7 6.81±0.13
*‡§
 70±2
*§
 
L-NNA + ODQ 12 7.14±0.12
*
 100±0 10 7.07±0.15
*
 98±1 10 6.63±0.15
†
 97±1 11 6.85±0.12
*
 99±1 
L-NNA + ODQ + 
TRAM-34 + apamin 
10 5.48±0.23
*
 59±10
*
 10 6.10±0.30
*
 70±9
*
 6 ND 1±1
*†
 7 ND 2±2
*‡
 
L-NNA + ODQ + 
TRAM-34 + 
apamin+Ibtx 
7 ND 3±3
*
 5 ND 2±2
*
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8.3.4 Relative contribution of NO and EDHF to endothelium-dependent relaxation  
 In normal mesenteric arteries, ACh-induced relaxation could be partly inhibited by 
either the combination of a NO synthase inhibitor, L-NNA and a sGC inhibitor, ODQ, or KCa 
channels inhibitors, TRAM-34, apamin and Ibtx, to block the IKCa, SKCa and maxi KCa 
respectively, indicating that both NO and EDHF contributed to endothelium-dependent 
relaxation. However, in diabetic arteries, ACh-induced relaxation could only be inhibited by 
the KCa channels inhibitors, suggesting that EDHF was the predominant contributor to 
endothelium-dependent relaxation in diabetes. In the presence of both NO and EDHF 
inhibitors, endothelium-dependent relaxation were abolished in all groups of rats (Table 8.2).  
 
8.3.5 Effect of DiOHF on NO-mediated relaxation   
To determine the NO-mediated component of the relaxation, responses to ACh were 
evaluated in the presence of TRAM-34+apamin or TRAM-34+apamin+Ibtx. When these 
responses were compared between arteries from normal (Figure 8.4a, Table 8.2) and diabetic 
(Figure 8.4b, Table 8.2) rats, it is apparent that diabetes decreased the maximum relaxation to 
ACh in the presence of TRAM-34+apamin (diabetic 66±8% vs. normal, 91±3%, n=11-12, 
p<0.05). A similar difference was also apparent in the presence of TRAM-34+apamin+Ibtx 
(diabetic 31±9% vs. normal, 68±10%, n=10, p<0.05), indicating that diabetes impaired the 
contribution of NO to endothelium-dependent relaxation. Treatment with DiOHF (1 mg/kg 
s.c.) for 7 days had no effect in normal rats but significantly increased the maximum 
relaxation to ACh (diabetic 66±8% vs. diabetic+DiOHF, 86±3%, n=11, p<0.05) in the 
presence of TRAM-34+apamin (Figure 8.4b, d, Table 8.2). A similar finding was observed in 
DiOHF-treated diabetic arteries (Figure 8.4b, d, Table 8.2) in the presence of TRAM-
34+apamin+Ibtx (diabetic 31±9% vs. diabetic+DiOHF, 69±6%, n=11, p<0.05), indicating that 
DiOHF treatment improved the contribution of NO to endothelium-dependent relaxation in 
diabetic arteries. In addition, in arteries precontracted with a depolarizing solution of 30 mM 
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K
+
, to eliminate any contribution of the opening of potassium channels, ACh-induced 
relaxation was significantly attenuated in diabetic arteries in comparison to normal arteries, 
but this response was significantly improved by 7 days treatment with DiOHF in diabetic rats 
(Figure 8.4, Table 8.2).  
The basal level of NO release was assessed by measuring the contraction induced by 
L-NNA in arteries with PE-induced tone (i.e. 20% KPSS) (Figure 8.3d). The L-NNA-induced 
contraction was significantly greater in arteries from normal rats compared with diabetic rats 
(normal, 66±2% vs. diabetic, 44±2%, n=6-7, p<0.05), indicating that diabetes impaired the 
basal release of NO. Treatment with DiOHF had no effect on L-NNA-induced contraction in 
normal arteries (normal+DiOHF, 57±7%), but significantly increased the L-NNA-induced 
contraction in diabetic arteries in comparison to untreated diabetic arteries (diabetic+DiOHF, 
61±2% vs. diabetic, 44±2%, n=5-6, p<0.05). 
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Figure 8.4 Contribution of NO to endothelium-dependent relaxation in mesenteric 
arteries. NO-mediated relaxation in mesenteric arteries isolated from normal (a), diabetic (b), 
normal+DiOHF (c), diabetic+DiOHF (d) rats. In each group of experiments, arteries were 
precontracted with PE to similar levels: 57±3 (a), 58±2 (b), 61±4 (c), 59±2 (d) %KPSS, n=9-
15 experiments. Results are shown as mean±s.e.m. See Table 8.2 for values.  
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8.3.6 Effect of DiOHF on EDHF-type relaxation  
 To characterize EDHF-type relaxation, the contribution of NO was eliminated by the 
combination of L-NNA and ODQ. In the presence of L-NNA+ODQ, the sensitivity to ACh 
was significantly lower in the diabetic compared to the normal arteries (pEC50 diabetic, 
6.63±0.15 vs. normal, 7.14±0.12, n=10-12, p<0.05), indicating that diabetes impairs the 
contribution of EDHF to endothelium-dependent relaxation. Treatment of normal and diabetic 
rats with DiOHF (1 mg/kg s.c.) for 7 days had no significant effect on ACh-mediated EDHF-
type relaxation (Table 8.2).  
The addition of TRAM-34 and apamin to the presence of L-NNA+ODQ, abolished 
ACh-induced relaxation in either untreated diabetic or DiOHF-treated diabetic arteries. In 
normal or DiOHF-treated normal arteries, however, ACh continued to cause a maximum 
relaxation of almost 60% (Figure 8.5, Table 8.2). The residual relaxation observed in normal 
and DiOHF-treated normal arteries could be abolished by the additional presence of Ibtx 
(Figure 8.5a, c, Table 8.2), suggesting an additional role of other endothelium-derived factors 
to cause relaxation in normal arteries, but not in diabetes.  
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Figure 8.5 Contribution of EDHF to endothelium-dependent relaxation in mesenteric 
arteries. EDHF-type relaxation in mesenteric arteries isolated from normal (a), diabetic (b), 
normal+DiOHF (c), diabetic+DiOHF (d) rats. In each group of experiments, arteries were 
precontracted with PE to similar levels: 62±3 (a), 63±4 (b), 63±4 (c), 61±2 (d) %KPSS, n=5-
12 experiments. Results are shown as mean±s.e.m. See Table 8.2 for values. 
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8.3.7 Effect of DiOHF on Nox2 and NOS expression, and eNOS uncoupling 
Diabetes significantly decreased the expression of total eNOS in the mesenteric 
arteries but this was reversed by treatment with DiOHF (Figure 8.6a). In addition, diabetes 
significantly decreased the proportion of eNOS expressed as a dimer. Treatment of diabetic 
rats with DiOHF significantly increased the proportion of eNOS expressed as a dimer (Figure 
8.6b). The expression of Nox2 was also significantly increased in diabetic arteries compared 
to normal arteries. In DiOHF-treated diabetic arteries, Nox2 expression was significantly 
reduced, but it remained significantly higher in comparison to DiOHF-normal arteries (Figure 
8.6c). Treatment with DiOHF in normal rats had no effect on eNOS and Nox2 expression.  
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Figure 8.6 Western blot analysis mesenteric arteries. Protein expression of eNOS (a, 130 
kDa), eNOS dimers and monomers (b, 260 kDa) and Nox2 (c, 58 kDa) in the normal and 
diabetic mesenteric arteries with or without DiOHF treatment. Diabetes significantly reduced 
the expression of eNOS and decreased the proportion of eNOS expressed as the dimer, and 
increased the expression of Nox2. Treatment with DiOHF significant increased the expression 
of eNOS, decreased the expression of Nox2 and increased the proportion of eNOS expressed 
as the dimer. Representative blots are shown on each of the corresponding graphs. n= 5-6 
experiments. Results are shown as mean±s.e.m. * p<0.05, ** p<0.01, *** p<0.001. 
Chapter 8-DiOHF treatment improves NO function in diabetes 
229 
 
8.4 Discussion 
This study demonstrated that treatment of type I diabetic rats with the synthetic 
flavonol DiOHF (1mg/kg, per day) for 7 days reduced the levels of vascular oxidative stress 
and improved endothelium-dependent relaxation in mesenteric arteries. Endothelial 
dysfunction in the diabetic rats is associated with a decreased contribution of both NO-
mediated and EDHF-type relaxation to endothelium-dependent relaxation. Treatment with 
DiOHF improved NO-mediated relaxation in diabetic rats accompanied by an increased 
expression of eNOS, reduced eNOS uncoupling and downregulation of Nox2 expression.  
 
8.4.1 Effect of DiOHF on endothelial function 
In the present study, diabetes increased the level of vascular ROS production, 
associated with an increase in Nox2 expression and a selective impairment of endothelium-
dependent relaxation, as we (Chapter 6) and others have previously described (De Vriese et 
al., 2000; Ding et al., 2005; Malakul et al., 2007). Treatment with the synthetic flavonol 
DiOHF (1mg/kg, per day) for 7 days in vivo reduced the levels of oxidative stress, at least in 
part, by inhibiting superoxide production by Nox2 and uncoupled eNOS in the diabetic 
mesenteric arteries, and improved endothelium-dependent relaxation in mesenteric arteries 
from diabetic rats. These observations are consistent with other studies that have 
demonstrated that treatment with flavonols in diabetic rats reduced vascular oxidant stress and 
preserved endothelial function in conduit arteries such as the aorta (Machha et al., 2007; 
Woodman et al., 2009) or renal vasculature (Anjaneyulu et al., 2004). Whilst there are several 
reports that flavonols attenuated diabetes-induced endothelial dysfunction, the mechanism of 
the vasoprotective effect of flavonols remain poorly understood, in particular the effect of 
flavonols on the relative contribution of NO and EDHF to endothelium-dependent relaxation. 
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8.4.2 Effects of DiOHF on NO-mediated relaxation  
In order to evaluate NO-mediated relaxation, the EDHF-type relaxation was inhibited 
either by endothelial KCa channel blockers or by the presence of a depolarizing K
+
 solution. 
This confirmed an impaired release of NO, as under those conditions the maximum relaxation 
to ACh was decreased in the diabetic mesenteric arteries in comparison to normal arteries. 
Treatment with DiOHF in vivo for 7 days significantly increased the maximum relaxation to 
ACh in diabetic arteries in comparison to untreated diabetic rats. In addition to stimulated NO 
release, basal release of NO was also decreased in diabetic mesenteric arteries as 
demonstrated by impaired contraction in response to NOS inhibition, and this was also 
reversed in DiOHF treated diabetic arteries. Hence, treatment with DiOHF preserved NO-
mediated relaxation in diabetic small mesenteric arteries. 
Consistent with impairment of NO-mediated relaxation, we found that the expression 
of total eNOS was decreased and uncoupling of eNOS was indicated by the decreased 
proportion of eNOS expressed as a dimer in the diabetic mesenteric vasculature. This suggests 
that in the diabetic rats, in addition to producing NO, eNOS is producing superoxide, further 
demonstrated by a reduction of superoxide levels in the diabetic mesenteric arteries in the 
presence of NOS inhibition (Chapter 3) (Hink et al., 2001). However, in DiOHF-treated 
diabetic rats, the expression of eNOS was increased to levels that were comparable to normal 
rats. In addition, treatment with DiOHF promoted the re-coupling of eNOS, which was shown 
by the increased proportion of eNOS expressed as a dimer compared to untreated diabetic rats 
and the lack of inhibitory effect of L-NNA on superoxide production in DiOHF-treated 
arteries. 
A further contributing factor to the restoration of NO activity by DiOHF treatment 
could be the reduction of vascular superoxide production in diabetic mesenteric arteries, 
which could then increase the bioavailability of NO by preventing the degradation of NO by 
superoxide to form peroxynitrite. The reduction of vascular ROS activity in the DiOHF-
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treated diabetic vasculature could be either due to the rapid free radical scavenging effect of 
DiOHF to preserve NO bioavailability (Chan et al., 2003) or by decreasing the expression 
and/or activity of the enzymatic sources of superoxide production in the vasculature such as 
the catalytic subunit of NADPH oxidases, Nox2 and its regulatory subunits (Jiang et al., 
2008). Taken together, DiOHF treatment protected the beneficial activity of NO by increasing 
eNOS expression, preventing eNOS uncoupling and decreasing Nox2-dependent superoxide 
production in the diabetic mesenteric arteries. 
 
8.4.3 Effect of DiOHF on EDHF-type relaxation  
In the rat mesenteric artery, endothelium-dependent relaxation is mediated by NO, the 
classical EDHF pathway and there is also a role for the non-classical EDHF pathway 
(Edwards et al., 2010). To investigate the role of EDHF, we assessed endothelium-dependent 
relaxation in the presence of L-NNA and ODQ to inhibit NO synthesis and sGC activity 
respectively. In the presence of L-NNA+ODQ, the sensitivity to ACh was decreased in 
diabetic arteries when compared to normal arteries, indicating that diabetes impaired the 
contribution of EDHF-type relaxation, which is consistent with several other studies (Fukao et 
al., 1997; Matsumoto et al., 2003b; Matsumoto et al., 2005). Treatment with DiOHF caused a 
modest improvement in EDHF-type relaxation in diabetic mesenteric arteries, but the change 
was not statistically significant. It should be noted however that whereas ACh-induced 
relaxation in the presence of L-NNA+ODQ was impaired in diabetes compared to normal 
arteries, under the same conditions there was no significant difference in the responses to ACh 
in arteries from normal and diabetic rats treated with DiOHF. Thus, the evidence is equivocal 
as to whether DiOHF improves EDHF-type relaxation in the diabetic mesenteric arteries. 
 The cause of the impairment of EDHF-type relaxation in diabetes remains 
controversial (Burnham et al., 2006; Makino et al., 2000b; Matsumoto et al., 2003b; 
Matsumoto et al., 2006; Weston et al., 2008) (Chapter 6) but is partly attributed to an 
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overproduction of ROS. Indeed, Ma and coworkers demonstrated that superoxide anions 
generated by auto-oxidation of pyrogallol could impair EDHF responses in rat mesenteric 
arteries, an effect which could be reversed by the acute presence of the flavones, apigenin 
and/or luteolin, in the tissue bath (Ma et al., 2008). In the present study, it is important to note 
that the final administration of the DiOHF was more than 24 hr before the conduct of all 
experiments. Although there appears to be no information available regarding the 
pharmacokinetics of flavonols in rats, in humans it is reported that quercetin reaches peak 
plasma concentrations within 2-5 hr after oral ingestion and is predominantly excreted in the 
urine within 5-12 hr (Erlund et al., 2000; Loke et al., 2008). Given the structural similarities 
between quercetin and DiOHF, it is unlikely that there will be any acute effect of DiOHF 
during experimentation. Therefore, the in vivo effect of DiOHF on EDHF-type relaxation 
remains to be elucidated. 
 
8.4.4 Conclusion 
We have demonstrated that the synthetic flavonol DiOHF increased NO activity to 
improve endothelial function in diabetic microvasculature. It was less certain as to whether 
DiOHF treatment had a beneficial effect on the EDHF-type component of endothelium-
dependent relaxation. The protective actions of DiOHF occur through at least two 
mechanisms. The flavonol is able to rapidly scavenge ROS and/or inhibit the enzymatic 
source for superoxide production to reduce inactivation of NO. In addition, treatment with 
DiOHF in vivo for 7 days prevented eNOS uncoupling and thus helps to maintain 
endothelium-dependent relaxation. The beneficial effect of DiOHF to protect NO activity 
found in this study indicates that it has potential as a therapeutic agent for use in the 
prevention of the microvascular complications of diabetes. 
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Chapter 9 
 
General Discussion 
 
9.1 Effects of diabetes on vascular function 
Endothelial dysfunction is recognized as an independent risk factor for cardiovascular 
disease and is an early phenomenon in the development of cardiovascular complications (De 
Vriese et al., 2000; Halcox et al., 2002). In this thesis, we investigated the pathological 
process underlying endothelial dysfunction over the course of STZ-induced diabetes. In the 
early stages of hyperglycaemia, our results (Chapter 3) indicated that endothelial function was 
preserved in diabetes despite an increased in ROS production and eNOS uncoupling. Further 
investigation revealed that endothelial function in diabetic arteries was maintained by 
increased NO production derived from an eNOS-independent pathway (s-nitrosothiol stores). 
This suggested that NO is an important modulator of vascular health and pharmacological 
agents targeting to improve NO activity would be useful in maintaining endothelial function 
during later stage of diabetes. 
In the later stages of diabetes, the overproduction of ROS impaired NO 
synthesis/activity, causing endothelial dysfunction (De Vriese et al., 2000; Fatehi-Hassanabad 
et al., 2010; Vanhoutte et al., 2009) (Chapter 6-8). This study (Chapter 4) indicated that 
endothelial dysfunction in diabetes was due to the selective impairment of NO-mediated 
relaxation. Recent reports suggest that HNO, the one electron reduced and protonated form of 
NO, is formed endogenously and contributes to endothelium-dependent relaxation in blood 
vessels (Andrews et al., 2009; Ellis et al., 2000a; Wanstall et al., 2001). HNO-mediated 
relaxation was not affected by diabetes as it was resistant to be scavenged by superoxide 
anion. Once again, the results suggested that the inactivation of NO activity by ROS is an 
important contributor to endothelial dysfunction in diabetes.  
Chapter 9-General discussion 
234 
 
In the microvasculature, endothelium-dependent relaxation is modulated by the 
contribution of both NO and EDHF. This study (Chapter 6) provided further insights into the 
mechanisms underlying endothelial dysfunction in the diabetic microvasculature. Our results 
indicated that the contribution of both NO and EDHF-type relaxation was impaired in 
diabetes. The NO component of relaxation was impaired in diabetes due to increased ROS 
production and/or eNOS uncoupling. Diabetes also caused an increase in the expression of the 
endothelial KCa channels (IKCa and SKCa), suggesting that, rather than a decrease in channel 
expression, the impairment of the EDHF-type relaxation may be due to oxidative stress, 
leading to defective downstream processes such as microdomain signaling and/or activity of 
myoendothelial gap junctions. These observations also suggested that the increased 
expression of endothelial KCa channels (IKCa and SKCa) in diabetic arteries could be due to a 
compensatory mechanism to maintain EDHF responses in the presence of hyperglycaemia. 
Taken together, the results from Chapter 3 to 6 provided further insights in the 
pathological process underlying endothelial dysfunction in both macro- and microvasculature 
over the duration of hyperglycaemia. At the early stages of diabetes, hyperglycaemia caused 
oxidative stress through the increase in NADPH oxidase expression/activity and eNOS 
uncoupling but endothelial function was maintained. At the latter stages of diabetes, the 
increase in NADPH oxidase expression/activity and eNOS uncoupling continued to contribute 
to oxidative stress. This was accompanied by endothelial dysfunction due to the impairment 
of both NO and EDHF pathways. This indicates that the increase in NADPH oxidase 
expression/activity and eNOS uncoupling are early contributors to hyperglycaemia-induced 
endothelial dysfunction. During the early stages of diabetes, however, alteration in vascular 
function to increase the production of NO and possibly increased expression of endothelial 
KCa channels (IKCa and SKCa) to increase EDHF responses in the microvasculature, was able 
to maintain endothelial function initially but as the duration of hyperglycaemia continued to 
progress, the initial compensatory mechanism failed and endothelial dysfunction developed. 
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Thus, therapies targeting ROS-derived from NADPH oxidase and eNOS uncoupling may 
have the potential in improving diabetes-induced endothelial dysfunction.  
Using an animal model that were artificially selected for LCR and HCR (Koch et al., 
2001), studies have shown that LCR animals display insulin resistance, increased blood 
pressure, increased blood glucose and higher body weights in comparison to their HCR 
counterparts (Lessard et al., 2009; Rivas et al., 2011; Wisløff et al., 2005) which was similar 
to the impairments observed in individuals at risk of developing type II diabetes (Mootha et 
al., 2003). The results from Chapter 5 demonstrated that there were differential vessel specific 
responses to vasodilators (ACh and SNP) and β-adrenceptor agonists (isoprenaline and 
fenoterol) between LCR and HCR animals. In the aorta, responses to isoprenaline were 
reduced in the LCR but responses to ACh, SNP and fenoterol were not different. In the 
mesenteric arteries from LCR animals, responses to ACh and fenoterol were reduced whereas 
responses to SNP and isoprenaline were not different.  
 
9.2 Protection of diabetes-induced endothelial dysfunction by DiOHF  
In diabetes, hyperglycaemia-induced oxidative stress plays a key role in the 
pathogenesis of vascular complications (Brownlee, 2001; Forstermann, 2008; Nishikawa et 
al., 2000a) (Chapters 3-6). Structure-activity relationship studies have demonstrated that a 
synthetic flavonol, DiOHF was significantly more potent than a number of natural flavones 
and flavonols in its antioxidant ability (Chan et al., 2000; Woodman et al., 2005), which 
could be used as a potential treatment for diabetic vascular complications. Indeed, recent 
study has demonstrated that DiOHF treatment could improve endothelial function in the 
diabetic aorta (Woodman et al., 2009). In this study (Chapter 7 and 8), the effect of DiOHF on 
diabetic microvascular function was investigated, demonstrating that treatment of type I 
diabetic rats reduced the levels of vascular oxidative stress and improved endothelial function. 
Endothelial dysfunction in the diabetic rats was associated with a decreased contribution of 
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both NO-mediated and EDHF-type relaxation to endothelium-dependent relaxation. 
Treatment with DiOHF selectively improved NO-mediated relaxation in diabetic rats 
accompanied by downregulation of NADPH oxidase expression/activity and reduced eNOS 
uncoupling. It is less certain as to whether DiOHF treatment had a beneficial effect on the 
EDHF-type component of endothelium-dependent relaxation. 
Short term treatment with DiOHF in diabetic rats had no effect on the glycaemic 
levels, indicating that DiOHF improves vascular function via a glucose lowering independent 
pathway. In addition, DiOHF treatment in normal animals did not produce any alteration to 
vascular function. The protective actions of DiOHF occur through at least two mechanisms. 
DiOHF is able to rapidly scavenge ROS and/or inhibit the enzymatic source for superoxide 
production (i.e. NADPH oxidase and eNOS uncoupling) to preserve NO activity. The ability 
of DiOHF to inhibit superoxide production derived from NADPH oxidase and eNOS 
uncoupling makes it a potential adjunctive treatment for diabetic vascular complications. 
 
9.3 Future directions 
 The data from Chapter 3 indicated that short term STZ-induced diabetes (6 weeks) 
have preserved endothelial function in the carotid arteries despite of increased oxidative stress 
and eNOS coupling. In the diabetic carotid arteries, the mechanisms of endothelium-
dependent relaxation was altered to compensate for the reduced NO (detected by DAF-FM 
fluorescence), which involved a role of nitrosothiol-derived NO/HNO-mediated relaxation. 
This observation was similar in the diabetic aorta (Joshi & Woodman, 2011, unpublished). 
Recent studies demonstrated that acute exposure to high glucose impairs the contribution of 
both NO and EDHF responses in the microvasculature (Brouwers et al., 2010; Tsai et al., 
2011). During early stages of STZ-induced diabetes (3 weeks), however, ACh-induced 
dilatation was affected in the diabetic microvasculature in vivo (Jenkins et al., 2012). The 
impairment of ACh-induced dilatation was revealed after the inhibition of NO and PGI2 
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production, indicating that during early stage of diabetes, the contribution of EDHF was 
selectively impaired (Jenkins et al., 2012). Thus, future experiments should investigate how 
early diabetes affects microvascular endothelial function and whether the contribution of 
either NO/EDHF or other factors was altered to preserved endothelial function during early 
stages of diabetes. 
The data from Chapter 4 indicated that at a prolonged stage of diabetes (10 weeks), 
NO but not HNO-mediated relaxation was impaired in the aorta. It was also demonstrated that 
HNO was unaffected by oxidative stress. Futhermore, there is a role of NOS-independent 
source (possibly derived from nitrosothiol) of HNO-mediated relaxation in the diabetic aorta. 
Future experiments should confirm the role of nitrosothiol in diabetic aorta using HPLC 
analysis. In addition, HNO is recently regarded as an endothelium-derived relaxing and 
hyperpolarizing factor in the mesenteric arteries (Andrews et al., 2009). HNO also has the 
ability to cause spreading vasodilatation in pressurised mesenteric arteries (Yuill et al., 2011). 
Future pharmacological and electrophysiological experiments should be aimed to explore the 
role of endothelium-derived HNO in diabetic mesenteric arteries.  
Rats artificially selected for LCR show a phenotype of hyperglycaemia, insulin 
resistance, hypertension and increased adiposity in comparison to their HCR counterparts. 
The LCR phenotype is associated with increased cardiovascular risk (Wisløff et al., 2005). 
The data in Chapter 5 demonstrated that there are vessel specific (aorta vs. mesenteric) 
differences in the responses to endothelium-dependent vasodilators and β-adrenoceptor-
induced vasorelaxation between the LCR and HCR phenotype. Whilst vessel specific changes 
were observed, the mechanism underlying these changes were not investigated, hence future 
experiments could be conducted to study the mechanisms of impaired endothelial function in 
the mesenteric arteries. Beside endothelial dysfunction, increased arterial stiffness associated 
with metabolic syndrome may at least in part contribute to the increased cardiovascular risk 
observed in the LCR animals (Stehouwer et al., 2008). Hence, future experiments should aim 
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to examine the passive compliance of arteries from both HCR and LCR animals. Furthermore, 
in this study (Chapter 5), all the experiments were conducted in the presence of endothelium, 
thus whether the reduction in the β-adrenoceptor function in LCR phenotype was associated 
with decreased endothelial function cannot be confirmed until experiments with endothelium-
denuded vessels are conducted.  
It is well established that superoxide directly interacts with NO to form peroxynitrite, 
causing the reduction of NO bioavailability and impairs NO-mediated relaxation. A recent 
study demonstrated that EDHF responses were reduced in the presence of pyrogallol-induced 
oxidant stress, indicating that superoxide could inhibit EDHF-type relaxation (Ma et al., 
2008). Consistent with this observation, the results from the present thesis (Chapter 6) also 
indicate that EDHF-type relaxation was reduced in diabetes, however, it still remains unclear 
how EDHF-type relaxation is affected by ROS, in particular how ROS affect the 
microdomain signaling in EDHF responses. The lack of a clear understanding of how ROS 
affect EDHF responses could probably explain why DiOHF treatment did not improve 
EDHF-type relaxation (Chapter 8). Thus, future experiments could be conducted to evaluate 
how ROS affect EDHF responses, in particular whether ROS affect either or both the classical 
and non-classical EDHF responses.  
In this thesis, short term DiOHF treatment (Chapter 8) was able to improve vascular 
function, at least in part, by inhibiting the expression/activity of NADPH oxidase-derived 
ROS in a animal model of chronic hyperglycaemia (type I diabetes). The clinical application 
of flavonols for the treatment of diabetic complications in humans is limited due to their poor 
water solubility. Recent discovery of water-soluble derivative of DiOHF with similar 
antioxidant potency to DiOHF may have greater potential for clinical use (Yap et al., 2008). 
Hence, future experiments could explore long term treatment with the water soluble derivative 
of DiOHF to reduce ROS in the vasculature and prevent the development of diabetic vascular 
complications.  
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Type II diabetes is characterized by insulin resistance and is the most prevalent from 
of diabetes, affecting 85-90% of the diabetic population (World Health Organization, 2011). 
The data from Chapter 7 demonstrated that in the arteries from the obese Zucker animals have 
increased ROS and impaired endothelial function. The presence of DiOHF in the organ bath 
was able to remove ROS and reverse endothelial dysfunction, however, the in vivo effect of 
DiOHF in type II diabetes remains unknown. Thus, the ability of the water soluble derivative 
of DiOHF to improve glucose homeostasis and/or reduce ROS in the vasculature, leading to 
improve endothelial function is warranted in the future.  
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